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Samar R. El Khoudary, PhD, MPH 
ABSTRACT 
 
Aims: Coronary heart disease (CHD) is a significant public health issue in the United States. The 
relationships of inflammatory and hemostatic biomarkers to subclinical CHD in women are 
uncertain. The aims of this study were to test the associations of baseline levels of four novel 
biomarkers with baseline coronary artery calcification (CAC) and CAC progression; and to 
evaluate if changes in these biomarkers were associated with CAC progression. 
Methods: Subjects were obtained from the Study of Women’s Health Across the Nation Heart 
Study. C-reactive protein (CRP), fibrinogen, plasminogen-activator inhibitor type 1 (PAI-1), and 
tissue plasminogen activator antigen (tPA-ag) were log-transformed. Logistic regression was 
used for the categorical outcomes (presence of baseline CAC and CAC progression), and tobit 
and linear regression were used for the continuous outcomes (extent of baseline CAC and CAC 
progression, respectively). Univariable and multivariable analyses were performed. 
Results: A total of 372 women with a mean age of 51.3 years (SD, 2.8) were included for the 
baseline CAC analyses of which 131 (35.2%) were black. In the univariable analyses, all novel 
biomarkers were positively associated with baseline CAC presence and extent (p<0.001). These 
were significant after adjusting for traditional risk factors, but not after adjusting for body mass 
index. A significant interaction of race on log(CRP) and CAC was present. In race-stratified 
multivariable analyses, log(CRP) was significantly associated with CAC presence and CAC 
INFLAMMATORY AND HEMOSTATIC BIOMARKERS AND CORONARY 
ARTERY CALCIFICATION IN WOMEN UNDERGOING THE MENOPAUSAL 
TRANSITION 
 
Norman C. Wang, MS 
University of Pittsburgh, 2013
 
 v 
extent in blacks, but not whites. There were 252 women for the CAC progression analyses. In the 
univariable analyses, log(PAI-1) and log(tPA-ag) were associated with presence of CAC 
progression and log(PAI-1) was associated with extent of CAC progression. After adjustment, 
only log(PAI-1) was associated with presence of CAC progression (OR, 1.91; 95% CI, 1.24-
2.93; p=0.003). There was a trend towards an association between log(PAI-1) and extent of CAC 
progression (p=0.06). Changes in biomarkers were not associated with CAC progression. 
Conclusions: Inflammatory and hemostatic biomarkers are associated with baseline CAC 
through obesity, except for CRP and CAC in blacks. Log(PAI-1) is associated with presence of 
CAC progression. These findings may improve CHD prevention in midlife women. 
 vi 
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1.0  INTRODUCTION 
Coronary heart disease (CHD) is the cause of approximately 1 of every 6 deaths in the United 
States (1). Risk prediction has traditionally been based on sex, age, blood pressure, total 
cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol 
(HDL-C), smoking, and diabetes status (2).  Current risk assessment based on the estimated risk 
for a cardiovascular (CV) event within 10-years, remains insufficient (3).Those with low short-
term, or 10-year, risk estimates are still at risk for CV disease (CVD) during their lifetimes (4). 
Studying relationships between novel biomarkers and CHD development is therefore important. 
1.1 CORONARY HEART DISEASE RISK PREDICTION IN WOMEN 
The Global Registry of Acute Coronary Events demonstrated that women with suspected acute 
coronary syndromes (ACS) are more likely to present with atypical symptoms, to be older, and 
to have more CV risk factors when compared to men (5). Despite similar rates of positive cardiac 
enzymes, women were twice as likely as men to have normal or mild CHD on cardiac 
catheterization (12% vs. 6%, p<0.001). From the Get With the Guidelines-Coronary Artery 
Disease database, women with a diagnosis of ST-elevation myocardial infarction were less likely 
to receive reperfusion therapy and more likely to have in-hospital death (6). There is continued 
debate as to whether the mortality differences are related to higher baseline risk in women versus 
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treatment bias. There is no debate, however, that differences exist in CHD development between 
women and men. 
Women at middle-age are of particular interest. Sex-related differences in CHD risk 
profile are particularly notable around the menopausal transition (7). The ratio of male-to-female 
CHD deaths begins to decrease at this point and continues until the eighth decade at which point 
the ratio approaches equivalency. In a study of individuals with CHD events, over 10% of 
women aged 46-55 years did not have any traditional risk factors and over 35% had only one risk 
factor (3). Understanding the mechanisms underlying CHD in women at midlife may optimize 
prevention strategies. 
1.2 CORONARY ARTERY CALCIFICATION 
Coronary artery calcification (CAC), as detected via computed tomography (CT) scanning, is 
absent in normal arteries and present in late stage atherosclerotic lesions (8). The amount 
detected on CT has been demonstrated to correlate with histomorphometric calcium and degree 
of coronary artery stenosis (9). 
1.2.1 CAC clinical implications and epidemiology 
In asymptomatic individuals, positive results in both a single quantification of CAC and CAC 
progression over time predict CHD events and all-cause mortality (10-13). Adjusted 10-year 
survival is 99.4% with a CAC score of 0 and 87.8% when >1,000 (11). CAC has emerged as a 
potential means to improve risk stratification (14-15). In an observational study, incorporation of 
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CAC into a traditional risk model improved accuracy by increasing the number of individuals 
with events into the high-risk category, and increasing the number without events into the low-
risk category (15). 
Men and women in the Multi-Ethnic Study of Atherosclerosis (MESA) who were 
considered to be low-risk for CHD event, or a predicted 10-year CHD risk <10% based on the 
Framingham risk score (FRS), had a CAC prevalence of 30% (16). The sample population 
included those without known CV disease with an average age of 55-60 years and included a 
broad ethnic base. CAC presence was defined as an Agatston score >0. The prevalence of 
advanced CAC, defined as a score >300, was 3.5%. 
1.2.2 CAC pathophysiology and CHD events 
The process of calcification in coronary atheromas is related to bone formation via an active 
process involving factors promoting and inhibiting calcification (17). Historically, the two major 
forms of vascular calcification are intimal atherosclerotic calcification and arterial medial 
calcification (18). Intimal atherosclerotic calcification is the more common, with dyslipidemia 
implicated in most studies. Arterial medial calcification, also known as Mönckeberg’s sclerosis, 
is prominent in type 2 diabetes mellitus. 
Despite the association between CAC and coronary events, calcified plaque within 
luminal calcified nodules do not contribute to the vast majority of ACS (19). ACS events are 
believed to be the result of sudden luminal thrombosis. The chief pathological causes consist of 
plaque rupture of a thin fibrous cap overlying a lesion with a necrotic core, plaque erosion in the 
absence of a connection with a necrotic core, and calcified nodules with discontinuity of the 
fibrous cap as a result of bony nodules overlying a calcified plate. Coronary thrombi are found in 
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60% of patients with sudden death. Of these, calcified nodules account for only 2% to 7%. 
Calcification has not been shown to disrupt mechanical stability of coronary atheroma (20). 
CAC, however, is strongly correlated with atherosclerotic plaque burden (21). 
As CAC is a part of late-stage atheromas, the use of statin medication was hoped to retard 
CAC progression. In a recent meta-analysis, statins lowered LDL levels and decreased the size of 
coronary atheromas, but had no effect on CAC (22). It has been speculated that CAC progression 
while individuals are on statins is a benign process that signifies conversion of non-calcified 
plaque to calcified plaque in the absence of worsening atherosclerosis. In those sustaining a CHD 
event, greater CAC progression in statin users compared with non-statin users suggests that this 
is unlikely to be true (13). While CAC is a marker for increased CHD risk, further 
pathophysiologic underpinnings must be elucidated before it can be effectively used as a 
therapeutic target. 
1.2.3 CAC methods of measurement 
The most commonly used technique to quantify CAC is the Agatston scoring system (23). A CT 
density of 130 Hounsfield units with an area of 1 mm2 is set as the threshold for a calcified 
lesion. A density factor is assigned based on the peak x-ray density in Hounsfield units: 1 for 130 
to 199, 2 for 200 to 299, 3 for 300 to 399, and 4 for ≥400. The Agatston unit score (U) is 
calculated by multiplying the area (mm2) by the density factor. The score corresponds with the 
degree of atherosclerotic plaque burden: 0 is none, 1 to 10 is minimal, 11 to 100 is mild, 101 to 
400 is moderate, and >400 is extensive or severe (24). Individuals with even mild atherosclerotic 
disease, or a CAC score between 11 and 100, have an adjusted relative risk for all-cause death of 
2.2, compared with those with no CAC (10). 
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An alternative method is the calcium volume score (CVS). It represents the actual volume 
of CAC as automatically calculated by software. The volume measured with units of mm3 with 
Hounsfield unit greater than 130 is multiplied by a factor of 1,000 in order to express the result 
as a whole number (25). 
1.2.4 CAC methods of progression measurement 
More recently, CAC progression has gained attention as a potential means to identify high risk 
individuals. In a study of subjects without known CHD who underwent annual CAC scoring, 
individuals with a baseline CAC score of 0 had a non-linear development of any CAC on 
subsequent scans (26). By year 5 of follow-up, 11.6% had converted to any CAC. In those who 
converted to any CAC, the mean average ± standard deviation (SD) time to conversion was 4.1 ± 
0.9 years with a mean average ± SD CAC score of 19 ± 19 at the time of conversion. No 
traditional risk factor was associated with conversion. The strongest predictor of CAC 
progression was the presence of any baseline CAC. 
There is no universally accepted method to define significant CAC progression (8). The 
Hokanson, or square root transformed difference, method defines significant change as a square 
root-transformed CAC score of ≥2.5 mm3. It was found to be the best predictor of mortality 
among several methods (12). Other accepted methods include the absolute difference between 
the second and first CAC measurements, the natural logarithm plus 25, and the percent change. 
The time between scans may be accounted for by dividing by the number of years (12). In those 
without CAC at baseline, an annual increase of 5-units in the Agatston score has been associated 
with an adjusted hazard ratio of 1.5 (95% confidence interval (CI), 1.1-2.1) for hard CHD 
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endpoints (13). For those with CAC at baseline, an annual increase of 100-units has been 
associated with an adjusted hazard ratio of 1.3 (95% CI, 1.1-1.5) for hard CHD endpoints. 
1.2.5 Sex differences in CAC 
CAC appears to be delayed in women by approximately one decade (27). This delay is similar to 
that in CHD deaths between women and men, which appears around the time of the menopausal 
transition (7). Significant increases in total cholesterol, LDL-C, and apolipoprotein B occur 
around the time of the final menstrual period (28). 
In a study of 70 men and 70 women, women were less likely to have calcification of 
atherosclerotic lesions compared to men despite similar degrees of luminal narrowing on 
coronary angiography (29). Women were significantly older than men (mean age 60 ± 12 years 
vs. 56 ± 12 years, p<0.05). They were also more likely to have hypertension and diabetes 
mellitus. Screening for CHD using CT may therefore be limited in younger women. 
A large cohort study of 10,746 white men and women without known CHD who 
underwent CAC evaluation highlight some of these differences (30). Among those who had a 
CHD event, women were much more likely to have had a CAC score of 0 compared with men 
(20.4% vs. 2.1%, p<0.01). The median CAC score was also markedly less in women (111 vs. 
634.5). This was despite the fact that women with CHD events were more likely to be older, to 
have hyperlipidemia, to have hypertension, and to have diabetes. The type of CHD events were 
also more significant as 38.8% were CHD deaths or nonfatal myocardial infarctions in women, 
compared with 26.1% in men. These differences highlight the importance of gender in the 
process of studying the atherosclerosis. The presence of even small amounts of CAC appears to 
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portend a more ominous prognosis in females compared to their male counterparts. Ethnicity 
does not appear to alter the predictive ability of CAC score for incident CHD (31). 
1.2.6 Diabetes and CAC 
The mechanism of vascular calcification in diabetes involves the process of arterial medial 
calcification. When present in the vascular extremities of diabetics, it predicts CV mortality and 
complications (32,33). In contrast to discrete plaques seen in intimal type calcification, a uniform 
linear “railroad track” appearance is seen in medial type calcification on radiography. 
Hoff et al. demonstrated that CAC had a greater prevalence and extent in diabetic 
individuals without known CHD, compared with non-diabetics (34). Male diabetics also 
exhibited a greater CAC burden compared with women. Raggi et al. reported that the absence of 
CAC in diabetics is associated with a similar 5-year mortality rate when compared to non-
diabetics (98.8 vs. 99.4%, p = 0.5) (35). A limitation of these two studies was that the diagnosis 
of diabetes was self-reported. No distinction was made between type 1 and type 2 diabetes 
mellitus, and current diabetic treatment was not reported. 
The Coronary Artery Calcification in Type 1 Diabetes (CACT1) study evaluated the 
association between CAC and type 1 diabetes mellitus in 1,420 subjects aged 20-55 years with 
no known CHD (36). The age-adjusted odds ratios (OR) for CAC prevalence for men versus 
women were 4.6 (95% CI, 3.2-6.9) in non-diabetics, and 2.5 (95% CI, 1.7-3.6) in type 1 
diabetics. The difference was diminished on adjustment for traditional risk factors, and then 
eliminated on adjustment for components used to measure insulin resistance. 
From the MESA study, CAC progression was found to be significantly greater in those 
with diabetes compared to those without (37). In those with diabetes and metabolic syndrome, 
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CAC progression was associated with CHD events that included myocardial infarction, angina, 
resuscitated cardiac arrest, or CHD death. 
It is therefore evident that CAC has a higher prevalence in diabetics, compared to non-
diabetes. Diabetics also demonstrate a greater rate of progression. Different pathophysiologic 
mechanisms are known to play a role in CAC development, as evident by different patterns on 
non-invasive imaging. Further insights into these mechanisms may improve preventative care. 
1.3 NOVEL CV RISK FACTORS 
1.3.1 C-reactive protein 
Detection of immune cells and mediators within atheromas led to the current understanding that 
inflammation has a vital role in the atherosclerotic process (38). C-reactive protein (CRP) is a 
protein synthesized mainly in the liver as an acute phase reactant (39). It is a nonspecific marker 
for conditions such as inflammation, infection, tissue damage and malignancy. CRP as a marker 
for atherosclerotic activity has been the subject of considerable investigation in part due to its 
stability, long plasma half-life, and availability of testing. Plasma-derived CRP proteins have 
been found concentrated on the surface of macrophages of ruptured plaques in human coronary 
arteries (40). Pro-inflammatory cytokines resulting from macrophages promote calcification of 
vascular smooth muscle cells (41). The role CRP in atherogenesis and calcification is still not 
well understood, but may involve a feedback amplification loop between persistent inflammatory 
cytokines and osteogenesis. 
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The first reported association between elevated CRP and CAC was from the Framingham 
Offspring Study (42). The 321 subjects were free of known CHD and had a low rate of diabetes. 
The Spearman correlation coefficient remained significant for men (0.19, P<0.05) but not 
women (0.14, P=0.09) after adjusting for age, FRS, and body mass index. A subsequent analysis 
of 3373 subjects enrolled in the Dallas Heart Study did not find a significant association between 
CRP and CAC when adjusted for traditional risk factors, BMI, estrogen, and statin use (43). 
Subsequent analysis from the Dallas Heart Study, however, found that increasing levels of CRP 
were associated with increased CAC prevalence in normal and overweight (but not obese) men, 
and in normal weight women (44). 
A study that combined 1299 subjects with type 2 diabetes mellitus from the Penn 
Diabetes Heart Study and 860 subjects without diabetes from the Study of Inherited Risk of 
Coronary Atherosclerosis assessed the relationships between CRP and CAC based on gender and 
diabetes (45). The associations were significant in diabetic and non-diabetic women, but not in 
men, when adjusted for age and race. This association was only significant in diabetic women 
after including medications, FRS, metabolic syndrome, and BMI into the model. 
Ultimately, the relationship of CRP to CAC among healthy middle-aged women is yet to 
be conclusively established. More study, particularly in those undergoing the menopausal 
transition, is warranted. 
1.3.2 Fibrinogen 
Fibrinogen is a glycoprotein that is mainly synthesized in hepatocytes (46). Synthesis is 
increased in the setting of inflammation. In the setting of vascular injury, fibrinogen plays an 
important role in hemostasis. First, it is an adhesive protein essential for platelet aggregation. 
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Second, it forms an insoluble fibrin clot as part of blood coagulation. In a large meta-analysis, 
fibrinogen has been associated with increased risk for CHD, stroke, vascular mortality, and 
nonvascular mortality (47). 
Histological studies of carotid artery plaques in subjects with prior transient ischemic 
attacks have noted elevated levels of plasma fibrinogen associated with a decrease in cap 
thickness, macrophage infiltration of the cap, and thrombosis (48). In diabetics, elevated 
fibrinogen is associated with a lower rate of clopidogrel-induced adenosine diphosphate receptor 
inhibition on platelet membranes (49). Increasing evidence suggests that activated platelets have 
a role in promoting atherosclerosis (50). 
Fibrinogen degradation products are not seen in normal and early stage atherosclerotic 
lesions, but are present in late stage atherosclerotic lesions using monoclonal antibody 
techniques (51). A positive-feedback loop between calcification and inflammation has been 
noted between microcalcifications and proinflammatory activity from macrophages (52). In a 
cross-sectional study of 354 Caucasian subjects with hypertension, a significant correlation of 
CAC with increasing quintiles of fibrinogen was present in women, but not men (53). Additional 
studies in apparently healthy women that take into account menopausal status may uncover 
important insight into the relationship. 
1.3.3 Plasminogen-activator inhibitor type 1 
Plasminogen-activator inhibitor type 1 (PAI-1) is a glycoprotein synthesized in platelets and 
endothelial cells that serves as a major inhibitor of fibrinolysis (54). Theoretically, inhibition of 
fibrinolysis may lead to an increase in arterial fibrin deposition and thrombosis. The presence of 
coronary artery disease has been associated with decreased fibrinolysis, and believed to be 
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mediated through increased PAI-1 activity (55). Higher concentrations of PAI-1 mRNA have 
been noted in atherosclerotic human arteries compared with normal human arteries, thereby 
suggesting a potential role in atherosclerotic progression (56). 
In a study of 560 subjects with type 1 diabetes and 693 subjects without diabetes, PAI-1 
was independently associated with CAC in those with type 1 diabetes who were 35 years and 
younger (57). PAI-1 expression and activity is enhanced by CRP in human aortic endothelial 
cells in the setting of hyperglycemia (58). Other inflammatory mediators, such as interleukin-6, 
have been demonstrated to increase PAI-1 activity in human adipocytes (59). 
Elevated levels of PAI-1 have been noted in healthy women with insulin resistance 
compared with normal healthy women (60). PAI-1 concentrations are higher in postmenopausal 
women when compared to premenopausal women (61). There are no studies, however, that have 
focused on healthy, midlife women and the relationship of PAI-1 and CAC. 
1.3.4 Tissue plasminogen activator antigen 
Tissue plasminogen activator (tPA) is responsible for endogenous fibrinolysis through 
conversion of plasminogen to plasmin. Measurement of tissue plasminogen activator antigen 
(tPA-ag) levels consists of active free tPA and inert tPA that is bound in activator/inhibitor 
complexes. Elevated levels of tPA-ag, therefore may reflect increased or decreased fibrinolytic 
activity. The British Regional Heart Study demonstrated a significant association between serum 
tPA-ag levels and CHD (62). 
Elevated levels of tPA-ag have been associated with CHD in post-menopausal women 
(63). In a group of women aged 45 years or less with acute myocardial infarction, there was 
significant association between non-fatal myocardial infarction and plasma tPA-ag that was felt 
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to result from reduced fibrinolytic activity (64). To date, there have been no studies to evaluate 
potential associations between tPA-ag and CAC in women. 
1.4 HYPOTHESES 
We conducted a literature review of the associations of CRP, fibrinogen, PAI-1, and tPA-ag with 
baseline CAC and CAC progression (APPENDIX A). Ultimately, questions still remain on the 
role of novel CV risk factors in atherogenesis in women around the menopausal transition. 
We sought to investigate the relationship between the novel CV risk factors CRP, 
fibrinogen, PAI-1, and tPA-ag with baseline CAC and CAC progression in a multicenter 
prospective cohort of middle-age women designed to study the menopausal transition. We also 
sought to examine the association between change in the four novel risk factors and progression 
of CAC. Our hypotheses were that baseline level and change in these biomarkers were associated 
with baseline level and progression of CAC beyond traditional risk factors for CHD. 
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2.0  METHODS 
2.1 STUDY POPULATION 
The Study of Women’s Health Across the Nation (SWAN) is a multicenter, multiethnic 
prospective cohort study in the United States that was designed to examine the menopausal 
transition (65). Seven clinical sites recruited women who were Caucasian and one additional pre-
determined ethnicity (African-Americans in Boston, Chicago, Detroit, Pittsburgh; Chinese in 
Oakland; Hispanic in New Jersey; Japanese in Los Angeles). Eligibility criteria for the SWAN 
parent study included age 42-52 years, an intact uterus, menstruating within the prior 3 months, 
and not using reproductive hormones. Those with a prior hysterectomy or bilateral 
oophorectomy were excluded. 
Two sites, Pittsburgh and Chicago, participated in the SWAN Heart ancillary study. It 
was designed to evaluate the changes in subclinical measures of atherosclerosis during the 
menopausal transition. These two sites, by design, enrolled only self-identified Caucasian and 
African-American women. This present study utilized data from both the baseline and follow-up 
visits of the SWAN Heart study. The baseline SWAN Heart visit occurred during SWAN parent 
study annual visits 4 through 7 (2001-2005) within 3 months after the corresponding annual core 
SWAN assessment (66). The baseline CAC measurement was obtained between years 2001 to 
2003, and the follow-up CAC measurement was obtained between years 2002 to 2005. For the 
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current project, subjects were excluded if they reported myocardial infarction, angina or stroke at 
any of the two evaluated visits (baseline and follow-up SWAN Heart visits); did not have 
baseline levels of CRP, fibrinogen, PAI-1, and tPA-ag; or did not have baseline and follow-up 
CAC measurements. 
 The SWAN Heart cohort originally consisted of 608 women from 2 sites in Chicago and 
1 site in Pittsburgh (Figure 1). Baseline CAC measurement were obtained in 561 subjects. 
Subjects with a history of myocardial infarction, angina, or stroke at the baseline SWAN Heart 
visit were excluded from the present study. One Chicago site did not collect the biomarkers of 
interest for the present analysis. The final sample size for those with both CAC determination 
and novel CV risk factors of interest was therefore 372 subjects. There were 258 subjects with 
baseline and follow-up CAC measurements, and baseline novel CV risk factors. For the change 
in novel risk factors and CAC progression analyses, 223 subjects had CAC measurements and 
biomarkers at baseline and follow-up. 
2.2 CV RISK FACTOR MEASUREMENTS 
Blood pressure was measured twice with a minimum 2-minute rest period between measures, 
with readings taken on the right arm, with the respondent seated and feet flat on the floor for at 
least 5 minutes before the measurement. Respondents had not smoked or consumed any 
caffeinated beverage within 30 minutes of blood pressure measurement. Appropriate cuff size 
was determined based on arm circumference. Two sequential blood pressure values were 
averaged. Smoking was coded into current versus past or never smoker. BMI was derived from 
in-clinic measures of weight and height. 
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Figure 1. Sample size flow chart. 
 
 
Total serum cholesterol, HDL-C, LDL-C, triglycerides, and glucose were determined from a 
fasting blood sample with standard methods described previously (67). The Homeostasis Model 
Assessment (HOMA) insulin resistance index was calculated using the following equation: 
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[insulin x glucose] / 22.5. Glucose in mg/dL was converted to millimoles per liter by multiplying 
by 0.0555. Insulin was in mg/dL. HOMA represents a computer model of the glucose-insulin 
feedback system during a fasting state, specifically regarding the functions of the tissues and 
organs related to glucose regulation. FRS assessment was the summation of all Framingham risk-
related points: age, LDL-C or total cholesterol, HDL-C, blood pressure, diabetes, and smoking 
(2). 
CRP, fibrinogen, PAI-1, and t-PA-ag were all measured in plasma. CRP was measured 
using ultrasensitive rate immunonephelometry (Dade-Behring, Marburg, Germany). Fibrinogen 
was measured in frozen citrated plasma using a clot-based turbidometric detection system (MLA 
ELECTRA 1400C; Medical Laboratory Automation Inc., Mt. Vernon, NY). PAI-1 was measured 
using a solid phased monoclonal antibody and a second enzyme-labeled goat antiserum for 
detection (IMUBIND plasma PAI-1 enzyme-linked immunosorbent assay; American 
Diagnostica, Greenwich, Connecticut). A double antibody in an enzyme-linked immunosorbent 
assay (American Diagnostica) measured t-PA-ag, with a human single chain t-PA-ag as a 
standard calibrated against an international standard (National Institute for Biological Standards 
and Control, Hertfordshire, United Kingdom). 
2.3 CAC MEASUREMENTS 
A CT scanner (C-150 Ultrafast CT Scanner, GE Imatron, San Francisco, California) was used to 
quantify levels of calcification in the coronary arteries. The first pass allowed an evaluation of 
the participant’s anatomy so that the landmarks for the coronary scans were identified. The 
second pass was for the coronary arteries in which 30 to 40 contiguous 3-mm thick transverse 
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images were obtained from the level of the aortic root to the apex of the heart. Images were 
obtained during a maximal breath hold, using electrocardiographic triggering so each 100-
millisecond exposure was obtained during the same phase of the cardiac cycle (60%) of the R-R 
interval. All scan data were saved to an optical disk for central scoring, using a DICOM 
workstation and software by AcuImage, Inc (South San Francisco, California). This software 
program implements the Agatston scoring method (23). CAC is defined as a hyper-attenuating 
lesion >130 Hounsfield units with an area of ≥3 pixels. The Agatston unit (U) score is calculated 
by multiplying the lesion area (mm2) by a density factor (between 1 and 4). The total calcium 
score was the sum of the individual scores for the four major epicardial coronary arteries. Under 
the supervision of a cardiologist, a technologist scored the scans. 
2.4 COVARIATES 
Menopausal status, obtained annually from reported bleeding patterns in the year preceding the 
visit, was categorized as premenopausal (bleeding in previous 3 months with no past year change 
in cycle predictability), early perimenopausal (bleeding the previous 3 months with decrease in 
cycle predictability in the past year), late perimenopausal (<12 to >3 months of amenorrhea), or 
postmenopausal (≥12 months of amenorrhea). Pre-menopausal and early perimenopausal women 
were combined into one group, as were late perimenopausal and post-menopausal women (68). 
For the baseline CAC analyses, surgical menopause was assigned for those who had undergone 
hysterectomy without bilateral oophorectomy. Women last classified as premenopausal or 
perimenopausal who reported taking hormones (oral contraceptives, oral estrogens and/or 
progestins, estrogen injections or patch) in the past year were considered indeterminate status 
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because of the impact of hormone use, even if discontinued, on bleeding patterns. For the CAC 
progression analysis, subjects with surgical menopause were excluded due to small numbers, and 
subjects who were indeterminate status and hormone therapy users were collapsed into a single 
category as hormone therapy users. 
Income was initially reported in eight categories. These were compressed into three 
categories: <$50,000; $50,000-$150,000, and >$150,000. A three level measurement, “how hard 
to make ends meet”, was measured as very hard, somewhat hard, and not very hard. This 
produced similar results to income, so income was used in the final models. Education was 
reported in 5 categories. These were compressed into three categories: high school graduate or 
less, some college or college graduate, and graduate degree.  
The HOMA insulin resistance index and FRS were derived from the SWAN longitudinal 
cardiovascular created variables dataset. All other covariates were derived from the annual 
SWAN interview or examination most closely corresponding to the SWAN HEART baseline. 
Race/ethnicity was determined in response to “How would you describe your primary racial or 
ethnic group?” Other covariates included age, SWAN Heart clinical site, CV medication use 
(blood pressure medication use and cholesterol medication use), diabetes, family history of 
CVD, and current smoking. Diabetes was defined as the use of any medication for diabetes or a 
fasting blood glucose of >125 mg/dl. 
2.5 STATISTICAL ANALYSIS 
Descriptive data was presented as frequencies of subjects for categorical variables and mean with 
standard deviation (SD) for continuous variables, except when skewed. Continuous variables 
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with skewed distributions were presented as median with first quartile (Q1) and third quartile 
(Q3) where indicated. Differences in descriptive data between groups were assessed by the 
Wilcoxon-Mann-Whitney test for continuous variables and the chi-square test for categorical 
variables. Preliminary analyses included examination of the distributions of the continuous 
variables for outliers and violations of the assumptions of normality and the frequencies of the 
categorical variables for small cell size. Test for transformations of data was used as needed. The 
change in risk factor variables was measured as the difference between the follow-up value and 
the baseline value, divided by the time in years between risk factor measurements. A 2-tailed 
value of p<0.05 was considered significant for all analyses. 
Of the four novel CV risk factors, fibrinogen levels were not obtained during SWAN 
annual visits 4 and 6. This missing data was adjusted for with imputation using two methods. In 
the first method, novel CV risk factor values from the prior annual visits were entered for the 
missing values. Values from visit 3 were used for missing visit 4 values, and values from visit 5 
were used for missing visit 6 values. In the second method, novel CV risk factor values from the 
prior annual visit and the subsequent annual visit were averaged and entered for the missing 
baseline values. Averaged values from visits 3 and 5 were used for missing visit 4 values, and 
averaged values from visits 5 and 7 were used for missing visit 6 values. Results from these two 
methods were used for the univariable analysis between novel CV risk factors and CAC 
presence. Both yielded similar results. Results from the first method resulted in greater statistical 
power and was selected for the final analysis.  
Spearman rank order correlations were utilized to examine the associations of the four 
novel CV risk factors with each other. Correlations of BMI and HOMA to the novel biomarkers 
were also examined. CRP, fibrinogen, PAI-1, and tPA-ag had skewed distributions and were 
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therefore log transformed using a base of e. For interpretation, one log unit was equivalent to 2.7 
units of the non-log transformed variable (i.e. 1 log(CRP) = 2.7 mg/L CRP). 
2.5.1 Baseline novel risk factors and presence of baseline CAC analyses 
Baseline CAC was evaluated as both a categorical outcome (presence of calcification), and a 
continuous outcome (extent of calcification). For the baseline CAC presence analyses, presence 
of calcification was analyzed as a two-level variable as those without CAC (CAC score = 0) and 
those with CAC (CAC score >0). Univariable logistic regression analysis was be performed to 
assess the associations between the novel CV risk factors and covariates with the presence of 
CAC. Covariates that were known to be associated with CAC were forced into the adjusted 
models as well as those with p<0.25 in the univariable analysis. Given the design of the study, 
study site and menopausal status were also forced into the models. Due to small numbers, 
diabetes was not used in the adjusted models. 
Multivariable logistic regression was performed using two different strategies. First, 
significant variables from the univariable analysis were introduced in a step-wise fashion. This 
was designated the traditional CV risk factor based models. Second, adjustment was made for the 
aggregate FRS and then other significant variables that were not part of the FRS, and designated 
the FRS based models. Interactions were assessed for race, menopausal status, and BMI on the 
relationships between the CV risk factors and CAC presence after introduction of BMI into the 
adjusted models. Interactions with menopausal status or BMI were not significant. 
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2.5.2 Baseline novel risk factors and extent of baseline CAC analyses 
For the baseline CAC extent analyses, log transformation of the CAC score plus a 
constant of 1 was performed and analyzed as a continuous outcome measure. Univariable tobit 
regression models were used to assess the associations between baseline variables and 
log(CAC+1). This method allowed for retention of subjects with CAC=0 and has been 
previously described (69,70). Multivariable tobit regression was performed using strategies 
described above. Interactions were assessed for race, menopausal status, and BMI on the 
relationships between the CV risk factors and CAC extent after introduction of BMI into the 
adjusted models. 
2.5.3 Baseline novel risk factors and presence of CAC progression analyses 
There is no agreed upon definition of CAC progression in the literature and we observed a 
skewed distribution for CAC progression data with large number of zeros. CAC progression was 
evaluated as both a categorical and continuous variable. 
For the presence of CAC progression analyses, a dichotomous variable of significant 
progression was created. Significant progression of CAC was defined as CAC >0 at follow-up in 
subjects with CAC = 0 at baseline, an annualized change of ≥10 U in subjects with 0<CAC<100 
at baseline, and annualized percent change ≥10% at follow-up in subjects with CAC ≥100 at 
baseline. This definition has been previously used in a study of low-risk subjects from the 
Coronary Artery Risk Development in Young Adults (CARDIA) study and MESA (71). Logistic 
regression was used to determine OR and 95% CI between novel CV risk factors and CAC 
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progression. Multivariable analyses were performed using strategies previously described in the 
baseline CAC analyses, with the addition of baseline CAC. 
2.5.4 Baseline novel risk factors and extent of CAC progression analyses 
Extent of CAC progression as a continuous outcome was assessed as the log transformed 
difference between the second and first CAC measurement plus a constant of 25 (72): 
 
[log(CAC(follow-up)+25) – log(CAC(baseline)+25)] / time (years) between first and second scans 
 
This method, known as the “MESA method”, has been shown to predict all-cause mortality (12). 
Univariable linear regression models were used to assess the significance between novel CV risk 
factors and change in the log-transformed CAC. Multivariable analyses were performed using 
strategies previously described in the baseline CAC analyses. 
2.5.5 Change in novel risk factors and CAC progression analyses 
The relationships between the change in CRP, fibrinogen, PAI-1, and tPA-ag with the presence 
and extent of CAC progression were evaluated. Change in the novel CV risk factors was 
calculated by the difference between the follow-up and baseline values, divided by the time 
between the visits corresponding to when the CAC measurements were performed. 
 Logistic regression analyses were performed for the outcome variable of presence of 
CAC progression based on the definition described above. Linear regression analyses were 
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performed for the continuous outcome of extent of CAC progression based on the MESA method 
described above (72). Univariable and multivariable analyses were performed for both. 
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3.0  RESULTS 
3.1 BASELINE CHARACTERISTICS OF THE BASELINE CAC POPULATION 
The characteristics of the population by presence of CAC at baseline are listed in Table 1. There 
were 372 subjects with baseline CAC and novel CV risk factor measurements available. The 
mean age of the population was 51.3 ± 2.8 years. The racial distribution was 35.2% black and 
64.8% white. CAC was present in 184 (49.5%) subjects of the study population. For those with 
CAC, the median Agatston score was 8.6 U with a range from 1.0 U to 598.6 U. 
Subjects with CAC present had a worse CV risk profile when compared to subjects 
without CAC. They were older and had a higher systolic blood pressure (SBP), BMI, LDL-C, 
triglycerides, and FRS. They had lower HDL-C. As a result, they were more likely to have used 
medications to control hypertension and hyperlipidemia. All four novel CV risk factors were also 
significantly higher in those with baseline CAC present. There was no significant difference 
between the two groups in relation to menopausal status or hormone therapy. 
There were no significant differences in socio-economic status covariates of income and 
education between groups with and without the presence of CAC. Approximately one-fourth of 
women had an income of >$100,000 per year and nearly one-third had a graduate degree. 
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Table 1. Baseline characteristics of the baseline CAC study population by the presence and absence 
of baseline CAC. 
 
Total CAC = 0 CAC >0 
 Characteristics n = 372 n = 188 n = 184 P value* 
Age at baseline CAC, mean (SD), y 51.3 (2.8) 50.9 (2.8) 51.6 (2.7) 0.005 
Site, n (%) 
   
0.5 
   Chicago, site 13 160 (43.0) 78 (41.5) 82 (44.6) 
    Pittsburgh, site 17 212 (57.0) 110 (58.5) 102 (55.4) 
 Race, n (%) 
   
0.004 
   Black 131 (35.2) 53 (28.2) 78 (42.3) 
    White 241 (64.8) 135 (71.8) 106 (57.6) 
 Menopausal status, n (%) 
   
0.7 
   Pre- and early perimenopausal 200 (53.8) 106 (56.4) 94 (51.1) 
    Late peri- and postmenopausal 141 (37.9) 66 (35.1) 75 (40.8) 
    Surgical menopause 12 (3.2) 7 (3.7) 5 (2.7) 
    Indeterminate 19 (5.1) 9 (4.8) 10 (5.4) 
 Income, n (%) 
   
0.1 
   <$50,000 121 (32.7) 55 (29.3) 66 (36.3) 
    $50,000-$100,000 154 (41.62) 77 (41.0) 77 (42.3) 
    >$100,000 95 (25.7) 56 (29.8) 39 (21.4) 
 Education, n (%) 
   
0.4 
   High school or less 58 (15.6) 25 (13.3) 33 (17.9) 
    Some college or college 192 (51.6) 102 (54.3) 90 (48.9) 
    Graduate 122 (32.8) 61 (32.5) 61 (33.2) 
 SBP, mean (SD), mmHg 118.4 (17.1) 113.3 (14.7) 123.5 (18.0) <0.0001 
BMI, mean (SD), kg/m2 29.4 (6.4) 25.7 (3.6) 33.0 (6.5) <0.0001 
HDL-C, mean (SD), mg/dL 57.4 (14.3) 60.4 (14.6) 54.5 (13.4) <0.0001 
LDL-C, mean (SD), mg/dL 119.9 (33.2) 116.0 (29.8) 123.9 (36.0) 0.03 
Triglycerides, median (Q1, Q3), 
mg/dL 99.0 (75.5, 137.5) 91.0 (70.0, 119.5) 116.5 (84.0, 170.0) <0.0001 
Hormone therapy, n (%) 55 (14.8) 31 (16.5) 24 (13.0) 0.3 
CV medication use, n (%) 81 (21.8) 24 (12.8) 57 (31.0) <0.0001 
Diabetes, n (%) 18 (4.8) 6 (3.2) 12 (6.5) 0.1 
Family history of CV disease, n (%) 251 (67.5) 118 (62.8) 133 (72.3) 0.05 
Current smoking, n (%) 50 (13.4) 29 (15.4) 21 (11.4) 0.3 
HOMA, median (Q1, Q3) 2.0 (1.5, 3.1) 1.6 (1.3, 2.2) 2.8 (1.8, 4.7) <0.0001 
FRS, mean (SD) 10.3 (3.5) 9.5 (3.3) 11.1 (3.5) <0.0001 
CRP, median (Q1, Q3), mg/L 2.1 (0.8, 5.6) 1.3 (0.6, 2.9) 3.9 (1.3, 8.0) <0.0001 
Fibrinogen, median (Q1, Q3), mg/dL 279 (242, 316) 262 (230, 300) 279 (256, 316) 0.0005 
PAI-1, median (Q1, Q3), ng/mL 13.2 (7.8, 24.7) 10.6 (6.8, 19.2) 18.2 (9.2, 32.4) <0.0001 
tPA-ag, median (Q1, Q3), ng/mL 6.8 (5.2, 9.3) 6.3 (4.7, 7.6) 8.1 (6.0, 10.4) <0.0001 
* P-value for CAC groups - Wilcoxon rank-sum test for continuous variables; Χ2 test for categorical variables 
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Spearman correlation coefficients demonstrated significant correlations between all four 
novel biomarkers, as well as BMI and HOMA, with the exception of fibrinogen and PAI-1 
(Table 2). There was a moderate correlation between CRP and fibrinogen and a moderate-to-
strong correlation between PAI-1 and tPA-ag. 
 
Table 2. Spearman correlation coefficients between baseline novel CV risk factors, BMI, and HOMA to 
baseline novel CV risk factors. 
  CRP (P value) Fibrinogen (P value) PAI-1 (P value) tPA-ag (P value) 
CRP, mg/dL 1.00 0.46 (<0.0001) 0.33 (<0.0001) 0.33 (<0.0001) 
Fibrinogen, mg/dL 
 
1.00 0.1 (0.07) 0.22 (<0.0001) 
PAI-1, ng/mL 
  
1.00 0.6 (<0.0001) 
tPA-ag, ng/mL 
   
1.00 
BMI, kg/m2 0.53 (<0.0001) 0.31 (<0.0001) 0.43 (<0.0001) 0.44 (<0.0001) 
HOMA 0.43 (<0.0001) 0.17 (0.004) 0.43 (<0.0001) 0.49 (<0.0001) 
3.2 BASELINE NOVEL BIOMARKERS AND THE PRESENCE OF BASELINE CAC 
Results of the univariable logistic regression analyses for the presence of baseline CAC are listed 
in Table 3. Older age was associated with increased odds of CAC presence. The odds of white 
race being positive for CAC was significantly lower compared to black race (OR, 0.53; 95% CI, 
0.35-0.82, p=0.004). Higher SBP, BMI, LDL-C levels, triglyceride levels, and CV medication 
use, and lower HDL-C levels were all associated with increased odds of CAC presence 
(p≤0.0003). The log-transformed values of all four novel CV risk factors had significant positive 
associations with CAC presence. 
Multivariable logistic regression with individual traditional CV risk factors demonstrated 
significant associations between novel CV risk factors and the presence of CAC after adjusting 
for age, study site, race, menopausal status, income, education, and SBP (Table 4). None of 
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these associations were significant after adjusting for BMI. Using the FRS based strategy, the 
associations between novel CV risk factors and the presence of CAC remained significant after 
adjusting for FRS, study site, race, menopausal status, income, and education (Table 5). 
Similarly, none of the associations were significant after introduction of BMI into the models. 
Effect modification for race, menopausal status, and BMI on novel CV risk factors and 
CAC presence was tested. There was a significant interaction with race on the relationship 
between log(CRP) and presence of CAC. Stratified analyses were performed on the relationship 
between log(CRP) and presence of CAC by race using the traditional CV risk factor based 
models (Table 6) and the FRS based models (Table 7). The models were similar. 
In black women, the significant association of log(CRP) to CAC presence remained even 
after introduction of BMI, log(HOMA), family history of CV disease, lipids, CV medication use 
and current smoking in the traditional model (OR, 3.38; 95% CI, 1.51-7.58; p=0.003); and BMI, 
log(HOMA), family history of CV disease, and CV medication use in the FRS based model (OR, 
3.25; 95% CI, 1.53-6.90; p=0.002). In white women, the relationship between log(CRP) and 
presence of CAC was similar to that seen in the total population in both the final multivariable 
traditional model (OR, 0.91; 95% CI 0.63-1.30; p=0.6) and the FRS based model (OR, 0.87; 
95% CI, 0.62-1.23; p=0.4). 
In the final multivariable models for the four novel CV risk factors, the strongest 
relationship with presence of CAC was related to BMI (p<0.0001 for all). This was present in 
both the traditional CV risk factor based models and the FRS based models. Log(HOMA) was 
significant in all traditional models (p≤0.02 for all) and for 3 of the risk factors in the FRS based 
models (p≤0.04 for all, except p=0.1 for log(PAI-1)). Family history of CV disease was 
significant in all models (p≤0.02 for all). 
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Table 3. Univariable logistic regression analyses between baseline characteristics and the presence and 
absence of baseline CAC. 
  n Odds Ratio 95% CI P Value C 
Age, y 372 1.10 1.03-1.19 0.009 0.583 
Sitea 372 0.88 0.59-1.33 0.5 0.515 
Raceb 372 0.53 0.35-0.82 0.004 0.571 
Menopausal statusc 372 
  
0.1 0.534 
  Late peri- and postmenopausal 
 
1.28 0.83-1.97 0.3 
   Surgical menopause 
 
0.81 0.25-2.62 0.7 
   Indeterminate 
 
1.25 0.49-3.22 0.6 
 Incomed 370 
  
0.1 0.554 
   $50,000-$100,000 
 
0.83 0.52-1.34 0.5 
    >$100,000 
 
0.58 0.34-1.00 0.05 
 Educatione 372 
  
0.4 0.534 
   Some college or college 
 
0.67 0.37-1.21 0.2 
    Graduate 
 
0.76 0.40-1.42 0.4 
 SBP, mmHg 372 1.04 1.03-1.06 <0.0001 0.672 
BMI, kg/m2 372 1.32 1.24-1.34 <0.0001 0.833 
HDL-C, mg/dL 372 0.97 0.95-0.99 0.0001 0.636 
LDL-C, mg/dL 372 1.01 1.00-1.01 0.02 0.564 
Log(Triglycerides), log mg/dL 372 2.88 1.80-4.61 <0.0001 0.639 
Hormone therapy 372 0.76 0.43-1.35 0.4 0.517 
CV medication use 372 3.07 1.81-5.21 <0.0001 0.591 
Diabetes 372 2.12 0.78-5.76 0.1 0.517 
Family history of CV disease 372 1.55 1.00-2.40 0.05 0.548 
Current smoking 372 0.71 0.39-1.29 0.3 0.520 
Log(HOMA) 336 5.52 3.41-8.94 <0.0001 0.750 
FRS 341 1.15 1.08-1.23 <0.0001 0.645 
Log(CRP), log mg/L 367 1.91 1.58-2.32 <0.0001 0.712 
Log(Fibrinogen), log mg/dL 317 8.19 2.61-25.72 0.0003 0.613 
Log(PAI-1), log ng/mL 356 1.67 1.31-2.12 <0.0001 0.640 
Log(tPA-ag), log ng/mL 357 3.67 2.16-6.25 <0.0001 0.668 
asite 17 versus site 13; bWhite versus Black; c Referenced to pre- and early perimenopausal; 
dReferenced to <$50,000; eReferenced to high school or less 
1 Log(biomarker) = 2.7 non-log transformed value 
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Table 4. Multivariable logistic regression analyses between baseline novel CV risk factors and the presence 
and absence of baseline CAC using traditional CV risk factor based models. 
 
n Odds Ratio 95% CI P Value C 
Model 1: Age, Site, Race 
   Log(CRP), log mg/L 367 1.84 1.51-2.24 <0.0001 0.723 
   Log(Fibrinogen), log mg/dL 317 6.16 1.91-19.89 0.002 0.640 
   Log(PAI-1), log ng/mL 356 1.71 1.33-2.19 <0.0001 0.683 
   Log(tPA-ag), log ng/mL 357 3.54 2.04-6.14 <0.0001 0.691 
Model 2: Age, Site, Race, Menopausal status 
   Log(CRP), log mg/L 367 1.85 1.52-2.26 <0.0001 0.724 
   Log(Fibrinogen), log mg/dL 317 6.32 1.94-20.57 0.002 0.649 
   Log(PAI-1), log ng/mL 356 1.74 1.35-2.24 <0.0001 0.691 
   Log(tPA-ag), log ng/mL 357 3.81 2.16-6.70 <0.0001 0.700 
Model 3: Age, Site, Race, Menopausal status, Income, Education 
   Log(CRP), log mg/L 365 1.88 1.53-2.30 <0.0001 0.733 
   Log(Fibrinogen), log mg/dL 315 6.32 1.91-20.94 0.003 0.670 
   Log(PAI-1), log ng/mL 354 1.73 1.34-2.24 <0.0001 0.695 
   Log(tPA-ag), log ng/mL 355 3.77 2.13-6.70 <0.0001 0.710 
Model 4: Age, Site, Race, Menopausal status, Income, Education, SBP 
   Log(CRP), log mg/L 365 1.80 1.46-2.21 <0.0001 0.762 
   Log(Fibrinogen), log mg/dL 315 5.88 1.70-20.39 0.005 0.724 
   Log(PAI-1), log ng/mL 354 1.56 1.20-2.03 0.001 0.730 
   Log(tPA-ag), log ng/mL 355 3.17 1.76-5.72 0.0001 0.745 
Model 5: Age, Site, Race, Menopausal status, Income, Education, SBP, BMI 
   Log(CRP), log mg/L 365 1.15 0.89-1.48 0.3 0.851 
   Log(Fibrinogen), log mg/dL 315 1.49 0.33-6.62 0.6 0.850 
   Log(PAI-1), log ng/mL 354 0.97 0.71-1.32 0.8 0.849 
   Log(tPA-ag), log ng/mL 355 1.15 0.60-2.21 0.7 0.848 
Model 6: Age, Site, Race, Menopausal status, Income, Education, SBP, BMI, Log(HOMA) 
   Log(CRP), log mg/L 331 1.17 0.89-1.53 0.3 0.864 
   Log(Fibrinogen), log mg/dL 282 2.64 0.52-13.47 0.2 0.866 
   Log(PAI-1), log ng/mL 319 0.87 0.61-1.25 0.5 0.865 
   Log(tPA-ag), log ng/mL 320 0.94 0.48-1.84 0.9 0.863 
Model 7: Age, Site, Race, Menopausal status, Income, Education, SBP, BMI, Log(HOMA), Family history 
   Log(CRP), log mg/L 331 1.16 0.88-1.52 0.3 0.870 
   Log(Fibrinogen), log mg/dL 282 2.36 0.46-12.25 0.3 0.872 
   Log(PAI-1), log ng/mL 319 0.81 0.56-1.17 0.3 0.872 
   Log(tPA-ag), log ng/mL 320 0.78 0.39-1.57 0.5 0.869 
Model 8: Age, Site, Race, Menopausal status, Income, Education, SBP, BMI, Log(HOMA), Family history, 
HDL-C, LDL-C, Log(Triglycerides) 
   Log(CRP), log mg/L 331 1.22 0.92-1.61 0.2 0.874 
   Log(Fibrinogen), log mg/dL 282 2.18 0.41-11.57 0.4 0.878 
   Log(PAI-1), log ng/mL 319 0.84 0.58-1.23 0.4 0.874 
   Log(tPA-ag), log ng/mL 320 0.87 0.42-1.79 0.7 0.874 
Model 9: Age, Site, Race, Menopausal status, Income, Education, SBP, BMI, Log(HOMA), Family history, 
HDL-C, LDL-C, Log(Triglycerides), CV medication use, Current smoking 
   Log(CRP), log mg/L 331 1.23 0.92-1.64 0.2 0.873 
   Log(Fibrinogen), log mg/dL 282 2.26 0.42-12.12 0.3 0.878 
   Log(PAI-1), log ng/mL 319 0.84 0.57-1.23 0.4 0.874 
   Log(tPA-ag), log ng/mL 320 0.86 0.42-1.78 0.7 0.874 
1 Log(biomarker) = 2.7 non-log transformed value 
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Table 5. Multivariable logistic regression analyses between baseline novel CV risk factors and the presence or 
absence of baseline CAC using FRS based models. 
 
n Odds Ratio 95% CI P Value C 
Model 1: FRS, Site, Race 
   Log(CRP), log mg/L 339 1.84 1.50-2.25 <0.0001 0.739 
   Log(Fibrinogen), log mg/dL 292 6.45 1.91-21.77 0.003 0.660 
   Log(PAI-1), log ng/mL 327 1.67 1.28-2.16 0.0001 0.689 
   Log(tPA-ag), log ng/mL 328 3.37 1.93-5.89 <0.0001 0.707 
Model 2: FRS, Site, Race, Menopausal status 
   Log(CRP), log mg/L 339 1.86 1.51-2.28 <0.0001 0.740 
   Log(Fibrinogen), log mg/dL 292 6.97 2.04-23.89 0.002 0.676 
   Log(PAI-1), log ng/mL 327 1.70 1.31-2.21 <0.0001 0.700 
   Log(tPA-ag), log ng/mL 328 3.64 2.06-6.46 <0.0001 0.720 
Model 3: FRS, Site, Race, Menopausal status, Income, Education 
   Log(CRP), log mg/L 337 1.86 1.52-2.31 <0.0001 0.753 
   Log(Fibrinogen), log mg/dL 290 7.07 2.01-24.94 0.002 0.695 
   Log(PAI-1), log ng/mL 325 1.72 1.32-2.25 <0.0001 0.712 
   Log(tPA-ag), log ng/mL 326 3.74 2.08-6.74 <0.0001 0.731 
Model 4: FRS, Site, Race, Menopausal status, Income, Education, BMI 
   Log(CRP), log mg/L 337 1.19 0.92-1.54 0.2 0.849 
   Log(Fibrinogen), log mg/dL 290 1.60 0.34-7.52 0.6 0.845 
   Log(PAI-1), log ng/mL 325 1.04 0.75-1.44 0.8 0.843 
   Log(tPA-ag), log ng/mL 326 1.36 0.70-2.61 0.4 0.844 
Model 5: FRS, Site, Race, Menopausal status, Income, Education, BMI, Log(HOMA) 
   Log(CRP), log mg/L 305 1.16 0.88-1.52 0.3 0.855 
   Log(Fibrinogen), log mg/dL 259 2.37 0.46-13.33 0.3 0.857 
   Log(PAI-1), log ng/mL 292 0.91 0.63-1.32 0.6 0.856 
   Log(tPA-ag), log ng/mL 293 1.07 0.54-2.13 0.9 0.856 
Model 6: FRS, Site, Race, Menopausal status, Income, Education, BMI, Log(HOMA), Family history, 
   Log(CRP), log mg/L 305 1.15 0.88-1.52 0.3 0.863 
   Log(Fibrinogen), log mg/dL 259 2.23 0.40-12.29 0.4 0.865 
   Log(PAI-1), log ng/mL 292 0.83 0.57-1.22 0.3 0.863 
   Log(tPA-ag), log ng/mL 293 0.88 0.43-1.79 0.7 0.863 
Model 7: FRS, Site, Race, Menopausal status, Income, Education, BMI, Log(HOMA), Family history, 
CV medication use 
   Log(CRP), log mg/L 305 1.16 0.88-1.53 0.3 0.863 
   Log(Fibrinogen), log mg/dL 259 2.22 0.40-12.28 0.4 0.865 
   Log(PAI-1), log ng/mL 292 0.83 0.57-1.22 0.3 0.863 
   Log(tPA-ag), log ng/mL 293 0.88 0.43-1.79 0.7 0.865 
1 Log(biomarker) = 2.7 non-log transformed value 
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Table 6. Multivariable logistic regression analyses between baseline novel CV risk factors and the presence 
and absence of baseline CAC using traditional CV risk factor based models by race. 
 
n Odds Ratio 95% CI P Value C 
Unadjusted 
   Log(CRP), log mg/L - Black 131 2.41 1.68-3.47 <0.0001 0.761 
   Log(CRP), log mg/L - White 236 1.65 1.31-2.08 <0.0001 0.670 
Model 1: Age, Site 
   Log(CRP), log mg/L - Black 131 2.41 1.67-3.47 <0.0001 0.768 
   Log(CRP), log mg/L - White 236 1.60 1.26-2.02 0.0001 0.674 
Model 2: Age, Site, Menopausal status 
   Log(CRP), log mg/L - Black 131 2.41 1.66-3.49 <0.0001 0.767 
   Log(CRP), log mg/L - White 236 1.62 1.27-2.05 <0.0001 0.682 
Model 3: Age, Site, Menopausal status, Income, Education 
   Log(CRP), log mg/L - Black 130 2.43 1.66-3.55 <0.0001 0.778 
   Log(CRP), log mg/L - White 235 1.65 1.29-2.11 <0.0001 0.692 
Model 4: age, site, menopausal status, income, education, SBP 
   Log(CRP), log mg/L - Black 130 2.41 1.62-3.59 <0.0001 0.802 
   Log(CRP), log mg/L - White 235 1.54 1.20-1.98 0.0008 0.749 
Model 5: Age, Site, Menopausal status, Income, Education, SBP, BMI 
   Log(CRP), log mg/L - Black 130 1.66 1.01-2.71 0.05 0.896 
   Log(CRP), log mg/L - White 235 0.93 0.67-1.28 0.6 0.835 
Model 6: Age, Site, Menopausal status, Income, Education, SBP, BMI, Log(HOMA) 
   Log(CRP), log mg/L - Black 119 2.58 1.34-4.96 0.005 0.932 
   Log(CRP), log mg/L - White 212 0.87 0.62-1.22 0.4 0.831 
Model 7: Age, Site, Menopausal status, Income, Education, SBP, BMI, Log(HOMA), Family history 
   Log(CRP), log mg/L - Black 119 2.56 1.33-4.94 0.005 0.932 
   Log(CRP), log mg/L - White 212 0.86 0.61-1.22 0.4 0.841 
Model 8: Age, Site, Menopausal status, Income, Education, SBP, BMI, Log(HOMA), Family history, 
HDL-C, LDL-C, Log(Triglycerides) 
   Log(CRP), log mg/L - Black 119 3.00 1.42-6.31 0.004 0.941 
   Log(CRP), log mg/L - White 212 0.90 0.63-1.29 0.6 0.847 
Model 9: Age, Site, Menopausal status, Income, Education, SBP, BMI, Log(HOMA), Family history, 
HDL-C, LDL-C, Log(Triglycerides), CV medication use, Current smoking 
   Log(CRP), log mg/L - Black 119 3.38 1.51-7.58 0.003 0.946 
   Log(CRP), log mg/L - White 212 0.91 0.63-1.30 0.6 0.849 
1 Log(CRP) = 2.7 non-log transformed value 
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Table 7. Multivariable logistic regression analyses between baseline novel CV risk factors and the presence 
and absence of baseline CAC using FRS based models by race. 
 
n Odds Ratio 95% CI P Value C 
Unadjusted 
   Log(CRP), log mg/L - Black 131 2.41 1.68-3.47 <0.0001 0.761 
   Log(CRP), log mg/L - White 236 1.65 1.31-2.08 <0.0001 0.670 
Model 1: FRS, Site 
   Log(CRP), log mg/L - Black 115 2.76 1.81-4.22 <0.0001 0.808 
   Log(CRP), log mg/L - White 224 1.56 1.23-1.97 0.0002 0.696 
Model 2: FRS, Site, Menopausal status 
   Log(CRP), log mg/L - Black 115 2.70 1.77-4.14 <0.0001 0.810 
   Log(CRP), log mg/L - White 224 1.60 1.26-2.03 0.0001 0.705 
Model 3: FRS, Site, Menopausal status, Income, Education 
   Log(CRP), log mg/L - Black 114 2.79 1.79-4.35 <0.0001 0.835 
   Log(CRP), log mg/L - White 223 1.61 1.26-2.06 0.0002 0.717 
Model 4: FRS, Site, Menopausal status, Income, Education, BMI 
   Log(CRP), log mg/L - Black 114 2.33 1.32-4.14 0.004 0.916 
   Log(CRP), log mg/L - White 223 0.94 0.68-1.30 0.7 0.825 
Model 5: FRS, Site, Menopausal status, Income, Education, BMI, Log(HOMA) 
   Log(CRP), log mg/L - Black 105 2.86 1.44-5.68 0.003 0.934 
   Log(CRP), log mg/L - White 200 0.88 0.63-1.23 0.5 0.825 
Model 6: FRS, Site, Menopausal status, Income, Education, BMI, Log(HOMA), Family history 
   Log(CRP), log mg/L - Black 105 3.18 1.53-6.63 0.002 0.941 
   Log(CRP), log mg/L - White 200 0.87 0.62-1.22 0.4 0.834 
Model 7: FRS, Site, Menopausal status, Income, Education, BMI, Log(HOMA), Family history, 
CV medication use 
   Log(CRP), log mg/L - Black 105 3.25 1.53-6.90 0.002 0.942 
   Log(CRP), log mg/L - White 200 0.87 0.62-1.23 0.4 0.837 
1 Log(CRP) = 2.7 non-log transformed value 
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3.3 BASELINE NOVEL BIOMARKERS AND THE EXTENT OF BASELINE CAC 
Univariable tobit regression analyses for the relationships between baseline variables and 
baseline log(CAC+1) as a continuous variable demonstrated significant positive correlations for 
age, race, SBP, BMI, HDL-C level, LDL-C level, log(triglyceride) level, CV medication use, 
diabetes, log(HOMA), FRS, and the four novel CV risk factors (Table 8). In the adjusted 
traditional CV risk factor based models, all novel biomarkers were significantly associated with 
extent of CAC after adjusting for age, study site, race, menopausal status, income, education, and 
SBP (Table 9). None had significant associations after the introduction of BMI. Similar results 
were demonstrated in the FRS based models (Table 10). 
Tests for interactions for race, menopausal status, and BMI on the relationship between 
the four novel CV risk factors and CAC extent were significant for race on the relationship 
between log(CRP) and CAC. In the univariable analyses, log(CRP) was significantly associated 
with baseline CAC extent in both black and white women (<0.0001) (Table 11). These 
relationships held in multivariable traditional models when adjusted for age, study site, 
menopausal status, income, education, and SBP in both black and white women. Upon 
introduction of BMI, the association was significant in blacks but not whites. The introduction of 
log(HOMA), family history of CV disease, HDL-C, LDL-C, log(triglycerides), CV medication 
use, and current smoking yielded similar results. Black women had a significant association of 
log(CRP) with log(CAC+1) (parameter estimate (β), 0.464; standard error (SE), 0.134; 
p=0.0006) whereas white women did not (β, -0.103; SE, 0.201; p=0.6). 
In the multivariable FRS based models, log(CRP) was significantly associated with 
baseline log(CAC+1) after adjusting for FRS, site, menopausal status, income, and education in 
both black (p<0.0001) and white women (p=0.0005) (Table 12). Introducing BMI into the 
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models attenuated the relationship in white women (p=0.9), but the relationship was still 
significant in black women (p=0.0005). After adding log(HOMA), family history, and CV 
medication use, the relationship of log(CRP) and baseline(CAC+1) was still significant in blacks 
(β, 0.488; SE, 0.141; p=0.0005), but not whites (β, -0.088; SE, 0.198; p=0.7). 
In the final adjusted models, BMI was the covariate that was most strongly associated 
with extent of CAC at baseline (p<0.0001). Age was significant in the traditional CV risk factor 
based models for all novel biomarkers (p≤0.02), except for log(CRP). The FRS also had a strong 
association (p≤0.002). Log(HOMA) had a borderline association with log(CRP) in the traditional 
model and FRS based model with p=0.06 and p=0.07, respectively. The associations of 
log(HOMA) to log(fibrinogen), log(PAI-1), and log(tPA-ag) were significant. 
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Table 8. Univariable tobit regression analyses between baseline characteristics and the extent of baseline 
CAC. 
  n Parameter Estimate Standard Error P value 
Age, y 372 0.191 0.055 0.0005 
Sitea 372 -0.091 0.312 0.8 
Raceb 372 -0.696 0.321 0.03 
Menopausal statusc 372 
     Late peri- and postmenopausal 
 
0.525 0.326 0.1 
  Surgical menopause 
 
0.370 0.894 0.7 
  Indeterminate 
 
0.315 0.708 0.7 
Incomed 370 
      $50,000-$100,000 
 
-0.080 0.360 0.8 
   >$100,000 
 
-0.583 0.416 0.2 
Educatione 372 
      Some college or college 
 
-0.746 0.437 0.09 
   Graduate 
 
-0.634 0.465 0.2 
SBP, mmHg 372 0.051 0.009 <0.0001 
BMI, kg/m2 372 0.232 0.021 <0.0001 
HDL-C, mg/dL 372 -0.510 0.011 <0.0001 
LDL-C, mg/dL 372 0.011 0.004 0.01 
Log(Triglycerides), log mg/dL 372 1.710 0.306 <0.0001 
Hormone therapy 372 -0.405 0.444 0.4 
CV medication use 372 1.317 0.358 0.0002 
Diabetes 372 1.430 0.681 0.04 
Family history of CV disease 372 0.439 0.335 0.2 
Current smoking 372 -0.166 0.462 0.7 
Log(HOMA) 336 1.721 0.232 <0.0001 
FRS 341 0.235 0.044 <0.0001 
Log(CRP), log mg/L 367 0.804 0.123 <0.0001 
Log(Fibrinogen), log mg/dL 317 2.905 0.797 0.0003 
Log(PAI-1), log ng/mL 356 0.764 0.165 <0.0001 
Log(tPA-ag), log ng/mL 357 1.461 0.301 <0.0001 
asite 17 versus site 13; bWhite versus Black; cReferenced to pre- and early perimenopausal; 
dReferenced to <$50,000; eReferenced to high school or less 
1 Log(biomarker) = 2.7 non-log transformed value 
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Table 9. Multivariable tobit regression analyses between baseline novel CV risk factors and the extent of 
baseline CAC using traditional CV risk factor based models. 
  n Parameter Estimate Standard Error P value 
Model 1: Age, Site, Race 
   Log(CRP), log mg/L 367 0.725 0.125 <0.0001 
   Log(Fibrinogen), log mg/dL 317 2.447 0.806 0.002 
   Log(PAI-1), log ng/mL 356 0.777 0.164 <0.0001 
   Log(tPA-ag), log ng/mL 357 1.343 0.297 <0.0001 
Model 2: Age, Site, Race, Menopausal status 
   Log(CRP), log mg/L 367 0.737 0.125 <0.0001 
   Log(Fibrinogen), log mg/dL 317 2.414 0.806 0.003 
   Log(PAI-1), log ng/mL 356 0.805 0.165 <0.0001 
   Log(tPA-ag), log ng/mL 357 1.422 0.301 <0.0001 
Model 3: Age, Site, Race, Menopausal status, Income, Education 
   Log(CRP), log mg/L 365 0.759 0.128 <0.0001 
   Log(Fibrinogen), log mg/dL 315 2.296 0.808 0.005 
   Log(PAI-1), log ng/mL 354 0.826 0.167 <0.0001 
   Log(tPA-ag), log ng/mL 355 1.407 0.305 <0.0001 
Model 4: Age, Site, Race, Menopausal status, Income, Education, SBP 
   Log(CRP), log mg/L 365 0.645 0.125 <0.0001 
   Log(Fibrinogen), log mg/dL 315 2.085 0.774 0.007 
   Log(PAI-1), log ng/mL 354 0.670 0.162 <0.0001 
   Log(tPA-ag), log ng/mL 355 1.131 0.296 0.0001 
Model 5: Age, Site, Race, Menopausal status, Income, Education, SBP, BMI 
   Log(CRP), log mg/L 365 0.157 0.121 0.2 
   Log(Fibrinogen), log mg/dL 315 0.609 0.695 0.4 
   Log(PAI-1), log ng/mL 354 0.204 0.151 0.2 
   Log(tPA-ag), log ng/mL 355 0.270 0.272 0.3 
Model 6: Age, Site, Race, Menopausal status, Income, Education, SBP, BMI, Log(HOMA) 
   Log(CRP), log mg/L 331 0.135 0.125 0.3 
   Log(Fibrinogen), log mg/dL 282 1.046 0.689 0.1 
   Log(PAI-1), log ng/mL 319 0.097 0.161 0.5 
   Log(tPA-ag), log ng/mL 320 0.124 0.277 0.7 
Model 7: Age, Site, Race, Menopausal status, Income, Education, SBP, BMI, Log(HOMA), Family history 
   Log(CRP), log mg/L 331 0.132 0.125 0.3 
   Log(Fibrinogen), log mg/dL 282 1.032 0.687 0.1 
   Log(PAI-1), log ng/mL 319 0.070 0.162 0.7 
   Log(tPA-ag), log ng/mL 320 0.048 0.278 0.9 
Model 8: Age, Site, Race, Menopausal status, Income, Education, SBP, BMI, Log(HOMA), Family history, 
HDL-C, LDL-C, Log(Triglycerides) 
   Log(CRP), log mg/L 331 0.159 0.126 0.2 
   Log(Fibrinogen), log mg/dL 282 0.997 0.688 0.1 
   Log(PAI-1), log ng/mL 319 0.054 0.162 0.7 
   Log(tPA-ag), log ng/mL 320 -0.009 0.283 1.0 
Model 9: Age, Site, Race, Menopausal status, Income, Education, SBP, BMI, Log(HOMA), Family history, 
HDL-C, LDL-C, Log(Triglycerides), CV medication use, Current smoking 
   Log(CRP), log mg/L 331 0.159 0.125 0.2 
   Log(Fibrinogen), log mg/dL 282 0.942 0.693 0.2 
   Log(PAI-1), log ng/mL 319 0.053 0.162 0.7 
   Log(tPA-ag), log ng/mL 320 -0.032 0.283 0.9 
1 Log(biomarker) = 2.7 non-log transformed value 
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Table 10. Multivariable tobit regression analyses between baseline novel CV risk factors and the extent of 
baseline CAC using FRS based models. 
  n Parameter Estimate Standard Error P value 
Model 1: FRS, Site, Race 
   Log(CRP), log mg/L 339 0.699 0.123 <0.0001 
   Log(Fibrinogen), log mg/dL 292 2.471 0.808 0.002 
   Log(PAI-1), log ng/mL 327 0.702 0.164 <0.0001 
   Log(tPA-ag), log ng/mL 328 1.189 0.297 <0.0001 
Model 2: FRS, Site, Race, Menopausal status 
   Log(CRP), log mg/L 339 0.709 0.124 <0.0001 
   Log(Fibrinogen), log mg/dL 292 2.496 0.808 0.002 
   Log(PAI-1), log ng/mL 327 0.198 0.045 <0.0001 
   Log(tPA-ag), log ng/mL 328 1.257 0.300 <0.0001 
Model 3: FRS, Site, Race, Menopausal status, Income, Education 
   Log(CRP), log mg/L 337 0.714 0.127 <0.0001 
   Log(Fibrinogen), log mg/dL 290 2.346 0.809 0.004 
   Log(PAI-1), log ng/mL 325 0.768 0.166 <0.0001 
   Log(tPA-ag), log ng/mL 326 1.248 0.300 <0.0001 
Model 4: FRS, Site, Race, Menopausal status, Income, Education, BMI 
   Log(CRP), log mg/L 337 0.193 0.123 0.1 
   Log(Fibrinogen), log mg/dL 290 0.782 0.713 0.3 
   Log(PAI-1), log ng/mL 325 0.228 0.155 0.1 
   Log(tPA-ag), log ng/mL 326 0.282 0.276 0.3 
Model 5: FRS, Site, Race, Menopausal status, Income, Education, BMI, Log(HOMA) 
   Log(CRP), log mg/L 305 0.148 0.129 0.3 
   Log(Fibrinogen), log mg/dL 259 1.064 0.715 0.1 
   Log(PAI-1), log ng/mL 292 0.125 0.169 0.5 
   Log(tPA-ag), log ng/mL 293 0.133 0.285 0.6 
Model 6: FRS, Site, Race, Menopausal status, Income, Education, BMI, Log(HOMA), Family history 
   Log(CRP), log mg/L 305 0.145 0.129 0.3 
   Log(Fibrinogen), log mg/dL 259 1.052 0.715 0.1 
   Log(PAI-1), log ng/mL 292 0.098 0.170 0.6 
   Log(tPA-ag), log ng/mL 293 0.061 0.286 0.8 
Model 7: FRS, Site, Race, Menopausal status, Income, Education, BMI, Log(HOMA), Family history, 
CV medication use 
   Log(CRP), log mg/L 305 0.153 0.129 0.2 
   Log(Fibrinogen), log mg/dL 259 1.013 0.720 0.2 
   Log(PAI-1), log ng/mL 292 0.096 0.170 0.6 
   Log(tPA-ag), log ng/mL 293 0.044 0.287 0.9 
1 Log(biomarker) = 2.7 non-log transformed value 
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Table 11. Multivariable tobit regression analyses between baseline novel CV risk factors and the extent of 
baseline CAC using traditional CV risk factor based models by race. 
  n Parameter Estimate Standard Error P value 
Unadjusted 
   Log(CRP), log mg/L - Black 131 0.817 0.161 <0.0001 
   Log(CRP), log mg/L - White 236 0.755 0.181 <0.0001 
Model 1: Age, Site 
   Log(CRP), log mg/L - Black 131 0.797 0.160 <0.0001 
   Log(CRP), log mg/L - White 236 0.640 0.182 0.0004 
Model 2: Age, Site, Menopausal status 
   Log(CRP), log mg/L - Black 131 0.806 0.162 <0.0001 
   Log(CRP), log mg/L - White 236 0.662 0.182 0.0003 
Model 3: Age, Site, Menopausal status, Income, Education 
   Log(CRP), log mg/L - Black 130 0.822 0.165 <0.0001 
   Log(CRP), log mg/L - White 235 0.684 0.186 0.0002 
Model 4: Age, Site, Menopausal status, Income, Education, SBP 
   Log(CRP), log mg/L - Black 130 0.729 0.159 <0.0001 
   Log(CRP), log mg/L - White 235 0.546 0.182 0.003 
Model 5: Age, Site, Menopausal status, Income, Education, SBP, BMI 
   Log(CRP), log mg/L - Black 130 0.357 0.133 0.007 
   Log(CRP), log mg/L - White 235 -0.079 0.192 0.7 
Model 6: Age, Site, Menopausal status, Income, Education, SBP, BMI, Log(HOMA) 
   Log(CRP), log mg/L - Black 119 0.443 0.135 0.001 
   Log(CRP), log mg/L - White 212 -0.148 0.199 0.5 
Model 7: Age, Site, Menopausal status, Income, Education, SBP, BMI, Log(HOMA), Family history 
   Log(CRP), log mg/L - Black 119 0.443 0.135 0.001 
   Log(CRP), log mg/L - White 212 -0.157 0.200 0.4 
Model 8: Age, Site, Menopausal status, Income, Education, SBP, BMI, Log(HOMA), Family history, 
HDL-C, LDL-C, Log(Triglycerides) 
   Log(CRP), log mg/L - Black 119 0.452 0.135 0.0009 
   Log(CRP), log mg/L - White 212 -0.103 0.204 0.6 
Model 9: Age, Site, Menopausal status, Income, Education, SBP, BMI, Log(HOMA), Family history, 
HDL-C, LDL-C, Log(Triglycerides), CV medication use, Current smoking 
   Log(CRP), log mg/L - Black 119 0.464 0.134 0.0006 
   Log(CRP), log mg/L - White 212 -0.103 0.201 0.6 
1 Log(CRP) = 2.7 non-log transformed value 
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Table 12. Multivariable tobit regression analyses between baseline novel CV risk factors and the extent of 
baseline CAC using FRS based models by race. 
  n Parameter Estimate Standard Error P value 
Unadjusted 
   Log(CRP), log mg/L - Black 131 0.817 0.161 <0.0001 
   Log(CRP), log mg/L - White 236 0.755 0.181 <0.0001 
Model 1: FRS, Site 
   Log(CRP), log mg/L - Black 115 0.841 0.164 <0.0001 
   Log(CRP), log mg/L - White 224 0.581 0.172 0.0007 
Model 2: FRS, Site, Menopausal status 
   Log(CRP), log mg/L - Black 115 0.817 0.164 <0.0001 
   Log(CRP), log mg/L - White 224 0.618 0.173 0.0004 
Model 3: FRS, Site, Menopausal status, Income, Education 
   Log(CRP), log mg/L - Black 114 0.837 0.166 <0.0001 
   Log(CRP), log mg/L - White 223 0.622 0.178 0.0005 
Model 4: FRS, Site, Menopausal status, Income, Education, BMI 
   Log(CRP), log mg/L - Black 114 0.483 0.138 0.0005 
   Log(CRP), log mg/L - White 223 -0.024 0.189 0.9 
Model 5: FRS, Site, Menopausal status, Income, Education, BMI, Log(HOMA) 
   Log(CRP), log mg/L - Black 105 0.488 0.142 0.0006 
   Log(CRP), log mg/L - White 200 -0.090 0.196 0.6 
Model 6: FRS, Site, Menopausal status, Income, Education, BMI, Log(HOMA), Family history 
   Log(CRP), log mg/L - Black 105 0.490 0.141 0.0005 
   Log(CRP), log mg/L - White 200 -0.104 0.197 0.6 
Model 7: FRS, Site, Menopausal status, Income, Education, BMI, Log(HOMA), Family history, 
CV medication use 
   Log(CRP), log mg/L - Black 105 0.488 0.141 0.0005 
   Log(CRP), log mg/L - White 200 -0.088 0.198 0.7 
1 Log(CRP) = 2.7 non-log transformed  value 
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3.4 BASELINE NOVEL BIOMARKERS AND THE PRESENCE OF CAC 
PROGRESSION 
There were 258 subjects with baseline CAC, follow-up CAC, and novel CV risk factor 
measurements. The final study population for these analyses was 252 subjects after excluding 
those with surgical menopause. The mean average time between scans was 2.3 ± 0.5 years. For 
the dichotomous outcome variable of presence of CAC progression, there were 199 subjects who 
did not progress and 53 subjects who demonstrated progression. Of the 132 subjects with 
CAC=0 at baseline, 29 (22.0%) had any CAC in follow-up. Of the 113 subjects with 0<baseline 
CAC<100, there were 18 subjects (15.9%) who demonstrated an annualized increase of ≥10 U. 
Of the 7 subjects who demonstrated an annualized increase of ≥10% compared to baseline, there 
were 6 (85.7%) that demonstrated progression. 
Subjects who had CAC progression by the categorical outcome variable were similar in 
age, study site, race, menopausal status, income, education, triglycerides, CV medication use, 
family history of CV disease, current smoking, and baseline CAC compared with subjects who 
did not exhibit progression (Table 13). Subjects who had CAC progression had a worse CV 
profile with higher SBP, higher BMI, lower HDL-C, higher LDL-C, higher HOMA, and higher 
FRS.  Among the 4 novel CV biomarkers, PAI-1 and tPA-ag were significantly higher in CAC 
progressors compared with non-progressors. There was no significant difference in CRP and 
fibrinogen levels. 
Univariable logistic regression demonstrated significant associations for SBP, BMI, 
HDL-C, LDL-C, log(triglycerides), FRS, and baseline log(CAC+1)  (Table 14). For the novel 
CV risk factors, significant positive correlations were present for the presence of CAC 
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progression for log(PAI-1) (OR, 1.94; 95% CI, 1.39-2.72; p=0.0001) and log(tPA-ag) (OR, 2.21; 
95% CI, 1.06-4.61; p=0.03), but not log(CRP) or log(fibrinogen). 
In the multivariable model based on traditional CV risk factors, log(tPA-ag) was no 
longer significantly associated with CAC progression after adjusting for baseline CAC, age, site, 
and race (Table 15). Of these covariates, log(CAC+1) at baseline attenuated the relationship 
between log(tPA-ag) and CAC progression. In contrast, log(PAI-1) maintained a significantly 
positive relationship after adjusting for baseline CAC, age, site, race, menopausal status, income, 
education, SBP, BMI, log(HOMA), family history of CV disease, HDL-C, LDL-C, 
log(triglycerides), CV medication use, and current smoking (OR, 1.91; 95% CI, 1.24-2.93; 
p=0.003). 
Similarly, log(tPA-ag) was no longer significantly associated with presence of CAC 
progression in the FRS based multivariable model after adjusting for baseline CAC, FRS, study 
site, and race (Table 16). Log(PAI-1) was significantly associated with presence of CAC 
progression after adjusting for multiple variables that included baseline CAC, FRS, study site, 
race, menopausal status, income, education, BMI, log(HOMA), family history of CV disease, 
and CV medication use (OR, 1.82; 95% CI, 1.18-2.79, p=0.006). 
In the final multivariable traditional CV risk factor based models for the four novel CV 
biomarkers, there was no covariate that was significantly associated with CAC progression using 
a dichotomous variable. Similar findings were present in the final multivariable FRS based 
models. 
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Table 13. Baseline characteristics of the CAC progression study population and by the presence and absence 
of CAC progression. 
 
Total CAC Stable CAC Progressed† 
 Characteristics n = 252 n = 199 n = 53 P value* 
Age at baseline CAC, mean (SD), y 51.2 (2.6) 51.1 (2.6) 51.7 (2.9) 0.2 
Site, n (%) 
   
0.6 
   Chicago, site 13 102 (40.5) 79 (39.7) 23 (43.4) 
    Pittsburgh, site 17 150 (59.5) 120 (60.3) 30 (56.6) 
 Race, n (%) 
   
0.6 
   Black 82 (32.5) 63 (31.7) 19 (35.9) 
    White 170 (67.5) 136 (68.3) 34 (64.2) 
 Menopausal status, n (%) 
   
0.1 
   Pre- and early perimenopausal 142 (56.4) 113 (56.8) 29 (54.7) 
    Late peri- and postmenopausal 77 (30.6) 56 (28.1) 21 (39.6) 
    Hormone therapy user 33 (13.1) 30 (15.1) 3 (5.7) 
 Income, n (%) 
   
0.7 
   <$50,000 82 (32.7) 65 (32.7) 17 (32.7) 
    $50,000-$100,000 96 (38.3) 74 (37.2) 22 (42.3) 
    >$100,000 73 (29.1) 60 (30.2) 13 (25.0) 
 Education, n (%) 
   
0.5 
   High school or less 41 (16.3) 32 (16.1) 9 (17.0) 
    Some college or college 133 (52.8) 102 (51.3) 31 (58.5) 
    Graduate 78 (31.0) 65 (32.7) 13 (24.5) 
 SBP, mean (SD), mmHg 117.1 (15.8) 116.0 (15.8) 121.4 (14.8) 0.009 
BMI, mean (SD), kg/m2 29.4 (6.5) 28.8 (6.4) 31.4 (6.7) 0.008 
HDL-C, mean (SD), mg/dL 57.2 (13.4) 58.3 (13.6) 53.4 (11.7) 0.02 
LDL-C, mean (SD), mg/dL 119.3 (34.4) 116.8 (33.2) 128.5 (37.5) 0.08 
Triglycerides, median (Q1, Q3), 
mg/dL 98.0 (74.0, 136.5) 97.0 (73.0, 133.0) 105.0 (76.0, 170.0) 0.1 
CV medication use, n (%) 56 (22.2) 40 (20.1) 16 (30.2) 0.1 
Diabetes, n (%) 9 (3.6) 4 (2.0) 5 (9.4) 0.01 
Family history of CV disease, n (%) 166 (65.9) 132 (66.3) 34 (64.2) 0.8 
Current smoking, n (%) 30 (11.9) 22 (11.1) 8 (15.1) 0.4 
HOMA, median (Q1, Q3) 1.9 (1.5, 3.1) 1.8 (1.4, 2.9) 2.4 (1.5, 3.9) 0.05 
FRS, mean (SD) 10.1 (3.3) 9.7 (3.1) 11.3 (3.7) 0.006 
CAC - baseline, median (Q1, Q3), U 0 (0, 7.2) 0 (0, 5.8) 0 (0, 31.2) 0.2 
CRP, median (Q1, Q3), mg/L 2.1 (1.0, 5.9) 2.1 (1.0, 5.9) 2.5 (1.3, 5.6) 0.5 
Fibrinogen, median (Q1, Q3), mg/dL 273 (242, 312) 273 (238, 316) 279 (247, 300) 0.7 
PAI-1, median (Q1, Q3), ng/mL 13.0 (7.2, 23.5) 12.0 (6.6, 21.8) 20.2 (10.0, 52.0) 0.0004 
tPA-ag, median (Q1, Q3), ng/mL 6.6 (5.0, 9.4) 6.6 (4.7, 9.2) 6.8 (5.8, 10.1) 0.06 
* P-value for CAC groups - Wilcoxon rank-sum test for continuous variables;  Χ2 test for categorical variables 
†CAC progression: any CAC for baseline CAC=0, ≥10 for 0<baseline CAC<100, ≥10% for baseline CAC≥100 
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Table 14. Univariable logistic regression analyses between baseline characteristics and the presence and 
absence of CAC progression. 
  n Odds Ratio 95% CI P Value C 
Age, y 252 1.09 0.97-1.22 0.1 0.556 
Sitea 252 0.86 0.47-1.59 0.6 0.518 
Raceb 252 0.83 0.44-1.57 0.6 0.521 
Menopausal statusc 252 
   
0.583 
   Late peri- and postmenopausal 
 
1.46 0.77-2.79 0.3 
    Hormone therapy user 
 
0.39 0.11-1.37 0.1 
 Incomed 251 
   
0.534 
   $50,000-$100,000 
 
1.14 0.56-2.32 0.7 
    >$100,000 
 
0.83 0.37-1.85 0.6 
 Educatione 252 
   
0.544 
   Some college or college 
 
1.08 0.47-2.51 0.9 
    Graduate 
 
0.71 0.28-1.84 0.5 
 SBP, mmHg 252 1.02 1.00-1.04 0.03 0.618 
BMI, kg/m2 252 1.06 1.01-1.11 0.01 0.618 
HDL-C, mg/dL 252 0.97 0.94-1.00 0.02 0.605 
LDL-C, mg/dL 252 1.01 1.00-1.02 0.03 0.579 
Log(Triglycerides), log mg/dL 252 2.08 1.13-3.82 0.02 0.571 
CV medication use 252 1.72 0.87-2.40 0.1 0.550 
Diabetes 252 5.08 1.31-19.63 0.02 0.537 
Family history of CV disease 252 0.91 0.48-1.71 0.8 0.511 
Current smoking 252 1.43 0.60-3.42 0.4 0.520 
Log(HOMA) 229 1.49 0.91-2.43 0.1 0.592 
FRS 232 1.15 1.05-1.27 0.003 0.628 
Log(CAC+1), baseline 252 1.29 1.06-1.56 0.01 0.554 
Log(CRP), log mg/L 247 1.06 0.83-1.36 0.6 0.522 
Log(Fibrinogen), log mg/dL 212 1.29 0.28-5.95 0.7 0.527 
Log(PAI-1), log ng/mL 239 1.94 1.39-2.72 0.0001 0.667 
Log(tPA-ag), log ng/mL 240 2.21 1.06-4.61 0.03 0.589 
asite 17 versus site 13; bWhite versus Black; c Referenced to pre- and early perimenopausal; 
dReferenced to <$50,000; eReferenced to high school or less 
CAC Progression: any CAC for baseline CAC=0, ≥10 for 0<baseline CAC<100; ≥10% for baseline CAC ≥100 
1 Log(biomarker) = 2.7 non-log transformed value 
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Table 15. Multivariable logistic regression analyses between baseline novel CV risk factors and the presence 
and absence of CAC progression using traditional CV risk factor based models. 
 
n Odds Ratio 95% CI P Value C 
Model 1: Baseline CAC, Age, Site, Race 
   Log(CRP), log mg/L 247 0.95 0.73-1.24 0.7 0.574 
   Log(Fibrinogen), log mg/dL 212 0.90 0.18-4.61 0.9 0.581 
   Log(PAI-1), log ng/mL 239 1.85 1.30-2.64 0.0006 0.681 
   Log(tPA-ag), log ng/mL 240 1.84 0.85-3.98 0.1 0.614 
Model 2: Baseline CAC, Age, Site, Race, Menopausal status 
   Log(CRP), log mg/L 247 0.97 0.74-1.27 0.8 0.614 
   Log(Fibrinogen), log mg/dL 212 0.77 0.14-4.18 0.8 0.647 
   Log(PAI-1), log ng/mL 239 1.79 1.25-2.56 0.002 0.691 
   Log(tPA-ag), log ng/mL 240 1.70 0.77-3.76 0.2 0.622 
Model 3: Baseline CAC, Age, Site, Race, Menopausal status, Income, Education 
   Log(CRP), log mg/L 246 0.98 0.74-1.29 0.9 0.634 
   Log(Fibrinogen), log mg/dL 211 0.80 0.14-4.42 0.8 0.671 
   Log(PAI-1), log ng/mL 238 1.95 1.33-2.84 0.0005 0.705 
   Log(tPA-ag), log ng/mL 239 1.94 0.86-4.38 0.1 0.639 
Model 4: Baseline CAC, Age, Site, Race, Menopausal status, Income, Education, SBP 
   Log(CRP), log mg/L 246 0.96 0.72-1.27 0.8 0.658 
   Log(Fibrinogen), log mg/dL 211 0.82 0.15-4.56 0.8 0.686 
   Log(PAI-1), log ng/mL 238 1.93 1.32-2.83 0.0007 0.711 
   Log(tPA-ag), log ng/mL 239 1.90 0.83-4.31 0.1 0.668 
Model 5: Baseline CAC, Age, Site, Race, Menopausal status, Income, Education, SBP, BMI 
   Log(CRP), log mg/L 246 0.89 0.65-1.21 0.5 0.668 
   Log(Fibrinogen), log mg/dL 211 0.81 0.14-4.65 0.8 0.687 
   Log(PAI-1), log ng/mL 238 1.93 1.31-2.85 0.0009 0.711 
   Log(tPA-ag), log ng/mL 239 1.81 0.76-4.30 0.2 0.670 
Model 6: Baseline CAC, Age, Site, Race, Menopausal status, Income, Education, SBP, BMI, Log(HOMA) 
   Log(CRP), log mg/L 225 0.87 0.63-1.22 0.4 0.654 
   Log(Fibrinogen), log mg/dL 191 0.70 0.11-4.37 0.7 0.693 
   Log(PAI-1), log ng/mL 216 1.92 1.26-2.92 0.002 0.695 
   Log(tPA-ag), log ng/mL 217 1.78 0.70-4.50 0.2 0.652 
Model 7: Baseline CAC, Age, Site, Race, Menopausal status, Income, Education, SBP, BMI, Log(HOMA), 
Family history 
   Log(CRP), log mg/L 225 0.87 0.63-1.21 0.4 0.653 
   Log(Fibrinogen), log mg/dL 191 0.71 0.11-4.41 0.7 0.702 
   Log(PAI-1), log ng/mL 216 1.91 1.25-2.91 0.003 0.695 
   Log(tPA-ag), log ng/mL 217 1.73 0.68-4.43 0.3 0.654 
Model 8: Baseline CAC, Age, Site, Race, Menopausal status, Income, Education, SBP, BMI, Log(HOMA), 
Family history, HDL-C, LDL-C, Log(Triglycerides) 
   Log(CRP), log mg/L 225 0.87 0.62-1.23 0.4 0.686 
   Log(Fibrinogen), log mg/dL 191 0.79 0.12-5.19 0.8 0.714 
   Log(PAI-1), log ng/mL 216 1.88 1.23-2.89 0.004 0.713 
   Log(tPA-ag), log ng/mL 217 1.42 0.53-3.80 0.5 0.681 
Model 9: Baseline CAC, Age, Site, Race, Menopausal status, Income, Education, SBP, BMI, Log(HOMA), 
Family history, HDL-C, LDL-C, Log(Triglycerides), CV medication use, Current smoking 
   Log(CRP), log mg/L 225 0.86 0.61-1.22 0.4 0.688 
   Log(Fibrinogen), log mg/dL 191 0.77 0.11-5.20 0.8 0.721 
   Log(PAI-1), log ng/mL 216 1.91 1.24-2.93 0.003 0.712 
   Log(tPA-ag), log ng/mL 217 1.42 0.53-3.84 0.5 0.680 
CAC Progression: any CAC for baseline CAC=0, ≥10 for 0<baseline CAC<100; ≥10% for baseline CAC ≥100 
1 Log(biomarker) = 2.7 non-log transformed value 
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Table 16. Multivariable logistic regression analyses between baseline novel CV risk factors and the presence 
and absence of CAC progression using FRS based models. 
 
n Odds Ratio 95% CI P Value C 
Model 1: Baseline CAC, FRS, Site, Race 
   Log(CRP), log mg/L 230 0.95 0.72-1.25 0.7 0.643 
   Log(Fibrinogen), log mg/dL 197 1.11 0.21-5.96 0.9 0.653 
   Log(PAI-1), log ng/mL 221 1.71 1.19-2.44 0.003 0.691 
   Log(tPA-ag), log ng/mL 222 1.59 0.71-3.52 0.3 0.650 
Model 2: Baseline CAC, FRS, Site, Race, Menopausal status 
   Log(CRP), log mg/L 230 0.98 0.74-1.29 0.9 0.658 
   Log(Fibrinogen), log mg/dL 197 1.04 0.19-5.77 1.0 0.687 
   Log(PAI-1), log ng/mL 221 1.66 1.15-2.39 0.006 0.703 
   Log(tPA-ag), log ng/mL 222 1.47 0.65-3.33 0.4 0.657 
Model 3: Baseline CAC, FRS, Site, Race, Menopausal status, Income, Education 
   Log(CRP), log mg/L 229 1.00 0.75-1.33 1.0 0.654 
   Log(Fibrinogen), log mg/dL 196 1.06 0.18-6.07 1.0 0.702 
   Log(PAI-1), log ng/mL 220 1.81 1.24-2.65 0.002 0.711 
   Log(tPA-ag), log ng/mL 221 1.69 0.73-3.91 0.2 0.665 
Model 4: Baseline CAC, FRS, Site, Race, Menopausal status, Income, Education, BMI 
   Log(CRP), log mg/L 229 0.90 0.65-1.25 0.5 0.684 
   Log(Fibrinogen), log mg/dL 196 0.99 0.17-5.82 1.0 0.706 
   Log(PAI-1), log ng/mL 220 1.79 1.21-2.64 0.004 0.715 
   Log(tPA-ag), log ng/mL 221 1.50 0.61-3.66 0.4 0.681 
Model 5: Baseline CAC, FRS, Site, Race, Menopausal status, Income, Education, BMI, Log(HOMA) 
   Log(CRP), log mg/L 209 0.91 0.65-1.27 0.6 0.665 
   Log(Fibrinogen), log mg/dL 177 0.91 0.14-5.78 0.9 0.694 
   Log(PAI-1), log ng/mL 199 1.78 0.16-2.73 0.008 0.688 
   Log(tPA-ag), log ng/mL 200 1.46 0.56-3.81 0.4 0.658 
Model 6: Baseline CAC, FRS, Site, Race, Menopausal status, Income, Education, BMI, Log(HOMA), 
Family history 
   Log(CRP), log mg/L 209 0.91 0.65-1.27 0.6 0.665 
   Log(Fibrinogen), log mg/dL 177 0.91 0.14-5.78 0.9 0.694 
   Log(PAI-1), log ng/mL 199 1.80 1.17-2.76 0.007 0.687 
   Log(tPA-ag), log ng/mL 200 1.49 0.57-3.94 0.4 0.657 
Model 7: Baseline CAC, FRS, Site, Race, Menopausal status, Income, Education, BMI, Log(HOMA), 
Family history, CV medication use 
   Log(CRP), log mg/L 209 0.90 0.64-1.26 0.5 0.678 
   Log(Fibrinogen), log mg/dL 177 1.00 0.16-6.45 1.0 0.714 
   Log(PAI-1), log ng/mL 199 1.82 1.18-2.79 0.006 0.691 
   Log(tPA-ag), log ng/mL 200 1.53 0.58-4.05 0.4 0.665 
CAC Progression: any CAC for baseline CAC=0, ≥10 for 0<baseline CAC<100; ≥10% for baseline CAC ≥100 
1 Log(biomarker) = 2.7 non-log transformed value 
 
 
 
 46 
3.5 BASELINE NOVEL BIOMARKERS AND THE EXTENT OF CAC 
PROGRESSION 
In the univariable linear regression analyses for extent of CAC, there were not significant 
relationships for study site, race, menopausal status, income, education, SBP, HDL-C, LDL-C, 
CV medication use, family history of CV disease, current smoking, and log(HOMA) (Table 17). 
There were positive associations for age, BMI, log(triglycerides), FRS, and baseline 
log(CAC+1). Of the four novel CV risk factors, only log(PAI-1) was significantly associated 
with extent of CAC progression (β, 0.020; SE, 0.007; p=0.006). 
Multivariable linear regression analysis using the traditional CV risk factor based model 
demonstrated that log(PAI-1) was positively and significantly associated with extent of CAC 
progression after adjusting for baseline CAC, age, study site, race, menopausal status, income, 
and education (Table 18). When BMI was added to the model, the association lost statistical 
significance (p=0.06). When log(HOMA) was added in the next model, the association regained 
borderline statistical significance (p=0.05). The addition for family history of CV disease, HDL-
C, LDL-C, log(triglycerides), CV medication use, and current smoking to the model no longer 
resulted in a significant positive association of log(PAI-1) to extent of CAC progression 
(β,0.017; SE, 0.009; p=0.06). Log(CRP), log(fibrinogen), and log(tPA-ag) did not have 
significant associations in any of the models. 
In the FRS based multivariable linear regression analyses of baseline novel CV risk 
factors, log(PAI-1) was not significantly associated to extent of CAC progression after adjusting 
for FRS, study site, race, and menopausal status (Table 19). This relationship was not significant 
through the rest of the adjusted models. Due to missing data, the final multivariable models for 
log(PAI-1) in the traditional CV risk factor based models had 17 more subjects than that in FRS 
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based models. As with the traditional CV risk factor based models, there was no significant 
associations between extent of CAC progression and log(CRP), log(fibrinogen), and log(tPA-
ag). 
In contrast to the final multivariable models for presence of CAC progression, the final 
models for extent of CAC progression were notable for particularly strong associations with 
BMI. This was present in models for all four novel biomarkers in the traditional CV risk factor 
based models (p≤0.04 for all), as well as the FRS based models (p≤0.02). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 48 
Table 17. Univariable linear regression analyses between baseline characteristics and the extent of 
CAC progression. 
  n Parameter Estimate Standard Error P value 
Age, y 252 0.005 0.003 0.04 
Sitea 252 0.003 0.014 0.8 
Raceb 252 0.011 0.015 0.4 
Menopausal status 252 
  
0.2 
   Late peri- and postmenopausal 
 
0.028 0.015 0.07 
   Hormone therapy user 
 
0.0004 0.021 1.0 
Incomed 251 
  
1.0 
   $50,000-$100,000 
 
-0.003 0.016 0.9 
   >$100,000 
 
0.002 0.017 0.9 
Educatione 252 
  
0.3 
   Some college or college 
 
-0.012 0.019 0.5 
   Graduate 
 
-0.030 0.021 0.2 
SBP, mmHg 252 0.0005 0.0004 0.3 
BMI, kg/m2 252 0.003 0.001 0.01 
HDL-C, mg/dL 252 -0.0004 0.0005 0.4 
LDL-C, mg/dL 252 0.0002 0.0002 0.3 
Log(Triglycerides), log mg/dL 252 0.037 0.014 0.009 
CV medication use 252 0.015 0.016 0.4 
Diabetes 252 0.056 0.037 0.1 
Family history of CV disease 252 0.0004 0.014 1.0 
Current smoking 252 0.003 0.021 0.9 
Log(HOMA) 229 0.009 0.011 0.5 
FRS 232 0.005 0.002 0.03 
Log(CAC+1), baseline 252 0.011 0.005 0.01 
Log(CRP), log mg/L 247 0.003 0.006 0.6 
Log(Fibrinogen), log mg/dL 212 -0.010 0.036 0.8 
Log(PAI-1), log ng/mL 239 0.020 0.007 0.006 
Log(tPA-ag), log ng/mL 240 0.012 0.016 0.4 
asite 17 versus site 13; bWhite versus Black; cReferenced to pre- and early perimenopausal; 
dReferenced to <$50,000; eReferenced to high school or less 
1 Log(biomarker) = 2.7 non-log transformed value 
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Table 18. Multivariable linear regression analyses between baseline novel CV risk factors and the 
extent of CAC progression using traditional CV risk factor based models. 
  n Parameter Estimate Standard Error P value 
Model 1: Baseline CAC, Age, Site, Race 
   Log(CRP), log mg/L 247 -0.002 0.006 0.8 
   Log(Fibrinogen), log mg/dL 212 -0.021 0.037 0.6 
   Log(PAI-1), log ng/mL 239 0.017 0.008 0.03 
   Log(tPA-ag), log ng/mL 240 0.005 0.016 0.8 
Model 2: Baseline CAC, Age, Site, Race, Menopausal status 
   Log(CRP), log mg/L 247 -0.001 0.006 0.8 
   Log(Fibrinogen), log mg/dL 212 -0.022 0.037 0.6 
   Log(PAI-1), log ng/mL 239 0.016 0.008 0.04 
   Log(tPA-ag), log ng/mL 240 0.002 0.017 0.9 
Model 3: Baseline CAC, Age, Site, Race, Menopausal status, Income, Education 
   Log(CRP), log mg/L 246 0.0004 0.006 0.9 
   Log(Fibrinogen), log mg/dL 211 -0.017 0.037 0.6 
   Log(PAI-1), log ng/mL 238 0.018 0.008 0.02 
   Log(tPA-ag), log ng/mL 239 0.005 0.017 0.7 
Model 4: Baseline CAC, Age, Site, Race, Menopausal status, Income, Education, SBP 
   Log(CRP), log mg/L 246 0.0001 0.006 1.0 
   Log(Fibrinogen), log mg/dL 211 -0.017 0.037 0.6 
   Log(PAI-1), log ng/mL 238 0.018 0.008 0.02 
   Log(tPA-ag), log ng/mL 239 0.005 0.017 0.8 
Model 5: Baseline CAC, Age, Site, Race, Menopausal status, Income, Education, SBP, BMI 
   Log(CRP), log mg/L 246 -0.006 0.007 0.4 
   Log(Fibrinogen), log mg/dL 211 -0.035 0.038 0.4 
   Log(PAI-1), log ng/mL 238 0.016 0.008 0.06 
   Log(tPA-ag), log ng/mL 239 -0.005 0.018 0.8 
Model 6: Baseline CAC, Age, Site, Race, Menopausal status, Income, Education, SBP, BMI, Log(HOMA) 
   Log(CRP), log mg/L 225 -0.004 0.007 0.6 
   Log(Fibrinogen), log mg/dL 191 -0.041 0.040 0.3 
   Log(PAI-1), log ng/mL 216 0.017 0.009 0.05 
   Log(tPA-ag), log ng/mL 217 -0.002 0.019 0.9 
Model 7: Baseline CAC, Age, Site, Race, Menopausal status, Income, Education, SBP, BMI, Log(HOMA), 
family history 
   Log(CRP), log mg/L 225 -0.004 0.007 0.6 
   Log(Fibrinogen), log mg/dL 191 -0.042 0.040 0.3 
   Log(PAI-1), log ng/mL 216 0.017 0.009 0.06 
   Log(tPA-ag), log ng/mL 217 -0.003 0.019 0.9 
Model 8: Baseline CAC, Age, Site, Race, Menopausal status, Income, Education, SBP, BMI, Log(HOMA), 
Family history, HDL-C, LDL-C, Log(Triglycerides) 
   Log(CRP), log mg/L 225 -0.004 0.007 0.6 
   Log(Fibrinogen), log mg/dL 191 -0.040 0.040 0.3 
   Log(PAI-1), log ng/mL 216 0.017 0.009 0.06 
   Log(tPA-ag), log ng/mL 217 -0.007 0.020 0.7 
Model 9: Baseline CAC, Age, Site, Race, Menopausal status, Income, Education, SBP, BMI, Log(HOMA), 
Family history, HDL-C, LDL-C, Log(Triglycerides), CV medication use, Current smoking 
   Log(CRP), log mg/L 225 -0.0004 0.007 0.6 
   Log(Fibrinogen), log mg/dL 191 -0.040 0.040 0.3 
   Log(PAI-1), log ng/mL 216 0.017 0.009 0.06 
   Log(tPA-ag), log ng/mL 217 -0.007 0.020 0.7 
1 Log(biomarker) = 2.7 non-log transformed value 
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Table 19. Multivariable linear regression analyses between baseline novel CV risk factors and the 
extent of CAC progression using FRS based models. 
  n Parameter Estimate Standard Error P value 
Model 1: Baseline CAC, FRS, Site, Race 
   Log(CRP), log mg/L 230 -0.0005 0.006 0.9 
   Log(Fibrinogen), log mg/dL 197 0.004 0.036 0.9 
   Log(PAI-1), log ng/mL 221 0.015 0.008 0.05 
   Log(tPA-ag), log ng/mL 222 0.004 0.016 0.8 
Model 2: Baseline CAC, FRS, Site, Race, Menopausal status 
   Log(CRP), log mg/L 230 -0.0007 0.006 0.9 
   Log(Fibrinogen), log mg/dL 197 0.002 0.036 1.0 
   Log(PAI-1), log ng/mL 221 0.014 0.008 0.07 
   Log(tPA-ag), log ng/mL 222 0.0008 0.017 1 
Model 3: Baseline CAC, FRS, Site, Race, Menopausal status, Income, Education 
   Log(CRP), log mg/L 229 0.001 0.006 0.8 
   Log(Fibrinogen), log mg/dL 196 0.005 0.036 0.9 
   Log(PAI-1), log ng/mL 220 0.017 0.008 0.04 
   Log(tPA-ag), log ng/mL 221 0.005 0.017 0.8 
Model 4: Baseline CAC, FRS, Site, Race, Menopausal status, Income, Education, BMI 
   Log(CRP), log mg/L 229 -0.006 0.007 0.4 
   Log(Fibrinogen), log mg/dL 196 -0.014 0.036 0.7 
   Log(PAI-1), log ng/mL 220 0.012 0.008 0.1 
   Log(tPA-ag), log ng/mL 221 -0.009 0.017 0.6 
Model 5: Baseline CAC, FRS, Site, Race, Menopausal status, Income, Education, BMI, Log(HOMA) 
   Log(CRP), log mg/L 209 -0.003 0.007 0.6 
   Log(Fibrinogen), log mg/dL 177 -0.017 0.037 0.7 
   Log(PAI-1), log ng/mL 199 0.014 0.009 0.1 
   Log(tPA-ag), log ng/mL 200 -0.006 0.019 0.7 
Model 6: Baseline CAC, FRS, Site, Race, Menopausal status, Income, Education, BMI, Log(HOMA), 
Family history 
   Log(CRP), log mg/L 209 -0.004 0.007 0.6 
   Log(Fibrinogen), log mg/dL 177 -0.018 0.037 0.6 
   Log(PAI-1), log ng/mL 199 0.013 0.009 0.1 
   Log(tPA-ag), log ng/mL 200 -0.008 0.019 0.7 
Model 7: Baseline CAC, FRS, Site, Race, Menopausal status, Income, Education, BMI, Log(HOMA), 
Family history, CV medication use 
   Log(CRP), log mg/L 209 -0.004 0.007 0.6 
   Log(Fibrinogen), log mg/dL 177 -0.016 0.037 0.7 
   Log(PAI-1), log ng/mL 199 0.013 0.009 0.1 
   Log(tPA-ag), log ng/mL 200 -0.008 0.019 0.7 
1 Log(biomarker) = 2.7 non-log transformed value 
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3.6 CHANGE IN NOVEL BIOMARKERS AND THE PRESENCE AND EXTENT OF 
CAC PROGRESSION 
There were 223 subjects who had baseline and follow-up CAC measurements, and novel 
biomarker measurements (Table 20). The mean average time between scans was 2.3 ± 0.4 years. 
For the dichotomous outcome variable of presence of CAC progression, there were 174 subjects 
who did not progress and 49 subjects who demonstrated progression. Of the 119 subjects with 
CAC=0 at baseline, 28 (23.5%) had any CAC in follow-up. Of the 97 subjects with 0<baseline 
CAC<100, there were 15 subjects (15.5%) who demonstrated an annualized increase of ≥10 U. 
Of the 7 subjects who demonstrated an annualized increase of ≥10% compared to baseline, there 
were 6 (85.7%) that demonstrated progression. 
There were no significant differences in the change of novel CV risk factors between 
subjects with the presence of CAC progression and subjects without (Table 20 and Table 21). 
The magnitude of change was not large for any of the biomarkers: -0.5 ± 1.2 mg/L for CRP, 5.6 
± 30.4 mg/dL for fibrinogen, -1.9 ± 14.9 ng/mL for PAI-1, and 0.06 ± 2.1 ng/mL for tPA-ag. 
Multivariable adjusted models did not demonstrate any significant association between the 
change in novel biomarkers and presence of CAC progression using traditional CV risk factor 
based models (Table 22) or FRS based models (Table 23). 
Similar to the presence of CAC progression analyses, there were no statistically 
significant associations between any of the novel CV risk factors and extent of CAC progression 
in the univariable linear regression models (Table 24). The non-significant relationships were 
maintained in all traditional risk factor based models (Table 25) and the FRS based models 
(Table 26). 
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Table 20. Characteristics of the change in novel CV risk factors study population by the presence and 
absence of CAC progression. 
 
Total CAC Stable CAC Progressed† 
 Characteristics n = 223 n = 174 n = 49 P value* 
Age at baseline CAC, mean (SD), y 51.1 (2.6) 51.0 (2.5) 51.5 (2.8) 0.4 
Site, n (%) 
   
0.8 
   Chicago, site 13 92 (41.3) 71 (40.8) 21 (42.9) 
    Pittsburgh, site 17 131 (58.7) 103 (59.2) 28 (57.1) 
 Race, n (%) 
   
0.4 
   Black 70 (31.4) 52 (29.9) 18 (36.7) 
    White 153 (68.6) 122 (70.1) 31 (63.3) 
 Menopausal status, n (%) 
   
0.1 
   Pre- and early perimenopausal 128 (57.4) 101 (58.1) 27 (55.1) 
    Late peri- and postmenopausal 66 (29.6) 47 (27.0) 19 (38.8) 
    Hormone therapy user 29 (13.0) 26 (14.9) 3 (6.1) 
 Income, n (%) 
   
0.6 
   <$50,000 74 (33.3) 58 (33.3) 16 (33.3) 
    $50,000-$100,000 85 (38.3) 64 (36.8) 21 (43.8) 
    >$100,000 63 (28.4) 52 (29.9) 11 (22.9) 
 Education, n (%) 
   
0.3 
   High school or less 38 (17.0) 30 (17.2) 8 (16.3) 
    Some college or college 115 (51.6) 85 (48.9) 30 (61.2) 
    Graduate 70 (31.4) 59 (33.9) 11 (22.5) 
 SBP, mean (SD), mmHg 117.4 (15.9) 116.1 (16.0) 122.0 (14.9) 0.007 
BMI, mean (SD), kg/m2 29.4 (6.6) 28.7 (6.4) 31.8 (6.6) 0.001 
HDL-C, mean (SD), mg/dL 56.8 (13.2) 57.9 (13.6) 52.9 (10.8) 0.01 
LDL-C, mean (SD), mg/dL 118.3 (34.1) 115.7 (32.9) 127.5 (37.2) 0.09 
Triglycerides, median (Q1, Q3), 
mg/dL 99.0 (75.0, 136.0) 97.5 (75.0, 133.0) 102.0 (76.0, 169.0) 0.2 
CV medication use, n (%) 50 (22.4) 36 (20.7) 14 (28.6) 0.2 
Diabetes, n (%) 8 (3.6) 3 (1.7) 5 (10.2) 0.005 
Family history of CV disease, n (%) 143 (64.1) 113 (64.9) 30 (61.2) 0.6 
Current smoking, n (%) 26 (11.7) 19 (10.9) 7 (14.3) 0.5 
HOMA, median (Q1, Q3) 2.0 (1.5, 3.1) 1.8 (1.4, 2.9) 2.5 (1.6, 3.9) 0.02 
FRS, mean (SD) 9.9 (3.2) 9.6 (3.0) 11.1 (3.7) 0.02 
CAC - baseline, median (Q1, Q3), U 0 (0, 6.52) 0 (0, 5.5) 0 (0, 32.6) 0.3 
ΔCRP/year, mean (SD), (mg/L)/y -0.06 (2.3) -0.07 (2.5) -0.05 (1.2) 0.3 
ΔFibrinogen/year, mean (SD), 
(mg/dL)/y 2.1 (28.3) 1.2 (27.8) 5.6 (30.4) 0.8 
ΔPAI-1/year, mean (SD), (ng/mL)/y -0.5 (12.1) -0.1 (11.3) -1.9 (14.9) 0.3 
ΔtPA-ag/year, mean (SD), (ng/mL)/y 0.4 (6.7) 0.5 (7.5) 0.06 (2.1) 0.9 
* P-value for CAC groups - Wilcoxon rank-sum test for continuous variables;  Χ2 test for categorical variables 
†CAC progression: any CAC for baseline CAC=0, ≥10 for 0<baseline CAC<100, ≥10% for baseline CAC≥100 
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Table 21. Univariable logistic regression analyses between characteristics of the change in novel CV 
risk factors study population and the presence and absence of CAC progression. 
  n Odds Ratio 95% CI P Value C 
Age, y 223 1.07 0.95-1.21 0.3 0.543 
Sitea 223 0.92 0.48-1.75 0.8 0.510 
Raceb 223 0.73 0.38-1.43 0.4 0.534 
Menopausal statusc 223 
   
0.582 
   Late peri- and postmenopausal 
 
1.51 0.77-2.99 0.2 
    Hormone therapy user 
 
0.43 0.12-1.53 0.2 
 Incomed 222 
   
0.546 
   $50,000-$100,000 
 
1.19 0.57-2.50 0.6 
    >$100,000 
 
0.77 0.33-1.80 0.5 
 Educatione 223 
   
0.570 
   Some college or college 
 
1.32 0.55-3.20 0.5 
    Graduate 
 
0.70 0.25-1.92 0.5 
 SBP, mmHg 223 1.02 1.00-1.04 0.02 0.627 
BMI, kg/m2 223 1.07 1.02-1.12 0.004 0.649 
HDL-C, mg/dL 223 0.97 0.94-1.00 0.02 0.604 
LDL-C, mg/dL 223 1.01 1.00-1.02 0.03 0.580 
Log(Triglycerides), log mg/dL 223 1.99 1.04-3.81 0.04 0.559 
CV medication use 223 1.53 0.75-3.15 0.2 0.539 
Diabetes 223 6.47 1.49-28.13 0.01 0.542 
Family history of CV disease 223 0.85 0.44-1.64 0.6 0.519 
Current smoking 223 1.36 0.54-3.45 0.5 0.517 
Log(HOMA) 201 1.53 0.91-2.54 0.1 0.612 
FRS 205 1.16 1.04-1.28 0.006 0.618 
Log(CAC+1), baseline 223 1.27 1.05-1.55 0.02 0.545 
ΔCRP/year, (mg/L)/y 218 1.00 0.87-1.15 1.0 0.514 
ΔFibrinogen/year, (mg/dL)/y 138 1.01 0.99-1.02 0.5 0.513 
ΔPAI-1/year, (ng/mL)/y 199 0.99 0.96-1.02 0.4 0.556 
ΔtPA-ag/year, (ng/mL)/y 201 0.99 0.91-1.07 0.7 0.510 
asite 17 versus site 13; bWhite versus Black; c Referenced to pre- and early perimenopausal; 
dReferenced to <$50,000; eReferenced to high school or less 
CAC Progression: any CAC for baseline CAC=0, ≥10 for 0<baseline CAC<100; ≥10% for baseline CAC ≥100 
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Table 22. Multivariable logistic regression analyses between the change in novel CV risk factors and the 
presence and absence of CAC progression using traditional CV risk factor based models. 
 
n Odds Ratio 95% CI P Value C 
Model 1: Baseline CAC, Age, Site, Race 
   ΔCRP/year, (mg/L)/y 218 1.02 0.88-1.17 0.8 0.573 
   ΔFibrinogen/year, (mg/dL)/y 138 1.01 0.99-1.02 0.4 0.568 
   ΔPAI-1/year, (ng/mL)/y 199 0.99 0.96-1.02 0.4 0.585 
   ΔtPA-ag/year, (ng/mL)/y 201 0.99 0.92-1.06 0.7 0.567 
Model 2: Baseline CAC, Age, Site, Race, Menopausal status 
   ΔCRP/year, (mg/L)/y 218 1.01 0.87-1.17 0.9 0.609 
   ΔFibrinogen/year, (mg/dL)/y 138 1.01 0.99-1.02 0.3 0.654 
   ΔPAI-1/year, (ng/mL)/y 199 0.99 0.96-1.02 0.6 0.608 
   ΔtPA-ag/year, (ng/mL)/y 201 0.99 0.92-1.06 0.7 0.594 
Model 3: Baseline CAC, Age, Site, Race, Menopausal status, Income, Education 
   ΔCRP/year, (mg/L)/y 217 1.00 0.86-1.15 1.0 0.644 
   ΔFibrinogen/year, (mg/dL)/y 138 1.01 1.00-1.03 0.2 0.689 
   ΔPAI-1/year, (ng/mL)/y 198 0.99 0.96-1.02 0.5 0.649 
   ΔtPA-ag/year, (ng/mL)/y 200 0.98 0.91-1.06 0.6 0.627 
Model 4: Baseline CAC, Age, Site, Race, Menopausal status, Income, Education, SBP 
   ΔCRP/year, (mg/L)/y 217 1.00 0.86-1.15 0.9 0.664 
   ΔFibrinogen/year, (mg/dL)/y 138 1.01 0.99-1.03 0.3 0.697 
   ΔPAI-1/year, (ng/mL)/y 198 0.99 0.96-1.02 0.5 0.668 
   ΔtPA-ag/year, (ng/mL)/y 200 0.98 0.91-1.06 0.7 0.662 
Model 5: Baseline CAC, Age, Site, Race, Menopausal status, Income, Education, SBP, BMI 
   ΔCRP/year, (mg/L)/y 217 1.01 0.87-1.17 0.9 0.683 
   ΔFibrinogen/year, (mg/dL)/y 138 1.01 0.99-1.03 0.2 0.712 
   ΔPAI-1/year, (ng/mL)/y 198 0.99 0.96-1.02 0.5 0.698 
   ΔtPA-ag/year, (ng/mL)/y 200 0.99 0.92-1.06 0.7 0.688 
Model 6: Baseline CAC, Age, Site, Race, Menopausal status, Income, Education, SBP, BMI, Log(HOMA) 
   ΔCRP/year, (mg/L)/y 197 1.01 0.87-1.18 0.9 0.664 
   ΔFibrinogen/year, (mg/dL)/y 123 1.01 0.99-1.03 0.2 0.696 
   ΔPAI-1/year, (ng/mL)/y 177 1.00 0.97-1.03 1.0 0.690 
   ΔtPA-ag/year, (ng/mL)/y 179 0.97 0.88-1.08 0.6 0.682 
Model 7: Baseline CAC, Age, Site, Race, Menopausal status, Income, Education, SBP, BMI, Log(HOMA), 
Family history 
   ΔCRP/year, (mg/L)/y 197 1.01 0.86-1.18 0.9 0.665 
   ΔFibrinogen/year, (mg/dL)/y 123 1.01 0.99-1.03 0.2 0.694 
   ΔPAI-1/year, (ng/mL)/y 177 1.00 0.97-1.03 1.0 0.688 
   ΔtPA-ag/year, (ng/mL)/y 179 0.97 0.88-1.08 0.6 0.682 
Model 8: Baseline CAC, Age, Site, Race, Menopausal status, Income, Education, SBP, BMI, Log(HOMA), 
Family history, HDL-C, LDL-C, Log(Triglycerides) 
   ΔCRP/year, (mg/L)/y 197 1.02 0.86-1.21 0.8 0.697 
   ΔFibrinogen/year, (mg/dL)/y 123 1.01 0.99-1.03 0.3 0.692 
   ΔPAI-1/year, (ng/mL)/y 177 1.00 0.97-1.04 0.8 0.708 
   ΔtPA-ag/year, (ng/mL)/y 179 0.97 0.88-1.08 0.6 0.703 
Model 9: Baseline CAC, Age, Site, Race, Menopausal status, Income, Education, SBP, BMI, Log(HOMA), 
Family history, HDL-C, LDL-C, Log(Triglycerides), CV medication use, Current smoking 
   ΔCRP/year, (mg/L)/y 197 1.02 0.86-1.21 0.8 0.699 
   ΔFibrinogen/year, (mg/dL)/y 123 1.01 0.99-1.03 0.3 0.711 
   ΔPAI-1/year, (ng/mL)/y 177 1.00 0.97-1.04 0.9 0.708 
   ΔtPA-ag/year, (ng/mL)/y 179 0.97 0.87-1.08 0.6 0.704 
CAC Progression: any CAC for baseline CAC=0, ≥10 for 0<baseline CAC<100; ≥10% for baseline CAC ≥100 
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Table 23. Multivariable logistic regression analyses between change in novel CV risk factors and the presence 
and absence of CAC progression using FRS based models. 
 
n Odds Ratio 95% CI P Value C 
Model 1: Baseline CAC, FRS, Site, Race 
   ΔCRP/year, (mg/L)/y 203 1.01 0.87-1.17 0.9 0.634 
   ΔFibrinogen/year, (mg/dL)/y 130 1.01 0.99-1.02 0.5 0.590 
   ΔPAI-1/year, (ng/mL)/y 184 0.99 0.97-1.02 0.6 0.612 
   ΔtPA-ag/year, (ng/mL)/y 186 0.99 0.91-1.07 0.7 0.612 
Model 2: Baseline CAC, FRS, Site, Race, Menopausal status 
   ΔCRP/year, (mg/L)/y 203 1.00 0.86-1.17 1.0 0.648 
   ΔFibrinogen/year, (mg/dL)/y 130 1.01 0.99-1.02 0.4 0.637 
   ΔPAI-1/year, (ng/mL)/y 184 1.00 0.97-1.02 0.8 0.629 
   ΔtPA-ag/year, (ng/mL)/y 186 0.99 0.91-1.07 0.7 0.624 
Model 3: Baseline CAC, FRS, Site, Race, Menopausal status, Income, Education 
   ΔCRP/year, (mg/L)/y 202 1.00 0.85-1.18 1.0 0.653 
   ΔFibrinogen/year, (mg/dL)/y 130 1.01 0.99-1.03 0.3 0.679 
   ΔPAI-1/year, (ng/mL)/y 183 0.99 0.97-1.02 0.7 0.639 
   ΔtPA-ag/year, (ng/mL)/y 185 0.98 0.91-1.07 0.7 0.634 
Model 4: Baseline CAC, FRS, Site, Race, Menopausal status, Income, Education, BMI 
   ΔCRP/year, (mg/L)/y 202 1.02 0.86-1.20 0.9 0.691 
   ΔFibrinogen/year, (mg/dL)/y 130 1.01 0.99-1.03 0.2 0.698 
   ΔPAI-1/year, (ng/mL)/y 183 0.99 0.97-1.02 0.6 0.703 
   ΔtPA-ag/year, (ng/mL)/y 185 0.99 0.91-1.06 0.7 0.696 
Model 5: Baseline CAC, FRS, Site, Race, Menopausal status, Income, Education, BMI, Log(HOMA) 
   ΔCRP/year, (mg/L)/y 183 1.01 0.86-1.19 0.9 0.645 
   ΔFibrinogen/year, (mg/dL)/y 115 1.01 0.99-1.03 0.4 0.671 
   ΔPAI-1/year, (ng/mL)/y 163 1.01 0.98-1.04 0.7 0.653 
   ΔtPA-ag/year, (ng/mL)/y 165 0.97 0.86-1.10 0.6 0.653 
Model 6: Baseline CAC, FRS, Site, Race, Menopausal status, Income, Education, BMI, Log(HOMA), 
Family history 
   ΔCRP/year, (mg/L)/y 183 1.02 0.86-1.21 0.8 0.671 
   ΔFibrinogen/year, (mg/dL)/y 115 1.01 0.99-1.03 0.2 0.674 
   ΔPAI-1/year, (ng/mL)/y 163 1.00 0.97-1.03 0.9 0.702 
   ΔtPA-ag/year, (ng/mL)/y 165 0.97 0.86-1.10 0.6 0.694 
Model 7: Baseline CAC, FRS, Site, Race, Menopausal status, Income, Education, BMI, Log(HOMA), 
Family history, CV medication use 
   ΔCRP/year, (mg/L)/y 183 1.02 0.87-1.21 0.8 0.676 
   ΔFibrinogen/year, (mg/dL)/y 115 1.01 0.99-1.03 0.3 0.689 
   ΔPAI-1/year, (ng/mL)/y 163 1.00 0.97-1.04 0.9 0.705 
   ΔtPA-ag/year, (ng/mL)/y 165 0.97 0.86-1.10 0.6 0.694 
CAC Progression: any CAC for baseline CAC=0, ≥10 for 0<baseline CAC<100; ≥10% for baseline CAC ≥100 
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Table 24. Univariable linear regression analyses between characteristics of the change in novel CV risk 
factors study population and the extent of CAC progression. 
  n Parameter Estimate Standard Error P value 
Age, y 223 0.004 0.003 0.1 
Sitea 223 0.003 0.015 0.8 
Raceb 223 0.011 0.016 0.5 
Menopausal status 223 
  
0.1 
   Late peri- and postmenopausal 
 
0.032 0.017 0.05 
   Hormone therapy user 
 
-0.009 0.023 0.7 
Incomed 222 
  
1.0 
   $50,000-$100,000 
 
0.002 0.018 0.9 
   >$100,000 
 
0.003 0.019 0.9 
Educatione 223 
  
0.3 
   Some college or college 
 
-0.006 0.021 0.8 
   Graduate 
 
-0.030 0.022 0.2 
SBP, mmHg 223 0.0005 0.0005 0.3 
BMI, kg/m2 223 0.003 0.001 0.004 
HDL-C, mg/dL 223 -0.0007 0.0006 0.2 
LDL-C, mg/dL 223 0.0003 0.0002 0.2 
Log(Triglycerides), log mg/dL 223 0.036 0.015 0.02 
CV medication use 223 0.014 0.018 0.4 
Diabetes 223 0.063 0.040 0.1 
Family history of CV disease 223 -0.005 0.015 0.7 
Current smoking 223 0.0009 0.023 1.0 
Log(HOMA) 201 0.007 0.012 0.6 
FRS 205 0.005 0.002 0.05 
Log(CAC+1), baseline 223 0.010 0.005 0.04 
ΔCRP/year, (mg/L)/y 218 0.002 0.003 0.6 
ΔFibrinogen/year, (mg/dL)/y 138 0.0001 0.0003 0.6 
ΔPAI-1/year, (ng/mL)/y 199 -0.0004 0.0007 0.5 
ΔtPA-ag/year, (ng/mL)/y 201 -0.0007 0.001 0.5 
asite 17 versus site 13; bWhite versus Black; cReferenced to pre- and early perimenopausal; 
dReferenced to <$50,000; eReferenced to high school or less 
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Table 25. Multivariable linear regression analyses between change in novel CV risk factors and the extent of 
CAC progression using traditional risk factor based models. 
  n Parameter Estimate Standard Error P value 
Model 1: Baseline CAC, Age, Site, Race 
   ΔCRP/year, mg/L*y 218 0.002 0.003 0.5 
   ΔFibrinogen/year, mg/dL*y 138 0.0001 0.0003 0.7 
   ΔPAI-1/year, ng/mL*y 199 -0.0004 0.0007 0.6 
   ΔtPA-ag/year, ng/mL*y 201 -0.0008 0.001 0.5 
Model 2: Baseline CAC, Age, Site, Race, Menopausal status 
   ΔCRP/year, mg/L*y 218 0.002 0.003 0.6 
   ΔFibrinogen/year, mg/dL*y 138 0.0002 0.0003 0.6 
   ΔPAI-1/year, ng/mL*y 199 -0.0002 0.0007 0.8 
   ΔtPA-ag/year, ng/mL*y 201 -0.0007 0.001 0.6 
Model 3: Baseline CAC, Age, Site, Race, Menopausal status, Income, Education 
   ΔCRP/year, mg/L*y 217 0.001 0.003 0.7 
   ΔFibrinogen/year, mg/dL*y 138 0.0003 0.0003 0.4 
   ΔPAI-1/year, ng/mL*y 198 -0.0003 0.0007 0.7 
   ΔtPA-ag/year, ng/mL*y 200 -0.0007 0.001 0.5 
Model 4: Baseline CAC, Age, Site, Race, Menopausal status, Income, Education, SBP 
   ΔCRP/year, (mg/L)/y 217 0.001 0.003 0.7 
   ΔFibrinogen/year, (mg/dL)/y 138 0.0003 0.0004 0.4 
   ΔPAI-1/year, (ng/mL)/y 198 -0.0003 0.0007 0.7 
   ΔtPA-ag/year, (ng/mL)/y 200 -0.0007 0.001 0.6 
Model 5: Baseline CAC, Age, Site, Race, Menopausal status, Income, Education, SBP, BMI 
   ΔCRP/year, (mg/L)/y 217 0.002 0.003 0.5 
   ΔFibrinogen/year, (mg/dL)/y 138 0.0004 0.0004 0.2 
   ΔPAI-1/year, (ng/mL)/y 198 -0.0003 0.0007 0.7 
   ΔtPA-ag/year, (ng/mL)/y 200 -0.0006 0.001 0.6 
Model 6: Baseline CAC, Age, Site, Race, Menopausal Status, Income, Education, SBP, BMI, Log(HOMA) 
   ΔCRP/year, (mg/L)/y 197 0.002 0.003 0.5 
   ΔFibrinogen/year, (mg/dL)/y 123 0.0004 0.0004 0.2 
   ΔPAI-1/year, (ng/mL)/y 177 -0.0001 0.0007 0.9 
   ΔtPA-ag/year, (ng/mL)/y 179 -0.001 0.001 0.4 
Model 7: Baseline CAC, Age, Site, Race, Menopausal Status, Income, Education, SBP, BMI, Log(HOMA), 
Family history 
   ΔCRP/year, (mg/L)/y 197 0.002 0.003 0.5 
   ΔFibrinogen/year, (mg/dL)/y 123 0.0004 0.0004 0.2 
   ΔPAI-1/year, (ng/mL)/y 177 -0.0001 0.0007 0.9 
   ΔtPA-ag/year, (ng/mL)/y 179 -0.001 0.001 0.4 
Model 8: Baseline CAC, Age, Site, Race, Menopausal Status, Income, Education, SBP, BMI, Log(HOMA), 
Family history, HDL-C, LDL-C, Log(Triglycerides) 
   ΔCRP/year, (mg/L)/y 197 0.003 0.003 0.4 
   ΔFibrinogen/year, (mg/dL)/y 123 0.0004 0.0004 0.3 
   ΔPAI-1/year, (ng/mL)/y 177 -0.00005 0.0007 1.0 
   ΔtPA-ag/year, (ng/mL)/y 179 -0.0009 0.001 0.4 
Model 9: Baseline CAC, Age, Site, Race, Menopausal Status, Income, Education, SBP, BMI, Log(HOMA), 
Family history, HDL-C, LDL-C, Log(Triglycerides), CV medication use, Current smoking 
   ΔCRP/year, (mg/L)/y 197 0.003 0.003 0.4 
   ΔFibrinogen/year, (mg/dL)/y 123 0.0004 0.0004 0.3 
   ΔPAI-1/year, (ng/mL)/y 177 -0.00007 0.0008 0.9 
   ΔtPA-ag/year, (ng/mL)/y 179 -0.0009 0.001 0.4 
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Table 26. Multivariable linear regression analyses between change in novel CV risk factors and the extent of 
CAC progression using FRS based models. 
  n Parameter Estimate Standard Error P value 
Model 1: Baseline CAC, FRS, Site, Race 
   ΔCRP/year, (mg/L)/y 203 0.002 0.003 0.6 
   ΔFibrinogen/year, (mg/dL)/y 130 0.0001 0.0004 0.7 
   ΔPAI-1/year, (ng/mL)/y 184 -0.0003 0.0006 0.7 
   ΔtPA-ag/year, (ng/mL)/y 186 -0.0008 0.001 0.5 
Model 2: Baseline CAC, FRS, Site, Race, Menopausal status 
   ΔCRP/year, (mg/L)/y 203 0.002 0.003 0.6 
   ΔFibrinogen/year, (mg/dL)/y 130 0.0002 0.0004 0.5 
   ΔPAI-1/year, (ng/mL)/y 184 -0.0001 0.0006 0.8 
   ΔtPA-ag/year, (ng/mL)/y 186 -0.0007 0.001 0.5 
Model 3: Baseline CAC, FRS, Site, Race, Menopausal status, Income, Education 
   ΔCRP/year, (mg/L)/y 202 0.002 0.003 0.6 
   ΔFibrinogen/year, (mg/dL)/y 130 0.0003 0.0004 0.4 
   ΔPAI-1/year, (ng/mL)/y 183 -0.0003 0.0007 0.7 
   ΔtPA-ag/year, (ng/mL)/y 185 -0.0008 0.001 0.5 
Model 4: Baseline CAC, FRS, Site, Race, Menopausal status, Income, Education, BMI 
   ΔCRP/year, (mg/L)/y 202 0.002 0.003 0.5 
   ΔFibrinogen/year, (mg/dL)/y 130 0.0005 0.0003 0.2 
   ΔPAI-1/year, (ng/mL)/y 183 -0.0003 0.0006 0.7 
   ΔtPA-ag/year, (ng/mL)/y 185 -0.0007 0.001 0.5 
Model 5: Baseline CAC, FRS, Site, Race, Menopausal status, Income, Education, BMI, Log(HOMA) 
   ΔCRP/year, (mg/L)/y 183 0.002 0.003 0.5 
   ΔFibrinogen/year, (mg/dL)/y 115 0.0005 0.0004 0.2 
   ΔPAI-1/year, (ng/mL)/y 163 -0.0001 0.0007 0.9 
   ΔtPA-ag/year, (ng/mL)/y 165 -0.001 0.001 0.3 
Model 6: Baseline CAC, FRS, Site, Race, Menopausal status, Income, Education, BMI, Log(HOMA), 
Family history 
   ΔCRP/year, (mg/L)/y 183 0.003 0.003 0.4 
   ΔFibrinogen/year, (mg/dL)/y 115 0.0005 0.0004 0.2 
   ΔPAI-1/year, (ng/mL)/y 163 -0.0001 0.0007 0.9 
   ΔtPA-ag/year, (ng/mL)/y 165 -0.001 0.001 0.3 
Model 7: Baseline CAC, FRS, Site, Race, Menopausal status, Income, Education, BMI, Log(HOMA), 
Family history, CV medication use 
   ΔCRP/year, (mg/L)/y 183 0.003 0.003 0.4 
   ΔFibrinogen/year, (mg/dL)/y 115 0.0004 0.0004 0.2 
   ΔPAI-1/year, (ng/mL)/y 163 -0.0001 0.0007 0.9 
   ΔtPA-ag/year, (ng/mL)/y 165 -0.001 0.001 0.3 
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4.0  DISCUSSION 
Our investigation yielded several important observations. First, CRP, fibrinogen, PAI-1, and 
tPA-ag were all associated with the presence and extent of baseline CAC. These relationships 
were all attenuated by BMI in the multivariable models. Second, a significant interaction was 
noted for race on the relationship between CRP and baseline CAC. CRP was associated with 
CAC in black women, but not white women. Third, PAI-1 levels obtained at the baseline visits 
were associated with CAC progression after adjustment for traditional CV risk factors and socio-
economic status. Fourth, changes in measurements of the four novel CV risk factors of interest 
were not associated with CAC progression. The magnitudes of change were small when 
compared to baseline values. 
4.1 BASELINE NOVEL RISK FACTORS AND BMI IN WOMEN 
Our study demonstrated that four novel CV risk factors associated with abnormalities in the 
inflammation and hemostasis were associated with the presence and extent of baseline CAC. 
These relationships were significant even after adjusting for traditional CV risk factors, or FRS. 
A notable finding was that all relationships were attenuated when BMI was added into the 
multivariable models. Therefore, the relationships between biomarkers and CAC appear to be 
largely mediated through the metabolic changes that are linked with increasing BMI. Higher 
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BMI levels were found to be independently associated with higher levels of CRP, fibrinogen, and 
PAI-1 in women, but not men, in a cross-sectional, community-based study of 166 healthy men 
and women with a mean age of 52.1 years (26-80 years) (73). 
Prior investigators have suggested that the association between adipose tissue and CRP, 
mediated through interleukin-6, may diminish the predictive value of CRP for CHD in obese 
individuals. The CRP signal from adipose tissue may overwhelm that from subclinical 
atherosclerosis (44). A similar mechanism may explain the correlation between PAI-1 levels and 
BMI (59). Thus, increasing adipose tissue may be the primary reason for increasing levels of 
CRP, fibrinogen, PAI-1, and tPA-ag in midlife women. 
High BMI was found to be a contributor to CHD deaths, independent of the FRS, in a 
sibling study of individuals with CHD who were younger than 60 years of age (74). In the United 
States, recent data estimated the prevalence rates for overweight and obese women between 40 to 
59 years of age to be 36.0% and 66.0%, respectively (75).  A decrease in age-adjusted death rates 
for CHD of nearly 50% was observed between 1980 and 2000 (76). This was explained by 
reductions in traditional risk factors and implementation of evidence-based therapies. The 
decrease in CHD-related deaths would have been greater, however, but increasing BMI and 
diabetes rates during that time contributed to additional CHD deaths. 
Our findings provide more evidence for abnormalities in inflammation and hemostasis as 
potential mechanisms underlying the association between elevated BMI and CHD. As such, they 
support the current recommendation of weight maintenance or reduction to achieve an 
appropriate body weight (77). 
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4.2 BASELINE CRP AND BASELINE CAC IN BLACK WOMEN 
Adjusting for BMI accounted for the associations between CAC and all four novel CV risk 
factors with the exception of CRP and CAC presence in black women. Prior results from SWAN 
demonstrated that black women had greater odds of CRP levels >3 mg/L when compared with 
white women (OR, 1.37; 95% CI, 1.07-1.75), even after adjusting for age, socio-economic status 
BMI, and other CV risk factors (78). Black women have less visceral adipose tissue, but 
paradoxically have higher CRP levels than white women (79). In human umbilical vein 
endothelial cells from blacks and whites, cells from blacks had higher nitric oxide levels, higher 
interleukin-6 levels, and lower superoxide dismutase activity (80). It strengthens the theory that 
genetic differences in oxidative stress and inflammation are involved in the difference in clinical 
CHD rates. At present, the precise mechanism for the racial difference in CHD development is 
unknown, but it may signify the presence of non-adipose mediated inflammatory conditions. 
Our observation may have important clinical implications. In a study of greater than 
22,000 women and men of black and white race who had established CHD, black women had the 
poorest unadjusted survival rates (81). The 15-year survival for black women remained worse 
compared with white women even after adjusting for traditional CV risk factors, socioeconomic 
status, treatment factors, and other significant predictors of mortality (41.5% vs. 45.5%, 
p<0.0001). Black women have been noted to have a significantly higher burden of traditional CV 
risk factors in those with and without prior CHD (82). Primary prevention is therefore of 
particular importance. 
The writing committee for the 2010 guidelines for CV risk in asymptomatic adults, 
published by the American College of Cardiology Foundation and the American Heart 
Association (AHA), did not recommend selective race-based risk assessment approaches despite 
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the recognition of disparities between races with regards to traditional risk factors, CHD 
incidence, and outcomes (83). In the Reasons for Geographic and Racial Differences in Stroke 
(REGARDS) prospective cohort study that enrolled subjects from 2003 to 2007, black women 
without prior CHD had higher age-standardized rates of acute CHD events than white women 
(84). These were also accounted for by higher traditional CV risk burden. The study, however, 
enrolled those 45 years and older, and thus had a mean age of 64.1 years. Preventative measures 
targeted towards non-traditional risk factors earlier in life may be important for certain 
subgroups, particularly those who are younger. 
Pharmacotherapy guideline recommendations from the AHA for primary prevention in 
non-diabetic women without high-risk features for CV disease focus on control of blood pressure 
and dyslipidemia, as well as aspirin (77). Medications for blood pressure control are 
recommended based on measured blood pressure values irrespective of the presence or absence 
of clinical CHD. In contrast, recommendations for aspirin and pharmacotherapy for dyslipidemia 
in the absence of established CHD are largely dependent upon CHD risk classification. Statins, 
but not aspirin, are associated with lower CRP levels in patients with stable CHD (85). This 
suggests that inflammatory mechanisms that promote atherogenesis may be particularly 
responsive to statins. 
Despite the existence of current AHA recommendations, statins in women without known 
CHD and <65 years of age have not been shown to impact total or CHD mortality (86). In fact, 
the only randomized placebo-controlled study to demonstrate significant reduction in total or 
CHD mortality for women has been the Justification for the Use of Statins in Prevention: an 
Intervention Trial Evaluating Rosuvastatin (JUPITER) that included 6,801 women (87). 
Inclusion criteria for JUPITER women were age 60 years or older, LDL-C less than 130 mg/dL, 
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and CRP of 2.0 mg/L or greater. It is reasonable to hypothesize that elevated CRP levels identify 
women who would benefit the most from statin medication. Routine screening for CRP, 
however, is not recommended by the AHA expert panel (77). 
Our finding that CRP was associated with the presence of CAC in black women with a 
mean age of 51 years, even after adjusting for traditional CV and socio-economic risk factors, 
suggests that CRP may have a role in CHD prevention in this particular subgroup. Inflammatory 
mechanisms of atherogenesis may have a more significant role in the development of subclinical 
CHD in black women at this age. At present, the study of CRP in blacks has been limited (88). 
Existing data is not substantial enough to recommend routine screening of CRP in middle-aged 
black women. One of the goals of risk prediction refinement is the potential to reclassify 
individuals based on low-, intermediate-, and high-risk estimation (89). For primary prevention 
of CHD, a major consideration is the threshold for recommending statin therapy. For non-
diabetics with LDL-C levels <190 mg/dL, the current threshold is an estimated 10-year 
atherosclerotic CV risk ≥7.5% (90). Based on our data, black women undergoing the menopausal 
transition who are of intermediate risk, but who do not have a 10-year risk ≥7.5%, may be 
considered for CRP screening. Those with an elevated CRP may benefit from statin use. 
Ultimately, a prospective trial on this strategy is warranted. 
4.3 BASELINE PAI-1 AND CAC PROGRESSION IN WOMEN 
In our study, baseline levels of PAI-1 were significantly associated with the presence and extent 
of CAC progression, independent of traditional CV risk factors and socio-economic status. To 
the best of our knowledge, there are no studies to date that have assessed the relationship 
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between PAI-1 and CAC progression. Interestingly, PAI-1 was not associated with presence or 
extent of baseline CAC. These findings are complimentary with a previous study that did not 
find a correlation of PAI-1 level with presence of CAC on a single measurement in non-
diabetics, as our population had few diabetics (57). Thus, PAI-1 may be an important temporal 
marker for individuals who are at elevated risk for aggressive atherosclerotic development at a 
particular time of life. Some have postulated that a single measure of CAC is a representation of 
long-term, or lifetime, atherosclerotic plaque burden whereas CAC progression is more 
indicative of short-term, or current, disease activity (91). 
Increased PAI-1 concentration as a marker for impaired fibrinolysis has been investigated 
as a potential contributor to ACS. PAI-1 has not been significantly associated with ACS after 
adjustment for traditional CV risk factors and insulin resistance (92, 93). The types of coronary 
lesions that are typically involved with ACS are not calcified (19). Inhibition of fibrinolysis 
through PAI-1 has been postulated as a potential mechanism to increase arterial fibrin deposition 
and thrombosis (54). PAI-1 may thus be an important factor in CAC progression in late stage 
atherosclerotic lesions as altered healing of ruptured atheromas may contribute to increasing 
CAC. CAC progression has been correlated with mortality and morbidity, and CAC magnitude 
has been correlated with atherosclerotic burden. 
To date, statins have failed to demonstrate significant decreases in CAC progression (22). 
Lipid regulation may not adequately affect the calcification process in coronary atheromas, 
which occurs late in the atherosclerotic process. Therefore, CHD events and CAC progression 
continue despite optimization of traditional CV risk factors, including statin use. The 
mechanisms that prevent worsening CAC burden may ultimately improve upon current state-of-
the-art CHD prevention recommendations. Our findings suggest that targeting hemostatic 
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abnormalities, as evidenced by elevated PAI-1 levels, may theoretically slow CAC progression 
and decrease CHD events. 
Increased activation of the renin-angiotensin-aldosterone system (RAAS) has been 
known to be associated with abnormalities in the fibrinolytic system, particularly endothelial 
expression of PAI-1 by angiotensin (94). Brown and colleagues demonstrated that angiotensin-
converting enzyme (ACE) inhibition using ramipril could block increases in PAI-1 levels that 
were stimulated by hydrochlorothiazide activation of the RAAS for the study duration of 6 
weeks. In contrast, angiotensin II type I (AT1) receptor blockade with losartan was efficacious 
for only 1 week (95). These investigators then demonstrated that furosemide-induced increases 
in PAI-1 levels could be inhibited by a combination of AT1 receptor and aldosterone receptor 
blockade using candesartan and spironolactone over a 2 week period. (96). Candesartan or 
spironolactone in isolation could not inhibit furosemide-induced PAI-1 expression. These results 
suggest that ACE inhibition alone or the combination of AT1 receptor and aldosterone receptor 
inhibition have the potential to chronically reduce elevated levels of PAI-1. This may 
theoretically relieve PAI-1 mediated suppression of fibrinolysis. 
Decreasing PAI-1 activity has also improved vascular structure in mouse models. AT1 
receptor blockade with azilsartan decreased PAI-1 expression in the aortic wall of mice fed a 
high fat diet (97). In addition, mice fed azilsartan had more stable plaques as evidenced by 
greater cellularity and collagen than mice that were fed placebo. Administration of apelin to mice 
has been shown to attenuate angiotensin II-induced perivascular fibrosis in coronary artery 
sections (98). The observed effect was postulated to be at least in part due to decreased PAI-1 
levels by blocking angiotensin II-mediated PAI-1 gene expression. These findings add evidence 
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to the potential histologic stability, and prevention of calcification, that may be conferred to 
atherosclerotic plaques by controlling PAI-1 expression. 
The association of PAI-1 with CAC progression in our study generates several interesting 
hypotheses. First, abnormalities in the fibrinolytic system may play an important role in CAC 
progression in middle-aged women undergoing the menopausal transition. Recent results from 
SWAN demonstrated that complement protein C3 was associated with PAI-1 and tPA-ag, and 
that C3 is higher in post-menopausal women compared to pre-menopausal women (68). Thus, 
the complement system may have an important role in the elevated risk of CHD in post-
menopausal women. There does not appear to be a significant contribution on PAI-1 level from 
gender (99). BMI and waist-to-hip ratio, however, have been shown to independently predict 
PAI-1 levels in women but not men (100). It is therefore important to limit our results to subjects 
who are similar to those in our study population. 
Second, midlife women with elevated PAI-1 levels with hypertension may benefit from 
using non-diuretic anti-hypertensive medications as these activate the RAAS and PAI-1 
expression. Third, blocking PAI-1 expression through the RAAS may prevent or decrease CAC 
progression. This in turn may be decrease CHD-related morbidity and mortality that is currently 
not prevented by optimization of traditional risk factors. Futures studies should evaluate the 
association of PAI-1 levels with subclinical atherosclerosis in a broader population. If similar 
relationships are present, then a randomized controlled trial on RAAS inhibition to decrease 
CAC progression in those with elevated PAI-1 levels may be warranted.  
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4.4 CHANGE IN NOVEL RISK FACTORS AND CAC PROGRESSION 
Finally, we demonstrated that changes in novel CV risk factors were not associated with CAC 
progression. The magnitude of change between baseline and follow-up CAC measurements was 
small, relative to baseline values. Thus our findings suggest that CRP, fibrinogen, PAI-1, and 
tPA-ag levels are relatively stable from year-to-year in midlife women, and repeat measures are 
unlikely to yield benefit. Due to limited sample size and a relatively short follow-up time, these 
results should be interpreted with caution. 
4.5 STRENGTHS AND LIMITATIONS 
Our study had several notable strengths. To the best of our knowledge, this is the first study to 
evaluate the relationships of CRP, fibrinogen, PAI-1, and tPA-ag to CAC in women undergoing 
the menopausal transition. This period is recognized as a critical time for the change in CHD risk 
in women. Although the analysis was retrospective, the data collection was performed in a 
systematic and prospective manner. By design, there were a significant proportion of black 
women in our study population. In addition, our analyses evaluated the presence and extent of 
baseline CAC, and the presence and extent of CAC progression over a follow-up period that 
averaged over 2 years. 
Our study also had several limitations. We only had women of white and black ethnicity, 
so the results may not be generalizable to other races. The number with diabetes was exceedingly 
low, so diabetes was not included as a separate covariate in our analyses. The follow-up time was 
on average less than 3 years so differences seen on the progression analyses may not be as great 
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compared to longer follow-up times. The majority of the subjects with CAC had low CAC scores 
so these results may not be applicable in subjects with higher CAC scores. Finally, there is not a 
universally accepted definition of CAC progression. Our definitions, however, have been used 
before in publications from other large cohort studies. 
4.6 CONCLUSIONS 
Our results demonstrate that the associations of inflammation and hemostasis with CAC presence 
are virtually all mediated through BMI in women undergoing the menopausal transition. The 
exception is the association of CRP with CAC presence in black women, which is independent of 
traditional CV risk factors and socio-economic factors. Additionally, PAI-1 is associated with 
CAC progression and suggests a potential new pathway to decrease CHD-related morbidity and 
mortality that is not accounted for with traditional CV risk factors and prevention strategies. 
Finally, changes in CRP, fibrinogen, PAI-1, and tPA-ag do not appear to be significant from 
year-to-year. This will, however, need to be replicated in a larger sample with longer follow-up. 
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APPENDIX: LITERTURE REVIEW 
A Review of the Association of Coronary Artery Calcification with C-Reactive Protein, 
Fibrinogen, Plasma Activator Inhibitor-1, and Tissue Plasminogen Activator: Implications 
for Further Study of Middle-Aged Women Undergoing the Menopausal Transition 
Norman C. Wang, MD 
ABSTRACT 
Novel cardiovascular (CV) risk factors associated with inflammation and hemostasis may be 
related to coronary artery calcification (CAC) and CAC progression as measured by cardiac 
computed tomography. Inflammatory markers that have been subjects of recent investigation 
include C-reactive protein and fibrinogen. Plasminogen activator inhibitor type 1 and tissue 
plasminogen activator are hemostatic markers which also be involved in the pathophysiologic 
process of coronary artery calcification. A literature search was performed of the Ovid 
MEDLINE database from 1948 to January Week 3 2013. The first search was performed using 
Medical Subject Headings (MeSH) “coronary artery calcification” or “coronary artery calcium”. 
The second search was performed using MeSH “C-reactive protein” or “fibrinogen” or 
“plasminogen activator inhibitor type 1” or “tissue plasminogen activator”. Articles were finally 
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reviewed by title, abstract, and text for inclusion. The search yielded 77 articles. There are few 
studies evaluating the association between novel CV risk factors and CAC. 
 
INTRODUCTION 
 
Cardiovascular disease (CVD) is the most common cause of death in the United States (1). 
Coronary artery calcification (CAC), a manifestation of subclinical CVD, is of particular 
importance as it may predict risk of non-fatal myocardial infarction and cardiac death (2). On a 
pathophysiologic level, this represents calcium deposition within fibroatheromas (3). Detection is 
typically made by cardiac computed tomography (CT) (4). There has been suggestion that 
increasing levels of CAC seen on serial measurements with cardiac CT, referred to as CAC 
progression, may be more predictive of future events than a single measurement (4). Traditional 
risk factors for CVD established by the Adult Treatment Panel III have been related to CAC (5). 
These include age, gender, total and high-density lipoprotein cholesterol levels, smoking, blood 
pressure, and hypertension. It has been established that inflammatory processes increase the risk 
of development of coronary artery disease (6-8). In addition, hemostatic factors are potential 
emerging risk factors given the role of thrombosis in atherogenesis and acute coronary 
syndromes (8-11). 
It has become evident that evaluating individuals during middle age can predict their 
lifetime risk of CVD (12). Focusing on long-term prevention of CVD events is of particular 
interest in women. Women presenting with acute myocardial infarction are more likely to have 
atypical symptoms and less likely to receive evidence-based therapies (13,14). It is accepted that 
differences in the benefits and risks associated with preventative measures exist between men 
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and women (15). Some of this may be related to differences in the pathophysiologic processes 
between men and women. Evidence has shown that associations between certain inflammatory 
markers and calcification are more pronounced in women compared to men (16-19). The 
menopausal transition is also a time of particular interest, given that the risk for CVD increases 
substantially in the post-menopause period (20). Adverse lipid increases occur within the one 
year period around the final menstrual period (21). Potential associations of inflammatory and 
hemostatic biomarkers with CAC in peri-menopausal women are largely unknown. 
The goal of the proposed literature review is to the evaluate the potential association 
between CAC, CAC progression and several factors related to inflammation and hemostasis, 
specifically C-reactive protein (CRP), fibrinogen, plasminogen activator inhibitor type 1 (PAI-1), 
and tissue plasminogen activator (tPA). Focus was given towards studies consisting of patients 
with no known heart disease or other significant chronic illnesses. Particular attention was 
directed towards women going through the menopausal transition with no known cardiac history 
and no significant co-morbid illnesses. The potential importance for evaluating the relationship 
between these risk factors and CAC and CAC progression using the Study of Women’s Health 
Across The Nation (SWAN) will be addressed. 
 
METHODS 
 
A literature search was performed of the Ovid MEDLINE database from 1948 to January Week 
3 2013. The first search was performed using Medical Subject Headings (MeSH) “coronary 
artery calcification” or “coronary artery calcium” or “CAC”. The second search was performed 
using MeSH “C-reactive protein” or “fibrinogen” or “plasminogen activator inhibitor type 1” or 
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“tissue plasminogen activator”. The intersection of the searches was used to find articles 
pertaining to the emerging risk factors of interest with CAC and CAC progression. 
The search was limited to the English language and humans. Articles were finally 
reviewed by title, abstract, and text for inclusion. Review articles were excluded. Inclusion 
criteria consisted of studies in which subjects had undergone assessment of coronary artery 
calcium score via computed tomography, and if analysis included at least one of the novel 
cardiovascular risk factors of interest. 
 
RESULTS 
 
The first search using Medical Subject Headings (MeSH) “coronary artery calcium” or “coronary 
artery calcification” yielded 995 articles (FIGURE 1). The second search performed using 
MeSH “c-reactive protein” or “fibrinogen” or “plasminogen activator inhibitor type 1” or “tissue 
plasminogen activator” yielded 75,545 articles. There were 105 articles which intersected both 
searches. The titles and abstracts were reviewed for relevance and review articles were excluded. 
The search ultimately yielded 77 pertinent articles. Of these 77 articles, 26 directly addressed the 
association of one of the four risk factors of interest with CAC and/or CAC progression. Studies 
relating to baseline CAC are listed on TABLE 1 (16-19, 22-38). Studies pertaining to CAC 
progression or development are listed on TABLE 2 (39-43). The other studies included those 
with established CVD, specific significant co-morbid conditions (i.e. dialysis), or did not directly 
address associations between the risk factors of interest and CAC. These are listed on TABLE 3 
(39-94). Brief summaries of the findings of the 26 citations that are directly related to the current 
study research question are list below. Of these 26 studies, only 4 addressed CAC progression. 
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Studies addressing inflammatory markers were the most common. CRP was assessed in 
25 of the 26 studies (96%). Fibrinogen was the next most common and analyzed in 9 studies 
(35%). There was only one study (4%) that included PAI-1 as a variable, and zero studies 
included TPA. 
 
Association of Baseline Novel CV Risk Factors to Baseline CAC 
 
Bielak et al. (2000, Table 1, Study #1) examined the relationship between fibrinogen and high 
quantities of CAC using 288 participants from the Epidemiology of Coronary Artery 
Calcification Study (18). This case-control study compared 57 men and 57 women with CAC 
that was 80th percentile or greater for their sex and 10-year age group, to sex-matched controls 
with no detectable CAC. They found in a univariate logistic regression model that an increase of 
1 standard deviation in fibrinogen concentration was associated with statistically significant odds 
ratio for high quantities of CAC in men (1.6, 95% CI 1.1-2.5) and women (2.5, 95% CI 1.6-4.1). 
Women 50 to 59 years of age with high fibrinogen were more likely to have high quantities of 
CAC than women with low fibrinogen. The multivariate model accounting for all major risk 
factors demonstrated that only fibrinogen and an interaction variable for fibrinogen and age were 
significant predictors of high CAC (<0.0001). A notable limitation of this study was excluding 
patients with low and intermediate quantities of CAC.  
Hunt et al. (2001, Table 1, Study #2) found that CRP was unrelated to CAC in a nest 
case-control study in 188 men in the Prospective Army Coronary Calcium study (22). Cases 
were those with any detectable CAC, or >0 CAC score via the Agatston method, whereas 
controls were those with a CAC score of 0. Subjects were active-duty Army personnel between 
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the ages of 40-45 years who participated at the time of a routine, periodic Army physical exam 
and were free of known CV disease. They were not typical of the general population, so the 
results may not be generalizable. 
Wang et al. (2002, Table 1, Study #3) used a sample of 321 individuals (48% women) 
without known CVD from the Framingham Heart Study to demonstrate that increasing CRP, 
analyzed as quintiles, was significantly correlated with the raw CAC score determined by the 
Agatston method (23). The majority of women were post-menopausal as the mean age ± 
standard deviation was 61 ± 9 years. Those with clinically apparent CVD were excluded. The 
age-adjusted Spearman correlation was 0.25 for men and 0.26 for women. This was significant 
even after adjustment for age and Framingham risk score for both men and women (P=0.01). The 
main limitation was that CRP levels were obtained 4 to 8 years prior to the CT scans. Subjects 
with high CRP may have had significant CAC progression prior to CT scan, which would in turn 
lead to a higher strength of association. 
Colhoun et al. (2002, Table 1, Study #4) analyzed 196 type 1 diabetics and 195 controls 
between the ages of 30-55 years (24). They grouped patients by diabetic status and sex. 
Menopausal status was not considered. In the univariate analysis, the raw CAC score and CRP 
were significantly and positively correlated in all groups except diabetic women. The 
investigators also calculated odds ratios for the relationship between CRP and the presence of 
any CAC (CAC score >0 via Agatston score). After adjustment for other CV risk factors and 
body-mass index, the association was significant in men but not women. A limitation of the 
study was that the average age was relatively young with a mean ± standard deviation of 37.9 ± 
0.3 years in nondiabetic women and 37.5 ± 0.5 years in diabetic women. The majority of these 
women were therefore likely to be pre-menopausal. 
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Kullo et al. (2003, Table 1, Study #5) examined 354 (58% women) non-Hispanic white 
hypertensive patients from Rochester, Minnesota (19). CAC was transformed to log(CAC + 1) to 
reduce skewness. The majority of women were post-menopausal as the mean age ± standard 
deviation was 66 ± 7 years, and menopause status was not analyzed. Approximately half the 
women were on estrogen. CRP, evaluated in quintiles, was not associated with Log(CAC + 1) in 
men or women. Increasing fibrinogen levels, also evaluated by quintiles, were positively 
associated with increasing Log(CAC + 1) in women. The association was attenuated after 
adjustment for conventional risk factors.  
Reilly et al. (2003, Table 1, Study #6) performed a cross-sectional study on 914 (45% 
women) predominantly Caucasian subjects recruited due to a family history of premature CVD 
(25). The median age for women was 50 years (range 34 to 71) and menopausal status was not 
accounted for. Ln(CAC + 1) was analyzed as a continuous variable and raw CAC scores as 
quintiles. Increasing levels of CRP categorized as tertiles was not associated with higher 
Ln(CAC + 1) in men. There was a positive association between CRP and CAC in women with 
all approaches performed in this study, even after adjusting for traditional risk factors. This was 
no longer significant, however, when BMI was included.  
Huang et al. (2005, Table 1, Study #7) studied 124 (37% women) subjects with chest pain 
in Taiwan who were referred for CAC determination (26). The mean age ± standard deviation 
was 67 ± 1 years. Menopausal status was not reported. Subjects were divided into three groups 
based on raw CAC scores via Agatston: 0, 1-199, and ≥200. There was no significant difference 
in CRP among the three groups. 
Bowden et al. (2005, Table 1, Study #8) demonstrated no association between CRP and 
CAC in subjects from the Diabetes Heart Study (27). CAC was analyzed as an outcome as both 
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log(CAC) if the CAC score was >0, and as a the binary outcome of presence of CAC (CAC 
score >0 via Agatston). The 666 subjects (59% women) were participating in a study of families 
with type 2 diabetes mellitus and had a mean age of 60.8 years. In the overall population, 83% of 
patients were affected with diabetes. Menopausal status was not reported.  
Khera et al. (2006, Table 1, Study #9) examined CRP levels in 3373 subjects between 30 
and 65 years of age who were in the Dallas Heart Study (28). Women represented 56% of the 
subjects and approximately half were black. The mean age by quartile ranged from 42.8 to 46.3 
years. Estrogen use was included as a covariate, but menopausal status was not. CAC was 
evaluated as a binary outcome (raw CAC score >10 via Agatston) and by three raw CAC score 
thresholds: >10, >100, and >400. There was no statistically significant association between CRP 
and CAC in either sex after adjusting for traditional CV risk factors, BMI, estrogen use, and 
statin use. 
Godsland et al. (2006, Table 1, Study #10) failed to demonstrate a positive correlation 
between CRP and CAC in 573 (36% women) type 2 diabetic subjects in the Prospective 
Evaluation of Diabetic Ischaemic Heart Disease by Computed Tomography (PREDICT) study 
(29). In fact, CRP tended to decrease with increasing CAC score. The Spearman correlation 
coefficient was rho = –0.07 (p=0.07) for the entire sample and rho = –0.12 (p=0.006) for the 
subgroup with detectable calcification. CAC was evaluated in six categories based on raw CAC 
scores via Agatston, and as a binary outcome based on detectable (>10) or undetectable CAC. 
CAC was also evaluated as log(CAC + 1). The mean ± standard deviation of age in women was 
63 ± 7 years and menopausal status was not reported.  The race distribution was 70% white and 
17% Asian Indian.  
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Ye et al. (2007, Table 1, Study #11) evaluated 32 (44% women) subjects with LDL-C 
levels >190 mg/dl and a history of familial hypercholesterolemia against 34 healthy control 
subjects (30). There was no report of menopausal status. The mean age ± standard deviation in 
the group with hypercholesterolemia was 36.0 ± 17.8 years. CAC was assessed as a binary (CAC 
score >0 via Agatston) outcome as detectable or undetectable. CRP was significantly higher in 
the CAC detectable group compared to the undetectable group (0.29 ± 0.08 vs. 0.07 ± 0.08 
mg/dl, p=0.001). In the multivariable analysis, CRP was the only independent predictor of 
detectable CAC (relative risk 5.034, 95% confidence interval 1.525-16.613, p=0.04).  
Wilund et al. (2008, Table 1, Study #12) studied 13 (6 women) highly trained, endurance 
athletes aged 60 to 80 years and 12 (6 women) sedentary controls to assess relationships between 
cardiorespiratory fitness, CAC, and bone mineral density (31). CAC score was determined by the 
Agatston method and this was log-transformed. CRP was no significantly correlated with 
logCAC when calculated using Pearson correlation coefficient. The main limitations of this 
study are the small sample size and the atypically high physical fitness of the subjects. 
Erbel et al. (2008, Table 1, Study #13) demonstrated that Adult Treatment Panel III risk 
categories were significantly and sex-dependently altered when CAC and CRP were included in 
a risk model (16). The 4345 (53% women) subjects were randomly selected from 3 cities in 
Germany and 6.8% of the subjects had a history of coronary artery disease. The raw CAC score 
via Agatston was used to partition subjects into categories: <100, 100-399, and ≥400. CRP was 
likewise partitioned into three categories. ≤1 mg/L, 1-3 mg/L, and >3 mg/L. CAC was of most 
utility in men whereas CRP was of most use in women. The correlation between CAC and CRP 
was weak in the univariate analysis (R2=0.02), but statistically significant (p<0.0001). An 
adjusted analysis of this relationship was not performed. 
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Ramadan et al. (2008, Table 1, Study #14) sought to assess the relation of CAC with 
endothelial function and inflammatory markers in 177 (42% women) asymptomatic individuals 
of intermediate risk with an average age of 50.6 ± 5.9 years (32). Raw CAC scores calculated via 
the Agatston method were categorized into four groups: 0, 1-99, 100-399, and ≥400. It was also 
transformed as log(CAC + 1). There was no significant difference in the mean CRP across CAC 
grades, although CRP was higher in the group that demonstrated positive CAC. This was no 
longer significant after adjusting for gender and body mass index (p=0.221). 
Michos et al. (2009, Table 1, Study #15) evaluated the relationship between several CV 
risk factors and measurements of subclinical vascular disease from the Multi-Ethnic Study of 
Atherosclerosis (33). Subjects were ≥70 years of age in this cross-sectional substudy. CAC score 
was calculated by the Agatston method and low subclinical disease was defined as CAC <25th 
percentile. There was no relationship between CRP and CAC, or other measures of subclinical 
CVD. The limitation of this study is that the average age was greater than 70 years of age, so the 
results are may not be applicable to middle-aged women. 
Pratte et al. (2009, Table 1, Study #16) evaluated 560 type 1 diabetes patients and 693 
non-diabetes patients from the Coronary Artery Calcification in Type 1 Diabetes (CACT1) 
Study, of which 51% were women (34). CAC was evaluated as a binary outcome based on the 
presence or absence of any CAC. PAI-1 levels were independently associated with CAC 
presence in type 1 diabetics between 20 and 55 years of age, but not non-diabetic subjects. In the 
univariate analysis, the mean average CRP level was higher in the CAC positive group in the 
non-diabetes subgroup (p<0.05). The mean average fibrinogen level was higher in the CAC 
positive group among diabetics (p<0.05). The main limitation of this study was the focus on 
young diabetic patients. Thus, the mean ± standard deviation of age was 37 ± 9.1 years in 
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diabetics and 39.1 ± 9.1 years in non-diabetics. The results may therefore not be applicable to 
older individuals. 
Jenny et al. (2010, Table 1, Study #17) evaluated the association of inflammatory 
biomarkers, including CRP and fibrinogen, with the presence of CAC as defined by Agatston 
score >0 (35). The study included 6783 (53% women) subjects from the Multi-Ethnic Study of 
Atherosclerosis (MESA). Menopausal status was not included. The relative risks in multivariable 
adjusted models were 1.05 (95% CI, 0.99-1.12, p=0.63) for CRP and 1.09 (1.02-1.16, p=0.01) 
for fibrinogen. An important limitation was that subjects were partitioned based on the finding of 
any CAC, since prognosis is dependent upon degree of CAC when it is present. 
Qasim et al. (2011, Table 1, Study #18) studied the relationship between CRP and CAC 
in 1299 subjects with type 2 diabetes from the Penn Diabetes Heart Study and 860 without 
diabetes from the Study of Inherited Risk of Coronary Atherosclerosis (17). Women accounted 
for 41% of the overall study population. CAC was analyzed with Tobit regression of log(CAC + 
1). CRP was associated with higher CAC in diabetic women (Tobit ratio 1.60, 95% confidence 
interval 1.03-2.47) even after adjustment for age, race, medications, Framingham risk score, and 
body mass index. The result was not significant in non-diabetic women (Tobit ratio 1.29, 95% 
confidence interval 0.98-1.69), and there was no association in CRP to CAC in men. The 
combined diabetic and non-diabetic women sample was significant (Tobit ratio 1.44, 95% 
confidence interval 1.13-1.83) 
Freitas et al. (2011, Table 1, Study #19) evaluated 178 (79% women) healthy subjects 
between the ages of 80 and 102 years who were enrolled in the GEROS study, a prospective 
cohort to identify CV risk markers in the primary prevention setting (36). CAC was examined as 
a raw CAC score via Agatston as well as a binary outcome with a CAC score cutoff of >100 
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considered as significant disease. Those above the 75th percentile of CRP had a significantly 
higher mean raw CAC scores than the first three quartiles. Binary logistic regression 
demonstrated an independent association between a CAC score of >100 as the dependent 
variable and CRP >75th percentile. 
Blaha et al. (2011, Table 1, Study #20) studied the relationship between obesity, CRP, 
and subclinical atherosclerosis in the Multi-Ethnic Study of Atherosclerosis using a CRP cut-off 
of ≥2 mg/L, which was suggested by the JUPITER trial as a means to guide statin 
recommendation (37). There were 950 (51% women) subjects who met the JUPITER criteria 
with a mean age of 66.7 years. The race composition of the subjects was 41% white, 31% black, 
5% Chinese, and 23% Hispanic. CAC was evaluated as a binary outcome with a CAC score via 
Agaston of >0, and in three groups: 0, 1-100, and >100. There was no association between CRP 
and CAC when anthropomorphic variables were included. 
Gupta et al. (2012, Table 1, Study #21) investigated the relationship of CRP and CAC 
across a range of body mass index categories in 2685 (53% women) subjects enrolled in the 
Dallas Heart Study (38). A CAC score calculated via Agatston of >10 was used to define the 
presence of CAC. CRP was divided into three groups of <1 mg/l, 1-3 mg/l, and >3 mg/l. 
Increasing CRP was associated with increased CAC prevalence in those with a normal BMI 
category women, but not overweight (<30 mg/m2) or obese (>30 mg/m2). In contrast, the 
relationship was significant in both normal and overweight men, but not obese men. 
 
Association of Baseline Novel CV Risk Factors to CAC Progression or Subsequent 
Development 
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 Anand et al. (2007, Table 2, Study #22) examined subjects with type 2 diabetes who were 
between 30 and 65 years of age and without known CVD (39). The study population was of 54% 
South Asian origin. The mean age was 52 years and menopause status was not accounted for. 
CAC was calculated by Agatston and volumetric scores. Volumetric scores were categorized into 
1-10 mm3, 11-100 mm3, 101-400 mm3, and 100-400 mm3. CAC progression was defined as a 
change of ≥2.5 between the square root transformed values of the CAC volumetric 
measurements. The mean follow-up interval was 2.5 ± 0.4 years. CRP was neither related to 
extent of CAC at baseline, nor CAC progression.  
Green et al. (2009, Table 2, Study #23) measured fibrinogen in 1396 young black and 
white participants from the Chicago and Minneapolis sites in the Coronary Artery Risk 
Development in Young Adults (CARDIA) study (40). Subjects were ages 18-30 years at 
baseline. Hemostatic factors were drawn at the year 7 follow-up visit and CAC was determined 
13 years later at the 20 year follow-up visit. The presence of CAC was determined by an 
Agatston CAC score of >0. An elevated fibrinogen level in those between the ages of 25 and 37 
years at the year 7 visit was independently associated with the presence of CAC.  The main 
limitations of this study are the very young age of the study population at the time of initial 
enrollment, and analysis of CAC using only a binary variable based on presence or absence of 
CAC. 
Saremi et al. (2009, Table 2, Study #24) evaluated the association of risk factors to 
baseline and follow-up CAC in 197 and 189 subjects, respectively (41). Individuals were 
enrolled in Veterans Affairs Diabetes Trial (VADT). Sex distribution was not reported, but 
subjects were 94% male in the main study. Progression was defined as an increase in the square 
root volumetric scores of ≥2.5 mm3, as well as a continuous variable. The average follow-up was 
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4.6 years. CRP was not significantly related to CAC progression. Correlation with baseline CAC 
was not analyzed. 
Green et al. (2010, Table 2, Study #25) repeated their analysis of the relationship between 
fibrinogen and CAC in the CARDIA study, this time including the Birmingham and Oakland 
sites with the Chicago and Minneapolis sites (42). They noted that fibrinogen increased from a 
mean of 3.32 g/L to a mean of 4.05 g/L over the 13-year study. CAC was evaluated as a binary 
outcome based on the presence of CAC as determined by an Agatston CAC score of >0. 
Fibrinogen was positively associated with CAC incidence longitudinally (P=0.037), but not in 
the cross-sectional analysis (p=0.147). 
Rodrigues et al. (2010, Table 2, Study #26) evaluated the relationship of fibrinogen to 
CAC progression over 2.4 ± 0.4 from the CACT1 prospective cohort (43). Progression was 
defined as an increase in the square-root transformed CAC volume of >2.5 mm3 or the 
development of clinical coronary artery disease. This study included 546 subjects with type 1 
diabetes and 640 controls without diabetes. Women accounted for 55% of the population, but 
menopausal status was not addressed. In the combined population of diabetics and non-diabetics, 
baseline fibrinogen levels were higher in progressors when compared to non-progressors (276 ± 
61 mg/dl vs. 259 ± 61 mg/dl, p=0.0003). 
 
DISCUSSION 
 
The major findings from this literature review is that 1) there are a number of articles that 
addressed the association of inflammatory biomarkers, CRP and fibrinogen, with CAC, 2) there 
is little data on the association between PAI-1 and CAC, 3) there are no manuscripts addressed 
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potential associations between TPA and CAC, 4) there is a paucity of data with any of these 
novel CV risk factors on CAC progression, and 5) few of these studies evaluated middle-aged 
women and none took menopausal status into account. 
The relationship of CRP to CAC in asymptomatic subjects was generally not consistent. 
Wang et al. found an association between CRP levels by quintile and raw CAC scores in healthy 
men and women (23). The delay of 4 to 8 years between CRP and CAC determination makes it 
unclear if higher CAC in this group was based on a greater baseline CAC presence at the time of 
CRP analysis. Qasim et al. found a positive association between CRP and CAC among diabetic 
women, but not in men or non-diabetic women (17). It is difficult to make conclusions based on 
these results as subjects were drawn from two cross-sectional studies. One study recruited 
subjects based on a history of premature CVD and the other based on a confirmed diagnosis of 
type 2 diabetes. A study of individuals with type 2 diabetes mellitus recruited from diabetes 
clinics by Godsland et al. actually demonstrated that CRP decreased with increasing CAC (29). 
The authors felt that this was a chance observation. These discrepancies may be related to the 
populations studied, the technique of analyzing the relationship between CRP and CAC, or a 
combination. Ultimately, the relationship of CRP to CAC among healthy middle-aged women is 
yet to be conclusively established and more study is warranted in subjects more representative of 
the general population. 
Early studies on the association of fibrinogen with CAC suggested a positive correlation, 
particularly in women (18,19). More recently, longitudinal studies demonstrated that high 
fibrinogen levels were associated with the development of CAC more than a decade later in life, 
and that patients with type 1 diabetes may be at particular risk (41,42). Fibrinogen has been 
cited, along with CRP, as a possible means by which CV event risk prediction may be enhanced 
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in those judged to be at intermediate risk (44). As with CRP, the understanding of the 
relationship of fibrinogen to CAC should be improved to gain insights into potential mechanisms 
for disease progression. Due to early studies demonstrating that fibrinogen may play an 
important role in CAC development in women, understanding more of this process taking into 
account the menopausal transition may uncover important insights into the relationship.  
The lone study that addressed the relationship between PAI-1 and CAC was performed in 
a relatively young group of subjects enrolled in a prospective cohort study designed to examine 
the development of subclinical atherosclerosis in those with and without type 1 diabetes (34). 
Subjects enrolled were between the ages of 20 and 55 years and otherwise healthy. Interestingly, 
only the diabetes subjects ages 35 years and younger maintained a positive relationship between 
PAI-1 and CAC. The association was weakened and no longer statistically significant after 
controlling for variables associated with insulin resistance. Weaknesses of the study included the 
relatively young average age of the study population, lack of accounting for race and menopause 
status, and assessment of CAC as a binary outcome based on presence or absence of any CAC. 
Further elucidation of the relationship between PAI-1 level and CAC, as well as CAC 
progression, are therefore needed.  
Only 5 studies evaluated the association of the four novel risk factors (CRP, fibrinogen, 
PAI-1, TPA) with CAC progression or CAC development. Of these, two studies by Green et al. 
were from the CARDIA study and only included one CAC measurement obtained 13 years after 
the baseline biomarker measurement (40, 42). Thus, only three studies addressed CAC 
progression between CT scans obtained at two different time points. A study performed in 
military veterans demonstrated no correlation between CRP and CAC progression (41). The 
patient population, however, was 94% men with a mean average age of 61.2 years. The study by 
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Anand et al., that did not find an association between CRP and CAC progression, was conducted 
entirely in subjects with type 2 diabetes and 54% were of South Asian ethnicity, so the results 
may not be relevant to healthy individuals of other ethnicities (39).  Those with CAC progression 
examined in the CACT1 study demonstrated a significant association with fibrinogen in those 
with type 2 diabetes, but not healthy controls (43). This may be due to the fact that 67% of 206 
individuals with CAC progression were diabetics and only 33% were otherwise healthy 
individuals. In short, there are no significant data for these risk factors and CAC progression in 
healthy middle-aged women. 
Menopause is a critical time period as risk assessment during this age predicts the 
lifetime risk of developing CVD (5). As CAC detected on a CT scan represents distinct stages in 
the atherosclerotic process, insights into the relationship between novel CV risk factors and CAC 
may enhance our understanding of the underlying pathophysiologic mechanisms and direct 
future treatment efforts. Thus, analysis of the subjects enrolled in SWAN Heart may offer 
significant insight into these potential relationships. 
 
CONCLUSION 
 
Additional studies are needed to determine subgroups that may have the highest correlation 
between CRP and fibrinogen with CAC and CAC progression. Data regarding potential 
associations between PAI-1 and TPA with CAC are virtually non-existent. Women progressing 
through the menopausal transition are at an age where identifying their lifetime CVD risk may 
modify the ultimate development of CVD (5). The SWAN Heart study provides an ideal 
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opportunity to study potential associations between inflammatory and hemostatic markers with 
CAC and CAC progression. 
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TABLE 1. Characteristics of Studies Examining Novel Cardiovascular Risk Factors with Baseline CAC. 
Study 
# 
1st Author (Year, 
reference) - Journal 
Study Design Population / Aim Sample CAC 
Measure(s) 
Novel CV Risk 
Factor 
Major Findings 
1 Bielak (2000, 18) – 
ATVB 
Case-control – 
Epidemiology 
of Coronary 
Artery 
Calcification 
(ECAC) Study 
Participants <70 yrs (but 
≥50 yrs women, ≥40 yrs 
men) without CAD / 
Assess relation of 
fibrinogen with high CAC 
(≥80th percentile for sex 
and age) 
227, 113 
(50%) 
women; race 
not specified 
Binary (80th 
percentile) using 
raw CAC score 
via Agatston 
CRP, Fibrinogen *High fibrinogen was 
associated with high 
quantities of CAC, 
particularly in young women. 
*CAC presence was not
associated with elevated CRP 
2 Hunt (2001, 22) – 
Am Heart J 
Nested case-
control – 
Prospective 
Army 
Coronary 
Calcium 
(PACC) 
Active-duty Army 
personnel ages 40-45 yrs / 
Assess relation of CRP 
with CAC presence 
188, 100% 
men; race not 
specified 
Binary (>0) 
CAC score and 
logCAC via 
Agatston 
CRP *The mean hsCRP level was
unrelated to the log-
transformed CAC score. 
3 Wang (2002, 23) – 
Circulation 
Cross-sectional 
– Framingham
Subjects aged 5-70 yrs / 
Assess relation between 
CRP and CAC 
321; 154 
(48%) 
women; race 
not specified 
Raw CAC score 
via Agatston 
CRP *High CRP levels were
associated with increased 
coronary calcification as 
measured by raw CAC score 
4 Colhoun (2002, 24) – 
Diabetes Care 
Cross-sectional T1DM and non-T1DM 
subjects aged 30-55 yrs 
196 T1DM, 
195 non-
T1DM; 199 
(51%) 
women; race 
not specified 
Raw CAC and 
binary (>0) 
CAC presence 
via Agatston  
CRP *The association of CRP and
CAC was present in men even 
after adjustment. 
*CRP was not associated with
CAC in women. 
5 Kullo (2003, 19) – 
Am J Cardiol 
Cross-sectional 
– Genetic
Network of 
Arteriopathy 
(GENOA) 
Hypertensive siblings / 
Assess relation of CRP 
and fibrinogen with CAC 
in hypertensive pts  
354; 206 
(58%) 
women; 100% 
white 
Log (CAC score 
via Agatston + 
1) 
CRP, fibrinogen *CRP was not associated with
CAC in either gender. In 
women, fibrinogen was 
associated with CAC. 
6 Reilly (2003, 25) – 
ATVB 
Cross-sectional 
- SIRCA 
Non-DM 30-75 yrs with 
FH of premature CVD but 
no CAD / Assess relation 
of CRP and CAC 
914; 414 
(45%) 
women; 95% 
white 
CACS via 
Agatston; linear 
reg. of ln (CAC 
+ 1), tobit reg. 
of ln (CAC + 1), 
CRP *CRP not associated with
CAC in men, but weakly 
associated in women. This 
was lost after adjustment for 
BMI. 
95 
binary (>0) 
CAC presence, 
Ordinal reg. by 
quintiles 
7 Huang (2005, 26) – 
Chest 
Cross-sectional Pts with suspected CAD / 
Assess relation of CAC to 
endothelial dysfunction 
124; 46 (37%) 
women; race 
not specified 
Raw CAC score 
via Agatston by 
tertiles 
CRP *Higher CAC scores strongly
predicted endothelial 
dysfunction 
*CRP was not associated with
degree of CAC 
8 Bowden (2005, 27) – 
Am Heart J 
Cross-sectional 
– Diabetes
Heart Study 
Siblings concordant for 
T2DM without renal 
dysfunction / Assess 
relation between CRP and 
CAC 
666; 393 (59% 
women); 84% 
white, 16% 
black 
Binary (>0) 
CAC score and 
raw CAC score 
if >0 via 
modified 
Agatston 
CRP *CRP was not significantly
associated with CAC. 
9 Khera (2006, 28) – 
Circulation 
Cross-sectional 
– Dallas Heart
Pts 30-65 yrs without 
prior CVD / Assess 
relation between CRP and 
CAC 
3373; 1885 
(56%) 
women; 52% 
black 
Binary (>10) 
CAC score via 
Agatston and by 
tertiles 
CRP *Subjects with higher CRP
had a modest increase in 
prevalence of CAC, but this 
was not independent of 
traditional risk factors. 
10 Godsland (2006, 29) 
– Diabetic Med
Cross-sectional 
– PREDICT
T2DM adults / Assess 
relation of novel CV risk 
factors and CAC 
573; 207 
(36%) 
women; 70% 
white, 17% 
Asian Indian 
Binary (>10) 
CAC score, raw 
CAC score, and 
log (CAC + 1) 
via Agatston 
CRP, fibrinogen *Age was the major 
contributing factor for CAC; 
other risk factors with little 
effect. 
*Negative association 
between CRP and CAC. 
11 Ye (2007, 30) – Am 
J Cardiology 
Case-control Pts with LDL-C levels 
>190 mg/dl and positive 
family history of 
hyperlipidemia in Taiwan 
/ Assess relation between 
CAC to FMD and CRP 
66 (32 case, 
34 controls); 
21 (47%) 
women; 100% 
Chinese 
Binary (>0) 
CAC score and 
raw CAC score 
via modified 
Agatston 
CRP *Familial hyperlipidemia pts
with positive CACS have 
decreased flow-mediated 
dilation and increase CRP. 
*Hs-CRP was the only
independent predictor of the 
presence of CAC. 
12 Wilund (2008, 31) – 
Metabolism 
Case-control Pts 60-80 yrs with no 
prior CAD / Assess 
relation between 
cardiorespiratory fitness, 
CAC, and BMD 
13 athletes, 12 
controls; 6 
(46% 
women); race 
N/A 
Raw CAC score 
and logCAC via 
Agatston 
CRP *Chronic exercise may 
simultaneously inhibit CAC 
and increase BMD. 
*CRP was not significantly
correlated to logCAC 
(Pearson -.151) 
13 Erbel (2008, 16) - Prospective Participants in the Heinz 4066; 2148 Raw CAC score CRP *Adding CAC and hs-CRP to
96 
Atherosclerosis cohort – Heinz 
Nixdorf Recall 
Study 
Nixdorf Recall study / 
estimate the sex 
dependent effect of risk 
factors and CAD on the 
presence of CAD, 
calculate RR for history 
of CAD, evaluate effect of 
CAD and CRP on NCEP 
ATP III class 
(53%) 
women; race 
N/A 
via Agatston by 
tertile and 
binary (75th 
percentile) 
NCEP ATP risk changed 
distribution of considerably 
with strong differences 
between sexes. 
*although statistically 
significant (p<0.0001), the 
correlation between CAC and 
hs-CRP was weak (R2=0.02). 
14 Ramadan (2008, 32) 
Circulation J 
Cross-sectional Asymptomatic Middle 
Eastern Egyptians 40-59 
yrs with intermediate risk 
/ Assess relation between 
CAC and FMD, NMD, 
CRP, IL-6, and OxLDL 
177; 74 (42%) 
women; 100% 
Egyptian 
Raw CAC score 
via Agatston by 
tertile 
CRP *FMD correlated negatively
with CAC 
*IL-6 was correlated with
CAC 
*CRP was not correlated with
CAC 
15 Michos (2009, 33) – 
Preventive 
Cardiology 
Cross-sectional 
- MESA 
 Asymptomatic people 
without known CAD ≥70 
yrs/ assess relation of risk 
factors with CAC 
1824; 949 
(52%) 
women; white, 
black, Chinese 
and Hispanic - 
% not 
specified 
Binary CAC 
score via 
Agatston (<25th 
percentile) 
CRP *No association CRP and
CAC 
16 Pratte (2009, 34) – J 
Diabetes and it’s 
Complications 
Cross-sectional 
– CACT1
Diabetes type I with no 
known CAD aged 19-56 
yrs / assess relation 
between PAI-1 and CAC 
1253 (560 
T1DM, 693 
non-T1DM); 
640 (51%) 
women; race 
N/A 
Binary CAC 
score via 
Agatston 
PAI-1, CRP, 
fibrinogen 
*PAI-1 was significantly
associated with the presence 
of CAC (OR 1.24, 95% CI 
1.13-1.36, P<.001); 
significant post-adjustment. 
*CRP associated with CAC in
non-T1DM. Fibrinogen 
associated with CAC in 
T1DM. 
17 Jenny (2010, 35) – 
Atherosclerosis 
Cross-sectional 
- MESA 
Asymptomatic people 
without known CAD / 
assess relation between 
inflammatory markers and 
CAC 
6783; 3578 
(53%) 
women; 39% 
white, 28% 
black, 12% 
Chinese, 22% 
Hispanic 
Binary (0 vs. 
>100) CAC 
score via 
Agatston 
CRP, fibrinogen * CRP, IL-6, fibrinogen were
weakly associated with CAC 
18 Qasim (2011, 17) – 
Clin Endocrinol 
Cross sectional 
– Penn 
Pts at risk for CAD (FH 
or T2DM) aged 35-75 yrs 
1299 PDHS – 
T2DM, 860 
Tobit regression 
of Ln(CAC + 1) 
CRP *female gender was 
associated with higher plasma 
97 
Diabetes Heart 
Study and 
Study of 
Inherited Risk 
of Coronary 
Atherosclerosis 
/ assess whether CRP has 
gender differences in 
association with CAC in 
DM and non-DM pts 
SIRCA – non-
DM; 883 
(41%) 
women; 75% 
white, 20% 
black 
score via 
Agatston 
CRP in DM and non-DM pts 
*in DM and non-DM women,
CRP was associated with 
higher CAC 
19 Freitas (2011, 36) – 
Atherosclerosis 
Cross-sectional Healthy, asymptomatic 
individuals between 80 
and 102 years / assess 
relation between 
mediators of 
inflammation and 
subclinical CVD 
178; 140 
(79%) 
women; race 
N/A 
Binary (>100) 
and raw CAC 
score via 
Agatston 
CRP, fibrinogen *Those above the 75th
percentile for CRP had higher 
CAC scores 
20 Blaha (2011, 37) – 
ATVB 
Cross-sectional 
- MESA 
Asymptomatic people 
without known CAD / 
assess relation between 
obesity, high hsCRP (≥2 
mg/dl), and CAC/cIMT 
6760; 53% 
female; 39% 
white, 27% 
black; 12% 
Chinese; 22% 
Hispanic 
Binary (>0) and 
raw CAC score 
via Agatston 
CRP *hsCRP not associated with
CAC when anthropomorphic 
variables were included 
*when hsCRP and obesity
were both present, no 
evidence of multiplicative 
interaction 
21 Gupta (2012, 38) – J 
Am Coll Cardiol 
Cross-sectional 
– Dallas Heart
Asymptomatic people 
without known CAD / 
assess if relation between 
CRP and atherosclerosis 
(i.e. CAC) differs by BMI 
2899 (2685 
with CAC 
measurement); 
1600 (55%) 
women; 31% 
white, 50% 
black, 17% 
Hispanic 
Binary CAC 
(>10) score via 
Agatston 
CRP *Increasing CRP was 
associated with increased 
CAC prevalence in normal 
and overweight men and 
normal women, but not obese 
men or women 
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TABLE 2. Characteristics of Studies Examining Novel Cardiovascular Risk Factors with CAC Progression. 
Study 
# 
1st Author (Year, 
reference) - Journal 
Study 
Design 
Population / Aim Sample CAC Measure(s) Novel CV Risk 
Factor 
Major Findings 
22 Anand (2007, 39) – J 
Am Coll Cardiol 
Prospective 
cohort 
T2DM 30-65 yrs without 
CHD – Assess relation 
between CV risk factors, 
select novel risk factors 
and CAC progression 
398; 154 
(39%) 
women; 
21% white, 
55% South 
Asian, 23% 
Afro-Carib. 
Difference in sq 
root transformed 
raw CAC score  
via Agatston;  
progression 2.5 
yrs; >2.5 mm3 
significant 
CRP *Baseline CAC and suboptimal
glycemic control of strong risk 
factors for progression. 
*CRP was not a predictor of
CAC progression. 
23 Green (2009, 40) – 
Atherosclerosis 
Prospective 
cohort - 
CARDIA 
Healthy black and white 
adults aged 18-30 yrs / 
assess relation of 
hemostatic factors to 
subclinical atherosclerosis 
13 years later 
1396; 753 
(54%) 
women; 
62% white, 
38% black 
Binary (>0) CAC 
score via 
Agatston 
CRP, fibrinogen *increasing quartiles of 
fibrinogen were associated 
with CAC and cIMT 13 years 
later 
*did not assess CRP to CAC
24 Saremi (2009, 41) – 
Atherosclerosis 
Cross-
sectional – 
Veterans 
Affairs 
Diabetes 
Trial 
(VADT) 
Age >40 yrs with T2DM 
enrolled in Veterans 
Affairs Diabetes Trial / 
assess relation between 
CRP, IL-6, and Lp-PLA2  
306;17 (6%) 
women; 
66% non-
Hispanic 
white 
Raw CAC score 
and ln(CAC + 1) 
via Agatston 
CRP *IL-6 remained significantly
associated with CAC S, 
particularly in those with lower 
abdominal artery calcium. 
*CACS did not increase with
CRP and Lp-PLA2. 
25 Green (2010, 42) – J 
Thrombosis & 
Hemostasis 
Prospective 
cohort – 
Coronary 
Artery Risk 
Development 
in Young 
Adults 
(CARDIA) 
Healthy black and white 
adults aged 18-30 yrs / 
assess relation of 
fibrinogen to subclinical 
atherosclerosis 
2969 for 
longitudinal; 
1636 (55%) 
women; 
56% white, 
44% black 
Binary (>0) CAC 
score via 
Agatston 
CRP, fibrinogen *higher levels of fibrinogen
during young adulthood are 
positively associated with 
incidence of CAC 
*fibrinogen increased 22%
over 13 yrs 
26 Rodrigues (2010, 43) 
– Atherosclerosis
Prospective 
cohort – 
CACT1 
Diabetes type I with no 
known CAD / assess if 
fibrinogen predicts CAC in 
adults with type 1 diabetes 
546 T1DM, 
640 
controls; 
650 (55%) 
women; 
race N/A 
Difference in sq 
root transformed 
raw CAC score  
via Agatston;  
progression 2.4 
yrs; >2.5 mm3 
significant 
fibrinogen *higher levels of fibrinogen
predicted CACS progression in 
T1DM, independent of 
standard CV risk factors 
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TABLE 3. Characteristics of Studies Examining Novel Cardiovascular Risk Factors with Coronary Artery Calcification (CAC) and CAC Progression in 
Subjects with Established Cardiovascular Disease, Significant Co-Morbid Illnesses, and/or Without Specific Assessment of Risk Factors with CAC. 
Study 
# 
1st Author (Year, 
reference) - Journal 
Study Design Population / Aim Sample CAC Measure(s) Novel CV Risk 
Factor 
Major Findings 
27 Meng (2002, 44) – 
Am Heart J 
Cross-sectional 
–ALIVE
African-American men 
aged 25-45 yrs with HIV / 
Assess relation of HIV PIs 
on SCD 
98; 29 
(30%) 
women; 
100% black 
Raw CAC score 
via Agatston 
CRP *The use of PIs are associated
with CAC. 
*no systematic assessment of
CRP to CAC 
28 Meng (2003, 45) – 
Int J Cardiol 
Cross-sectional 
– ALIVE
African-American men 
aged 25-45 yrs with 
cocaine use / Assess 
relation of CRP and 
endothelial function with 
CAC, lipid profile, and 
cardiac changes 
53; 16 
(30%) 
women; 
100% black 
Raw CAC score 
via Agatston 
CRP *Elevated CRP is associated
with CAC. 
29 Lai (2003, 46) – 
AIDS Patient Care 
Cross-sectional 
– AIDS Links
to the 
Intravenous 
Experience 
(ALIVE) study 
African-American men 
aged 25-45 yrs with HIV / 
Assess relation of 
individual protease 
inhibitors on CV risk 
factors 
98; 29 
(30%) 
women; 
100% black 
Raw CAC and 
binary (>5) CAC 
presence via 
Agatston 
CRP *Those taking nelfinavir, 
ritonavir, or saquinavir were 
more likely to have higher 
CACS than those on non-PI 
regimens. 
*no systematic assessment of
CRP to CAC 
30 Grahame-Clarke 
(2003, 47) – 
Circulation 
Cross-sectional Cohort of DM and non-
DM / Assess relation of 
anti-IgG antibodies to 
CMV and HSV to 
endothelial dysfunction 
400; 194 
(51%) 
women; 
race not 
specified 
CACS via 
Colhoun 
CRP *CMV-seropositive
individuals have endothelial 
dysfunction. 
*no systematic assessment of
CRP to CAC 
31 Tong (2004, 48) – 
Am J Cardiol 
Cross-sectional African-American men 
aged 25-45 yrs with HIV 
or cocaine use / Assess 
relation of LV mass and 
CAC 
159; 52 
(33%) 
women; 
100% black 
Binary (>0) 
CAC presence 
via Agatston 
CRP *LV mass indicies were larger
in CAC-positive groups than 
CAC-negative groups. 
*no systematic assessment of
CRP to CAC 
32 Reilly (2004, 49) – 
Circulation 
Cross-sectional 
- SIRCA 
Non-DM 30-75 yrs with 
FH of premature CVD but 
no CAD / Assess relation 
of insulin resistance and 
metabolic syndrome with 
CAC 
840; 397 
(47%) 
women; 
95% white 
Ln (CAC + 1) 
via Agatston, 
Ordinal reg. by 
quintiles 
CRP *Metabolic syndrome and
homeostasis model assessment 
were associated with CAC, 
independent of traditional risk 
factors. 
*no systematic assessment of
100 
CRP to CAC 
33 Deo (2004, 50) – J 
Am Coll Cardiol 
Cross-sectional 
– Dallas
Pts 30-65 yrs without prior 
CVD / Assess relation 
between monocyte 
chemoattractant protein-1 
and CAC 
3499; 1915 
(55%) 
women; 
52% black, 
29% white, 
17% 
Hispanic 
Binary (>10) 
CAC presence 
via Agatston 
CRP *no systematic assessment of
CRP to CAC 
34 Ferramosca (2005, 
51) – Am Heart J 
Randomized 
trial 
ESRD on HD / Assess 
sevelamer vs. calcium 
acetate on CAC 
progression at 1 yr and 
risk factor measurements 
108; 38 
(35%) 
women; 
36% black, 
64% non-
black 
Raw CAC score 
via Agatston 
CRP *CACS did not progress in
sevelamer group but did in 
Ca-acetate groiup (P<0.001). 
*CRP did not change 
significantly. 
*no systematic assessment of
CRP to CAC 
35 Burdon (2006, 52) – 
Am Heart J 
Cross-sectional 
– Diabetes
Heart Study 
Siblings concordant for 
T2DM without renal 
dysfunction / Assess 
relation between CD40 
gene and CAC 
620; 345 
(56%) 
women; 
100% white 
Ln (CAC) via 
modified 
Agatston 
CRP *Genetic variation in CD40 is
associated with CAC in 
diabetic families. 
*no systematic assessment of
CRP to CAC 
36 Steffes (2006, 53) – 
Obesity 
Cross-sectional 
– CARDIA
Healthy black and white 
adults aged 18-30 yrs / 
assess relation of 
adiponectin to CV risk 
factors and CAC 
2483; 1348 
(40%) 
women; 
43% black, 
57% white 
Binary (>0) 
CAC presence 
via Agatston 
CRP *Adiponectin correlated 
positively with CAC. 
*no systematic assessment of
CRP to CAC 
37 Anand (2006, 54) – J 
Am Coll Cardiol 
Cross-sectional T2DM / Assess relation of 
CRP, IL-6, 
osteogrotegerin with CAC 
and near-term CV events 
510; 201 
(39%) 
women; 
22% white, 
54% Asian; 
23% black 
Raw CAC score 
via Agatston by 
quintiles 
CRP *Osteoprotegerin predicted 
CAC. 
*CRP was not related to
extent of CAC. 
38 Jung ( 2006, 55) – 
Nephrology Dialysis 
Transpl 
Prospective 
cohort 
>18 yrs on HD / Assess 
relation of CAC 
progression over 2 yrs 
with risk factors 
40; 14 
(35%) 
women; 
100% 
Korean 
Difference in sq 
root transformed 
raw CAC score  
via Agatston;  
progression 2 
yrs; >2.5 mm3 
significant 
CRP *Degree of CAC progression
was associated with the time-
integrated level of CRP. 
39 Coutinho (2007, 56) 
– Am J Hypertension
Cross-sectional Pts with ≥2 siblings with 
HTN before age 60 yrs / 
1107; 657 
(59%) 
Log (CAC + 1) 
score via 
CRP, fibrinogen *Serum UA was associated
with 10-year probability of 
101 
Assess relation of serum 
uric acid with 10-yr 
probability of CAD and 
CAC 
women; 
race not 
specified 
Agatston CHD, metabolic syndrome, 
log CRP, and fibrinogen. 
*no systematic assessment of
CRP to CAC 
40 Reilly (2007, 57) – J 
Investigative Med 
Cross-sectional 
- SIRCA 
Non-DM 30-75 yrs with 
FH of premature CVD but 
no CAD / Assess relation 
of IL-6 and TNFR2 with 
metabolic syndrome, CRP, 
and CAC 
875; 402 
(46%) 
women; 
95% white 
Raw CAC score 
and log (CAC + 
1) via Agatston
CRP *IL-6 and TNFR2 were
independently associated with 
CAC. 
*no systematic assessment of
CRP to CAC 
41 Mehta (2007, 58) – 
Hypertension 
Cross-sectional 
- Dallas Heart 
Pts 30-65 yrs without prior 
CVD / Assess relation 
between LVH and CAC 
and CRP 
2633; sex 
not 
specified; 
≈50% black, 
≈30% white, 
≈20% 
Hispanic 
Binary (>10) 
CAC score and 
log (CAC + 1) 
via Agatston 
CRP *LV wall thickness is 
associated with CAC, but not 
CRP in multivariable adjusted 
model. 
*no systematic assessment of
CRP to CAC 
42 Nettleton (2007, 59) 
– Am J Clin 
Nutrition 
Cross-sectional 
– MESA
Pts 45-84 yrs free of CVD 
at baseline / Assess 
relation between diet and 
CVD 
5089; ≈50% 
women 
Binary (>0) 
CAC presence 
via Agatston 
CRP, fibrinogen *Subtle differences in dietary
pattern composition affect 
associations with markers of 
SCD. 
*no systematic assessment of
CRP or fibrinogen to CAC 
43 Lutsey (2007, 60) – 
Br J Nutrition 
Cross-sectional 
- MESA 
Pts 45-84 yrs without 
CVD / Assess relation 
between whole grain 
intake, CVD risk factors 
and measures of SCD 
5496; ≈50% 
women 
Binary (>0) 
CAC presence 
via Agatston 
CRP *whole grain intake was
unrelated to subclinical CVD 
*no systematic assessment of
CRP to CAC 
44 Lakoski (2007, 61) – 
Atherosclerosis 
Cross-sectional 
– MESA
Pts 45-84 yrs without 
CVD / estimate the 
proportion of 
intermediate-risk 
participants who might be 
reclassified as high risk 
based on CRP or CACS 
1450 
intermediate 
risk; 195 
(8%) 
women; 
31% white, 
30% 
Chinese, 
29% black, 
30% 
Hispanic 
Binary (>100) 
CAC presence 
via Agatston, as 
well as age-
gender-specific 
75th percentile 
CRP *Differences in 
reclassification was based on 
the screening test used, cut 
points selected, and 
demographics of the 
individual. 
*no systematic assessment of
CRP to CAC 
45 Mohler (2007, 62) – J Prospective Pts with moderate-to- 61; sex and N/A CRP *No significant reduction in
102 
Heart Valve Disease cohort severe aortic stenosis / 
assess treatment with 
statin on CAC and AC 
race N/A calcification with statin 
treatment. 
*Baseline CRP predicted CAC
progression. 
46 Dotsenko (2007, 63) 
– J Thrombosis and
Hemostasis 
Nested 
substudy of 
Peripheral 
artery disease 
in South Asian 
and European 
men with CAD 
(PARSEC) 
Men >45 years from 
European and South Asia / 
Assess relation between 
platelet/leukocyte 
activation and 
atherosclerosis, also 
between races 
54; 0% 
women; 
56% white, 
44% South 
Asian 
Raw CAC score 
(using 
proprietary 
softward from 
Philips MxView) 
by tertiles 
CRP *Increased PMC are related to
aortic and femoral, but not 
coronary or carotid, 
atherosclerosis. CRP related to 
PMC. 
*no systematic assessment of
CRP to CAC 
47 Reiner (2007, 64) – 
ATVB 
Prospective 
cohort - 
CARDIA and 
Cardiovascular 
Health Study 
(CHS) 
Pts 18-30 yrs / assess 
relation between USF1 
tagSNPs, CVD risk 
factors, and aging-related 
phenotypes 
1875 
CARDIA, 
4536 CHS; 
sex N/A; 
100% white 
Not described CRP *Complex relationship 
between USF1 genotype, 
atherosclerosis phenotypes, 
and CVD risk. 
*no systematic assessment of
CRP to CAC 
48 Nettleton (2008, 65) 
– Am J Clin 
Nutrition 
Cross-sectional 
– MESA
Pts 45-84 yrs free of CVD 
at baseline / Assess 
relation between diet and 
CVD 
5042; 2601 
(52%) 
women; 
white, 
black, 
Chinese and 
Hispanic - 
% not 
specified 
Raw CAC and 
binary (>0) CAC 
presence via 
Agatston 
CRP, fibrinogen *The Comprehensive Healthy
Dietary Pattern was associated 
with favorable changes in a 
variety of CVD risk factors. 
*no systematic assessment of
CRP to CAC 
49 Qasim (2008, 66) – J 
Am Coll Cardiol 
Cross-sectional 
- SIRCA 
Non-DM 30-75 yrs with 
FH of premature CVD but 
no CAD / Assess relation 
between adiponectin and 
leptin with CVD risk 
factors and CAC 
860; 403 
(47%) 
women; 
95% white 
CAC score via 
Agatston; tobit 
regression of ln 
(CAC + 1) and 
binary (70th 
percentile) 
CRP *Leptin was a significant
predictor of CAC 
*no systematic assessment of
CRP to CAC 
50 Chung (2008, 67) – 
Arthritis & 
Rheumatism 
Cross-sectional Pts >18 yrs with 
rheumatoid arthritis / 
Assess relation between 
decreased insulin 
sensitivity and 
inflammation, by studying 
SLE and RA 
103 SLE (73 
women, 
89% white), 
124 RA 
(91% 
women, 68 
white) 
Raw CAC score 
via Agatston 
CRP *RA and SLE are associated
with insulin resistance, but 
different mechanisms 
*no systematic assessment of
CRP to CAC 
103 
51 Kao (2008, 68) – Am 
J Cardiology 
Case-control Non-DM women with 
SLE and RA / assess rates 
of CAC relative to healthy 
controls and investigate 
relation to inflammatory 
markers 
157 SLE, 
181 RA, 
157 
controls; 
100% 
women, 
96% white 
Raw CAC score 
by quartile and 
binary (>0) CAC 
presence via 
Agatston 
CRP, fibrinogen *Women with SLE/RA have
increased odds of CAC 
compared with controls 
*the highest CRP quartile was
associated with CAC 
outcomes 
52 Solus (2008, 69) – 
Arthritis & 
Rheumatism 
Case-control Pts >18 yrs with 
rheumatoid arthritis / 
Assess relation between 
NT-proBNP and CAC and 
inflammation 
159 RA, 88 
controls; 
165 67% 
women; 
87% white 
Raw CAC score 
via Agatston 
CRP *NT-proBNP is not associated
with CACS 
*no systematic assessment of
CRP to CAC 
53 Elkeles (2008, 70) – 
Eur Heart J 
Prospective 
cohort – 
Prospective 
evaluation of 
diabetic 
ischaemic 
heart disease 
by computed 
tomography 
(PREDICT) 
Pts with T2DM aged 50-
75 yrs recruited from an 
outpatient clinic / assess 
relation between CACS, 
events, and risk factors 
589; 216 
(37%) 
women; 
71% white; 
20% Asian 
Indian 
Raw CAC via 
Agatston as 
continuous and 
by quintile 
CRP *CACS is a powerful 
predictor of CV events 
*no systematic assessment of
CRP to CAC 
54 Hosseinsabet (2008, 
71) – Cardiology 
Journal 
Cross-sectional Pts referred for CABG / 
assess relation between 
CRP and CACS 
143; 26% 
women 
Log(CAC + 1) 
via Agatston 
CRP *no relation between CRP and
CACS 
55 Michos (2009, 72) – 
Calcified Tissue 
International 
Cross-
sectional; 
Amish Family 
Calcification 
Old Order Amish people / 
assess relation between 
serum 25(OH)D levels and 
CAC, cIMT, or CRP 
654; 370 
(57%) 
women; 
100% white 
Amish 
Raw CAC score 
and log(CAC + 
1) via Agatston
CRP *No association between 
25(OH)D and CAC, cIMT, or 
CRP. 
*no systematic assessment of
CRP to CAC 
56 Tanaka (2009, 73) – 
Atherosclerosis 
Cross-sectional Pts with suspicion of CAD 
who received angiography 
/ assess relation between 
CV risk factors and 
characteristics on 
angiography 
424; 137 
(32%) 
women; 
race N/A 
but probably 
100% Japan. 
Binary (≥400) 
CAC score and 
log(CAC + 1) 
via Agatston 
CRP *Positive remodeling by CT
correlates to an increase in 
CRP. 
57 Fensterseifer (2009, 
74) – Nephrology 
Cross-sectional Hemodialysis for >3 
months, age >18 yrs, sinus 
rhythm / assess CACs in 
HD pts and correlate 
59; 24 
(41%) 
women; 
76% white 
Raw CAC score 
via Agatston by 
tertiles 
CRP *CAC detected in 64.5% of
pts. 
*Correlation between CACS
and advanced age, but not 
104 
CACS with clinical 
parameters and mortality 
mortality. 
*Trend towards higher CRP in
severe CACS 
58 Gutiérrez (2009, 75) 
– Circulation
Case-control Pre-dialysis chronic 
kidney disease / assess 
relation between FGF-23 
and LVH and CAC 
162 CKD, 
58 controls; 
76 (35%) 
women; 
30% black 
Binary (≥100) 
and raw CAC 
score via 
Agatston 
CRP *FGF-23 is independently
associated with LV mass 
index and LVH in patients 
with CKD, but not CAC 
*no systematic assessment of
CRP to CAC 
59 Shea (2009, 76) – 
Am J Clin Nutrition 
Randomized 
controlled trial 
Men or post-menopausal 
women aged 60-80 yrs; 
Determine effect of 
vitamin K1 
supplementation on CAC 
progression (after 3 yrs) in 
older adults 
388; 235 
(61%) 
women; 
93% white 
Raw CAC score 
via Agatston; 
change in CACS 
between 1st and 
2nd CT (after 3 
yrs) 
CRP *Vitamin K1 supplementation
slows CAC progression in 
older adults with pre-existing 
CAC. 
*no systematic assessment of
CRP to CAC 
60 Ohtake (2010, 77) – 
Hemodialysis 
International 
Cross-sectional 
and 
prospective 
cohort 
Hemodialysis patients / 
evaluate risk factors for 
CAC and impact of CAC 
on CV events in HD pts 
74 cross-
sectional, 56 
prospective 
cohort; 27 
(36%) 
women; 
Japanese? 
Raw CAC score 
via Agatston; 
change in CACS 
between 1st and 
2nd EBCT (15 
months) 
CRP, fibrinogen *CRP and fibrinogen 
associated with baseline CAC 
and CAC progression in the 
univariate analyses; CRP 
associated with baseline CAC 
and CAC progression in 
multiple regression analysis  
61 Park (2010, 78) – 
Respiratory Med 
Cross-sectional Korean males without 
CVD participating in 
annual medical check-up 
program /  assess relation 
between decreased lung 
function and CAC and 
other variables 
4905; 0% 
women; 
100% 
Korean 
Raw CAC score 
via Agatston 
CRP *Metabolic syndrome, insulin
resistance, coronary 
atherosclerosis, and systemic 
inflammation are closely 
related to the impaired lung 
function. 
*no systematic assessment of
CRP to CAC 
62 Roe (2010, 79) – 
Atherosclerosis 
Prospective 
cohort 
Renal transplant recipients 
/ assess relation between 
inflammatory markers and 
CAC; also CAC and CV 
events 
112; 48% 
women; 
63% white 
Raw CAC score 
via Agatston by 
quintiles 
CRP *CRP was predictive of CAC
severity at time of transplant 
*CAC is predictive of CV
events and mortality 
63 Rodrigues (2010, 80) 
– Diabetes Technol
Therapeutics 
Prospective 
cohort – 
Coronary 
Artery 
Diabetes type I with no 
known CAD aged 19-56 
yrs / assess relation 
between heart rate 
1416; 764 
(54%) 
women; 
race N/A 
Difference in sq 
root transformed 
raw CAC score  
via Agatston;  
CRP, fibrinogen *reduced HRV predicted 
progression of CAC in adults 
with and without T1D 
*only univariate comparison
105 
Calcification 
Type 1 
Diabetes Study 
(CACT1) 
variability and CAC 
progression 
progression 6.0 
yrs; >2.5 mm3 
significant 
of  CRP and fibrinogen to 
CAC progression 
64 Sposito (2011, 81) – 
Atherosclerosis 
Cross-sectional 
– Brasilia
Heart 
STEMI / assess frequency 
that STEMI pts would be 
candidates for intensive 
lipid-lowering therapy 
based on current 
guidelines 
355; 25% 
women; 
race N/A 
CACS via 
Agatston 
CRP *more than half would not be
candidates for intensive lipid 
lowering therapy by current 
clinical algorithms 
*no correlation between CRP
and CAC 
65 Banks (2011, 82) – 
JACC: Cardiovasc 
Imaging 
Cross-sectional 
– Dallas Heart
Women 30-65 yrs / assess 
relation between angina 
and SCA and assess 
factors associated with 
angina in women without 
CAC 
1480; 100% 
women; 
30% white, 
49% black, 
20% 
Hispanic 
Binary (>10) 
CAC score via 
Agatston 
CRP *angina is not associated with
CAC 
* no difference in CRP for
women with and without 
angina 
66 Salem (2011, 83) – 
Acta Diabeologica 
Cross-sectional Adolescents 12-18 yrs 
with DM type I / assess 
relations between CAC 
and hsCRP, dyslipidemia, 
glycemic control, and 
microvascular 
complications 
60 patients, 
60 controls; 
30 (50%) 
girls; race 
N/A 
Raw CAC score 
via Agatston by 
quartile 
CRP *12 pts (20%) with DM have
CAC 
*hsCRP was higher in CAC-
positive DM pts compared to 
CAC-negative DM pts, not 
significant 
67 Mathews (2011, 84) 
– Am J Nephrol
Prospective 
cohort - 
feasibility 
Chronic hemodialysis 
patients with CACS >50 / 
assess the feasibility and 
safety of sodium 
thiosulfate, and potential 
efficacy on CAC and AC 
22; 36% 
women; 
86% black 
Difference in sq 
root transformed 
raw CAC score  
via Agatston;  
progression 5.0 
mos; >2.5 mm3 
significant 
CRP *STS is safe and feasible
*no systematic assessment of
CRP to CAC 
68 Möhlenkamp (2011, 
85) – J Am Coll 
Cardiol 
Prospective 
cohort – Heinz 
Nixdorf Recall 
Study 
Healthy volunteers 
between 45 and 75 years / 
assess the value of hsCRP 
and CAC in addition to 
traditional factors in 
predicting incident CV 
events 
4814; 2096 
(44%) 
women; 
race N/A 
Log(CAC + 1) 
score via 
Agatston, and 
CAC by quartile 
CRP *hsCRP appears to improve
CV risk prediction especially 
in persons with very low CAC 
scores 
*no systematic assessment of
CRP to CAC 
69 Turkmen (2011, 86) 
– Clin J Am Soc
Nephrol 
Cross-sectional ESRD receiving PD or HD 
for ≥6 months / assess 
relation between epicardial 
80 ESRD,31 
(39%) 
women; 27 
Binary (>10) and 
raw CAC score 
via Agatston 
CRP *significant relationship 
between EAT and components 
of MIAC syndrome in ESRD 
106 
adipose tissue (EAT) and 
malnutrition, 
inflammation, 
atherosclerosis / 
calcification (MIAC) 
control; race 
N/A 
pts 
*no systematic assessment of
CRP to CAC 
70 Blaha (2011, 87) – 
Lancet 
Prospective 
cohort – 
MESA 
JUPITER pop.: men ≥50 
yrs, women ≥60 yrs, LDL 
<3.37 mmol/L,no lipid 
therapy, no DM, TRIG 
<5.65 mmol/L, Cr <176.8 
μmol/L, hsCRP ≥2 mg/L 
950; 486 
(51%) 
women; 
41% white, 
31% black, 
5% Chinese, 
23% 
Hispanic 
Binary (>0) and 
raw CAC via 
Agatston 
CRP *CAC further stratifies 
JUPITER pts 
*increased CAC burden led to
similar increases in absolute 
CHD and CVD events in both 
the low (<2) and high (≥2) 
hsCRP groups 
*no systematic assessment of
CRP to CAC 
71 Baker (2011, 88) – J 
Rheumatology 
Case cohort Non-pregnant women with 
SLE / assess relation 
between resistin and 
systemic inflammation, 
disease measures and 
CAC 
159 lupus, 
70 control; 
100% 
women; 
39% white; 
51% black 
Binary (>0) 
CAC score via 
Agatston 
CRP *higher resistin level 
correlated with CRP 
*SLE with CAC had higher
levels of resistin than SLE 
without CAC 
*no systematic assessment of
CRP to CAC 
72 Cao (2011, 89) – 
Cardiology 
Cross-sectional Symptomatic people with 
suspected CAD and eGFR 
30 mL/min/1.73 m2 or 
greater / assess relations 
between kidney function 
and CAC 
1572; 439 
(28%) 
women; 
race N/A, 
but likely 
high in 
Chinese 
Raw CAC score 
via Agatston 
CRP *kidney dysfunction was an
independent predictor of CAC 
*no systematic assessment of
CRP to CAC 
73 Huang (2012, 90) – 
Atherosclerosis 
Cross-sectional 
from 
randomized 
trial 
Asymptomatic women age 
42-58 years randomized to 
placebo or hormone 
therapy / assess relation 
between fat deposition 
with CVD risk factors & 
CAC 
650; 100% 
women; 
74% white 
Binary (>0) 
CAC score via 
Agatston 
CRP *hepatic fat is associated with
CRP and insulin 
*cardiac fat is associated with
CAC 
*no systematic assessment of
CRP to CAC 
74 Martin (2012, 91) – 
Obesity 
Cross-sectional Asymptomatic people with 
BMI 25 or greater / assess 
relation between leptin 
and CAC, in high and low 
CRP 
1460; sex 
N/A, race 
N/A 
CAC score N/A CRP *leptin associated with 
increased CAC in the presence 
of high CRP levels 
*no systematic assessment of
CRP to CAC 
107 
75 Zhang (2012, 92) – 
Clinical Cardiology 
Cross-sectional Men presenting for routine 
medical checkup in Korea 
/ assess relation between 
bilirubin and CAC 
3408; 0% 
women; 
race N/A, 
but likely 
high in 
Korean 
Raw CAC score, 
presumed 
Agatson (not 
specified), by 
quintiles and 
log(CAC + 1) 
CRP *inverse relation between
CAC and CRP 
*no systematic assessment of
CRP to CAC 
76 Yeboah (2012, 93) – 
JAMA 
Prospective 
cohort – Multi-
Ethnic Study 
of 
Atherosclerosis 
(MESA) 
Asymptomatic people 
without known CAD  or 
DM / predict incident 
CVD with 6 novel risk 
markers 
1330 
intermediate 
risk; 443 
(33%) 
women; 
36% white, 
22% black, 
16.9% 
Chinese, 
25% 
Hispanic 
Ln(CAC + 1) 
score via 
Agatston 
CRP *CAC superior to other risk
markers 
*no systematic assessment of
CRP to CAC 
77 Park (2012, 94) – 
Atherosclerosis 
Retrospective 
cohort 
Asymptomatic people 
without known CAD / all 
CV events by plaque type  
4690; 1892 
(40%) 
women; 
race N/A, 
but likely 
high in 
Korean 
Raw CAC score 
via Agatston by 
quartiles 
CRP *hsCRP >3 mg/L was an
independent predictor of 
adverse CV events with non-
calcified plaques after 
adjusting for FHS and CACS 
*did not assess CRP to plaque
presence or type 
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